
<html lang="en"     class="pb-page"  data-request-id="a20c6a98-17a8-492c-a396-297c43d5667c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c00395;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-9;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma" /></meta><meta name="dc.Creator" content="Deeba  Ensan" /></meta><meta name="dc.Creator" content="David  Smil" /></meta><meta name="dc.Creator" content="Carlos A.  Zepeda-Velázquez" /></meta><meta name="dc.Creator" content="Dimitrios  Panagopoulos" /></meta><meta name="dc.Creator" content="Jong Fu  Wong" /></meta><meta name="dc.Creator" content="Eleanor P.  Williams" /></meta><meta name="dc.Creator" content="Roslin  Adamson" /></meta><meta name="dc.Creator" content="Alex N.  Bullock" /></meta><meta name="dc.Creator" content="Taira  Kiyota" /></meta><meta name="dc.Creator" content="Ahmed  Aman" /></meta><meta name="dc.Creator" content="Owen G.  Roberts" /></meta><meta name="dc.Creator" content="Aled M.  Edwards" /></meta><meta name="dc.Creator" content="Jeff A.  O’Meara" /></meta><meta name="dc.Creator" content="Methvin B.  Isaac" /></meta><meta name="dc.Creator" content="Rima  Al-awar" /></meta><meta name="dc.Description" content="Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identificati..." /></meta><meta name="Description" content="Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identificati..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 5, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00395" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00395" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00395" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00395" /></link>
        
    
    

<title>Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00395" /></meta><meta property="og:title" content="Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0015.jpeg" /></meta><meta property="og:description" content="Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention. In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant. Initial efforts resulted in the discovery of M4K2009, an analogue of the previously reported ALK2 inhibitor LDN-214117. Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel. Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analogue M4K2149 with reduced off-target affinity for the ion channel. Additional modifications yielded 2-fluoro-6-methoxybenzamide derivatives (26a–c), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00395"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00395">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00395&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00395&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00395&amp;href=/doi/10.1021/acs.jmedchem.0c00395" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4978-4996</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00388" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00547" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Deeba Ensan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deeba Ensan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</div><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deeba++Ensan">Deeba Ensan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3251-1521" title="Orcid link">http://orcid.org/0000-0002-3251-1521</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Smil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Smil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Smil">David Smil</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6232-6087" title="Orcid link">http://orcid.org/0000-0002-6232-6087</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlos A. Zepeda-Velázquez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlos A. Zepeda-Velázquez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlos+A.++Zepeda-Vel%C3%A1zquez">Carlos A. Zepeda-Velázquez</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8130-2232" title="Orcid link">http://orcid.org/0000-0002-8130-2232</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dimitrios Panagopoulos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dimitrios Panagopoulos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dimitrios++Panagopoulos">Dimitrios Panagopoulos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jong Fu Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jong Fu Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jong+Fu++Wong">Jong Fu Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eleanor P. Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eleanor P. Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eleanor+P.++Williams">Eleanor P. Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roslin Adamson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roslin Adamson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roslin++Adamson">Roslin Adamson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alex N. Bullock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alex N. Bullock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alex+N.++Bullock">Alex N. Bullock</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Taira Kiyota</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Taira Kiyota</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Taira++Kiyota">Taira Kiyota</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahmed Aman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed Aman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed++Aman">Ahmed Aman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Owen G. Roberts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Owen G. Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">M4K Pharma Inc., 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Owen+G.++Roberts">Owen G. Roberts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aled M. Edwards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aled M. Edwards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">M4K Pharma Inc., 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aled+M.++Edwards">Aled M. Edwards</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff A. O’Meara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff A. O’Meara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+A.++O%E2%80%99Meara">Jeff A. O’Meara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Methvin B. Isaac</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Methvin B. Isaac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Methvin+B.++Isaac">Methvin B. Isaac</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rima Al-awar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rima Al-awar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7c2e15111d523d101d0b1d0e3c13151f0e521312521f1d"><span class="__cf_email__" data-cfemail="44162d29256a052825332536042b2d27366a2b2a6a2725">[email protected]</span></a>. Phone: +1 (416) 673-8577.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rima++Al-awar">Rima Al-awar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4185-055X" title="Orcid link">http://orcid.org/0000-0002-4185-055X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00395&amp;href=/doi/10.1021%2Facs.jmedchem.0c00395" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4978–4996</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 5, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 March 2020</li><li><span class="item_label"><b>Published</b> online</span>5 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00395" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00395</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00395"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2639</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00395" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Deeba&quot;,&quot;last_name&quot;:&quot;Ensan&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Smil&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;A. Zepeda-Velázquez&quot;},{&quot;first_name&quot;:&quot;Dimitrios&quot;,&quot;last_name&quot;:&quot;Panagopoulos&quot;},{&quot;first_name&quot;:&quot;Jong&quot;,&quot;last_name&quot;:&quot;Fu Wong&quot;},{&quot;first_name&quot;:&quot;Eleanor&quot;,&quot;last_name&quot;:&quot;P. Williams&quot;},{&quot;first_name&quot;:&quot;Roslin&quot;,&quot;last_name&quot;:&quot;Adamson&quot;},{&quot;first_name&quot;:&quot;Alex&quot;,&quot;last_name&quot;:&quot;N. Bullock&quot;},{&quot;first_name&quot;:&quot;Taira&quot;,&quot;last_name&quot;:&quot;Kiyota&quot;},{&quot;first_name&quot;:&quot;Ahmed&quot;,&quot;last_name&quot;:&quot;Aman&quot;},{&quot;first_name&quot;:&quot;Owen&quot;,&quot;last_name&quot;:&quot;G. Roberts&quot;},{&quot;first_name&quot;:&quot;Aled&quot;,&quot;last_name&quot;:&quot;M. Edwards&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;A. O’Meara&quot;},{&quot;first_name&quot;:&quot;Methvin&quot;,&quot;last_name&quot;:&quot;B. Isaac&quot;},{&quot;first_name&quot;:&quot;Rima&quot;,&quot;last_name&quot;:&quot;Al-awar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4978-4996&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00395&quot;},&quot;abstract&quot;:&quot;Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention. In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant. Initial efforts resulted in the discovery of M4K2009, an analogue of the previously reported ALK2 inhibitor LDN-214117. Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel. Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analogue M4K2149 with reduced off-target affinity for the ion channel. Additional modifications yielded 2-fluoro-6-methoxybenzamide derivatives (26a–c), which possess high inhibitory activity against ALK2, excellent selectivity,&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00395&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00395" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00395&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00395" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00395&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00395" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00395&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00395&amp;href=/doi/10.1021/acs.jmedchem.0c00395" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00395" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00395" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00395%26sid%3Dliteratum%253Aachs%26pmid%3D32369358%26genre%3Darticle%26aulast%3DEnsan%26date%3D2020%26atitle%3DTargeting%2BALK2%253A%2BAn%2BOpen%2BScience%2BApproach%2Bto%2BDeveloping%2BTherapeutics%2Bfor%2Bthe%2BTreatment%2Bof%2BDiffuse%2BIntrinsic%2BPontine%2BGlioma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D9%26spage%3D4978%26epage%3D4996%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/jmcmar.2020.63.issue-9/20200514/jmcmar.2020.63.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention. In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant. Initial efforts resulted in the discovery of <b>M4K2009</b>, an analogue of the previously reported ALK2 inhibitor <b>LDN-214117</b>. Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, <b>M4K2009</b> is also moderately active against the hERG potassium channel. Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analogue <b>M4K2149</b> with reduced off-target affinity for the ion channel. Additional modifications yielded 2-fluoro-6-methoxybenzamide derivatives (<b>26a–c</b>), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37584" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37584" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design and development of brain-penetrant kinase inhibitors as a therapy for the treatment of primary central nervous system (CNS) tumors entail numerous challenges. This is in part due to the remarkably different structural properties that CNS drugs and kinase inhibitors have. Approved CNS drugs, for instance, have fewer hydrogen bond donors (HBDs), lower molecular weights, and half the topological polar surface area (tPSA) of kinase inhibitors on average.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Elevated expression levels of efflux transporters at the blood–brain barrier (BBB) constitute an additional obstacle that drugs must overcome in order to reach therapeutically relevant concentrations at sites of lesion.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CNS drug exposure is further limited by the endothelial tight junctions of the BBB, which impede paracellular transport.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite these difficulties, the recent approval of Lorlatinib by the FDA for the treatment of metastatic anaplastic lymphoma kinase-positive nonsmall cell lung cancer demonstrates that the development of BBB penetrant kinase inhibitors is possible. There are multiple kinases in addition to the anaplastic lymphoma kinase that play pivotal roles in oncogenesis. Of interest to us are proteins involved in the bone morphogenetic protein (BMP) signaling pathway.</div><div class="NLM_p">BMPs are a group of cytokines that modulate a plethora of physiological processes, including musculoskeletal development and neural differentiation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The signal elicited by BMP binding to type II BMP receptors is transduced by type I BMP receptors, which promote the translocation of downstream effector proteins (SMADs) to the nucleus where they can regulate the transcription of target genes <i>via</i> chromatin remodeling.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Aberrant BMP signaling is implicated in a number of diseases,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> such as fibrodysplasia ossificans progressiva (FOP). Germline mutations (c.617G>A; p.R206H) in the juxtamembrane glycine–serine (GS)-rich domain of activin receptor-like kinase-2 (ALK2) confer gain-of-function activity to the type I BMP receptor and contribute to the abnormal skeletal phenotype observed in individuals affected by FOP.<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3,6)</a> Somatic missense mutations in the <i>ACVR1</i> gene encoding ALK2 have also been reported in approximately 24% of children with the rare pediatric disease diffuse intrinsic pontine glioma (DIPG),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> with a higher prevalence of mutation occurring in the serine/threonine kinase domain of the receptor.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">DIPG is a grade IV tumor originating in the glial tissue of the pons.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Children affected by the disease have a 5-year relative survival rate of less than 1%.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Treatment options are limited to focal radiation therapy because of the sensitive area in which the tumor resides and the failure of currently available chemotherapeutic drugs to prolong survival.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> The mechanism by which ALK2 contributes to DIPG pathogenesis has not yet been elucidated.<a onclick="showRef(event, 'ref3 ref7 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref7 ref10">(3,7,10)</a> However, a recent study by Carvalho and coworkers demonstrated that shRNA knockdown of <i>ACVR1</i> elicits apoptosis in HSJD-DIPG-007 cells, harboring <i>ACVR1</i> R206H mutations in conjunction with histone H3.3 K27M mutations.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Their work suggests that DIPG cells are dependent on enhanced BMP signaling. This was further recapitulated in their orthotopic patient-derived xenograft model in which administration of two ALK2 inhibitors extended survival compared to controls.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Although targeting the serine/threonine kinase may constitute a viable treatment, monotherapies are seldom efficacious for DIPG.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Targeting proteins with the potential to restore normal epigenetic signatures, such as histone deacetylase (HDAC), has gained momentum in recent years.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> It is likely that the most beneficial treatment option for patients will consist of combinatorial therapies.</div><div class="NLM_p">Several inhibitors of ALK2 have emerged in the past decade,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> including the pyrazolo[1,5-α]pyrimidine compound <b>LDN-193189</b>,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> as well as a relatively new class of 3,5-diarylpyridine analogues: <b>K02288</b>, <b>LDN-213844</b>, and <b>LDN-214117</b>.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> Triazolamine CP466722 represents another novel chemotype with moderate binding affinity for ALK2 and unparalleled selectivity over other proteins in the serine/threonine kinase receptor (STKR) family.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Structure–activity relationship (SAR) studies surrounding this new scaffold should also be explored. As <b>LDN-214117</b> has been reported to have low cytotoxic activity and excellent kinome-wide selectivity,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> we sought to explore whether additional modifications to the hinge-binding pyridyl core could improve ALK2 potency and selectivity over the closely related TGF-βRI receptor ALK5. Cardiotoxicity and gastrointestinal inflammation are adverse effects of ALK5 inhibition.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, a major focus of our SAR studies was to synthesize analogues with reduced off-target affinity for this receptor. Shifting the methyl substituent from the C-2 position of the pyridyl core of <b>LDN-214117</b> to the C-4 position (<b>M4K2009</b>) maintained potency and selectivity as determined by the <i>in vitro</i> and cell-based assays employed throughout our study (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibitory and off-target activity of previously reported ALK2 inhibitors and novel analogues. Reported values were obtained from the corresponding references.<a onclick="showRef(event, 'ref15 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref17 ref18">(15,17,18)</a> Measured values were determined utilizing a radioactive biochemical kinase assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although <b>M4K2009</b> has good structural and physicochemical properties, it poses the risk of eliciting torsades de pointes arrythmia <i>in vivo</i> because of the moderate affinity it has for the protein product encoded by the human ether-a-go-go related gene (hERG) (IC<sub>50</sub> = 8 μM).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Additional modifications made to the trimethoxyphenyl moiety led to the identification of the benzamide analogue <b>M4K2149</b>, which has a hERG IC<sub>50</sub> of >50 μM and comparable inhibitory activity against ALK2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In our pursuit of a potent, selective, orally bioavailable, and brain-penetrant type I inhibitor of ALK2, <b>M4K2149</b> was an excellent starting point from which to expand our SAR studies.</div><div class="NLM_p">Our initial work with <b>M4K2009</b> revealed that the inhibitor was equipotent against both wild-type (WT) and mutant ALK2 (G328V, R206H, and R258G) in the biochemical kinase assay.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These results are in alignment with the data generated by Mohedas and coworkers.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Utilizing a thermal shift kinase assay, they were able to demonstrate that FOP-causing mutations in both the GS and serine/threonine kinase domain of ALK2 had negligible effects on the kinase’s affinity for type I inhibitors.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As FOP and DIPG patients harbor very similar mutations in the <i>ACVR1</i> gene,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> the inhibitory activity of the compounds in our series was determined primarily against WT ALK2.</div><div class="NLM_p">The potency and selectivity of our analogues was assessed using a radioactive <i>in vitro</i> kinase assay, employing <b>LDN-193189</b> as a control. To test the activity of the compounds in cells, a HEK293 cell-based NanoBRET assay from Promega was used. In this assay, the competitive displacement of a fluorescent tracer (PBI-6908) from the binding pocket of ALK2 by test compounds elicits reductions in BRET ratios, which are used to generate IC<sub>50</sub> values. Cell-based potency against ALK5 was subsequently determined using a dual luciferase assay (DLA) in HEK293 cells.</div><div class="NLM_p last">The biological evaluation of these compounds was made possible by the <i>pro bono</i> contributions of Reaction Biology Corporation. This work, which was initiated by the open science pharmaceutical company M4K Pharma Inc., was performed in collaboration with the not-for-profit organizations, the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC). Adopting an open science approach enabled us to freely share and discuss results with experts in the field, forging collaborations that advanced the science without the delays associated with confidentiality agreements and intellectual property ownership.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Analogues</h3><div class="NLM_p">The synthetic route employed to prepare <b>M4K2149</b> and related analogues ultimately depended on the commercial availability of starting materials, ease of synthesis, and reaction efficiency. The compounds were initially accessed as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Suzuki–Miyaura coupling of 3,5-dibromo-4-methylpyridine (<b>2</b>) with <b>1</b> generated intermediate <b>3</b>, which subsequently underwent Miyaura borylation to yield the boronate ester <b>4a</b>. Aromatic methyl esters <b>5a–b</b> were coupled with <b>4a</b> to afford intermediates <b>6a–b</b>, which were transformed to the corresponding primary amides <b>7a–b</b> by refluxing in methanolic ammonia, which was then followed by the removal of the carbamate protecting groups with trifluoroacetic acid (TFA). The preparation of analogues <b>8a–c</b> followed a similar synthetic route in which <b>4a</b> was coupled with the aromatic amides <b>5c–e</b> and then deprotected with TFA. Approximately 50% of intermediate <b>3</b> was converted to the undesired dehalogenated side product <b>4b</b> in step <i>b</i>, which contributed to significantly low yields for the final products.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7a–b</b> and <b>8a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 85 °C, overnight; (b) B<sub>2</sub>pin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 110 °C, 4 h; (c) aryl halide (<b>5a–b</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 2 h; (d) 7 N NH<sub>3</sub> in MeOH, 90 °C, 3 d; (e) TFA, DCM, rt, overnight; (f) aryl halide (<b>5c–e</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h.</p></p></figure><div class="NLM_p">To overcome yield constraints, a second synthetic scheme was devised in which a wide variety of boronate esters were coupled with the pyridyl derivatives <b>3</b>, <b>10</b>, or <b>15</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The synthesis of the carboxylic acid intermediates <b>13a–b</b> was accomplished <i>via</i> a two-step, one-pot Suzuki–Miyaura coupling sequence. HATU-mediated coupling with ammonium chloride followed by deprotection furnished the final amide regioisomers <b>14a–b</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>14a–b</b>, <b>M4K2149</b>, <b>18a–b</b>, and <b>20a–e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (b) XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (c) NH<sub>4</sub>Cl, HATU, DIPEA, DCM, rt, 3 h; (d) TFA, DCM, rt, 1 h; (e) 7 N NH<sub>3</sub> in MeOH, 75 °C, 3 d; (f) methylamine, MeOH, 85 °C, 5 h; (g) KOH, THF/H<sub>2</sub>O, rt, 2 h; (h) dimethylamine, HOBt, EDC, DIPEA, DCM/DMF, 50 °C, overnight; (i) 4 M HCl in dioxane, MeOH, rt, 30 min.</p></p></figure><div class="NLM_p">Suzuki–Miyaura coupling of <b>15</b> with the boronate ester <b>16</b> afforded the methyl ester intermediate <b>17</b>, which was converted to the corresponding primary, secondary, or tertiary amide <i>via</i> aminolysis or base-catalyzed hydrolysis followed by EDC-mediated coupling with the desired amine. Deprotection using TFA or HCl afforded the compounds <b>M4K2149</b> and <b>18a–b</b>. A similar synthetic route was used to access analogues <b>20a–e</b>, although additional transformations beyond the standard Suzuki–Miyaura coupling and deprotection were not required, as the boronate esters <b>19a–e</b> already had the desired amide substituents installed.</div><div class="NLM_p">The synthesis of analogues <b>26a–f</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) was initiated by the nucleophilic aromatic substitution of 4-bromo-2,6-difluorobenzonitrile (<b>21</b>) with sodium methoxide to yield both 4-bromo-2-fluoro-6-methoxybenzonitrile (<b>22a</b>) and 2,6-dimethoxybenzonitrile (<b>22b</b>). Both intermediates were hydrolyzed to the corresponding amides <b>5d–e</b> using hydrogen peroxide and an aqueous solution of sodium hydroxide. Miyaura borylation of <b>5d–e</b> followed by Suzuki–Miyaura coupling with 3-bromo-5-chloro-4-methylpyridine (<b>10</b>) afforded <b>24a–b</b>, which were subjected to a second coupling reaction with a variety of (4-(piperazin-1-yl)phenyl)boronate ester derivatives (<b>25a–c</b>) to furnish the final compounds <b>26a–f</b> in excellent yields.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>26a–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, MeOH, dioxane, rt, overnight; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/H<sub>2</sub>O, overnight; (c) B<sub>2</sub>pin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 110 °C, 4 h; (d) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (e) XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structure Activity Relationship Studies</h3><div class="NLM_p">It has been disclosed by Mohedas and coworkers that the pyridyl nitrogen of <b>LDN-213844</b> participates in a key hydrogen bond interaction with the backbone amide of H286 in the hinge region of ALK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Our own crystallographic efforts led to the generation of a co-crystal structure of <b>M4K2149</b> with the kinase in high resolution, which revealed that the same interaction had been preserved (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T6D">6T6D</a>). Furthermore, the trimethoxyphenyl motif of <b>LDN-213844</b> was reported to occupy a hydrophobic pocket of ALK2, where the <i>meta</i>-methoxy group participates in a water-mediated hydrogen bond with K235 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Substitution of the <i>para</i>-methoxy group of <b>LDN-213844</b> with a primary amide results in the establishment of a direct hydrogen bond between the carbonyl O of the amide and the NH<sub>3</sub><sup>+</sup> group of K235 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Additionally, the phenyl ring of <b>M4K2149</b> stacks between G289 and V214,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> while the protonated piperazine NH<sub>2</sub><sup>+</sup> is in close proximity to D293. This is suggestive of an electrostatic interaction. An intramolecular hydrogen bond between the amide NH<sub>2</sub> and O of the <i>ortho</i>-methoxy substituent can also be observed in the co-crystal structure.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>M4K2149</b> (light yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T6D">6T6D</a>). Hydrogen bonds are established with H286 and K235. The benzamide moiety of <b>M4K2149</b> occupies a hydrophobic pocket (green) of ALK2 and is flanked by several hydrogen bond-donating (blue; K235) and hydrogen bond-accepting residues (red; D354 and E248). The protonated piperazine motif is in close proximity to D293, indicative of an electrostatic interaction. (B) Cocrystal structure of <b>LDN-213844</b> (light yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>). <b>M4K2149</b> and <b>LDN-213844</b> have similar modes of binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial SAR studies focused on varying the substitution pattern of the amide in order to determine if the group could interact with other residues in the pocket, such as D354 of the DLG motif or E248.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Inverting the amide and methoxy substituents (<b>14a</b>) resulted in a complete loss of activity against ALK2 in the biochemical kinase assay. This correlated well with the results obtained by NanoBRET and DLA (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Moving the methoxy group from an ortho- to a meta-position with respect to the amide (<b>14b</b>) improved the biochemical potency compared to <b>14a</b>; however, this did not translate into a significant improvement in cell-based potency. Replacement of the phenyl ring with five-membered heterocycles gave rise to the thiophene analogues <b>7a–b</b> and <b>8a</b>, which were profiled to further investigate the effect that the amide geometry had on potency and selectivity. A greater than 40-fold decrease in inhibitory activity against ALK2 was measured for <b>7a</b> and <b>7b</b>, while <b>8a</b> was found to be completely inactive against the kinase in both assays. It became evident that positioning the primary amide on a six-membered aromatic ring para to the hinge-binding pyridyl core was critical for maintaining key binding interactions with ALK2.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory and Off-Target Activities of <b>14a–b</b>, <b>7a–b</b>, and <b>8a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0006.gif" alt="" id="GRAPHIC-d7e1084-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0007.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Average of duplicate measurements.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Average of triplicate measurements.</p></div></div><div></div></div><div class="NLM_p">The consideration of several physicochemical parameters, such as lipophilicity (cLogP), tPSA, and number of HBD, is pertinent in the design of small molecule inhibitors that must penetrate the BBB to exert their pharmacological effects. The ideal values that brain-penetrant drugs should have vary between reviews.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In the case of lipophilicity, the consensus is that immoderate increases in cLogP should be avoided. Although increasing the lipophilicity of a drug typically enhances potency and permeability, concomitant increases in nonspecific tissue binding also occur, which would ultimately decrease the concentration of the free drug at its intended site of action within the brain.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The number of HBD that a molecule possesses, in addition to its tPSA, can also influence its ability to permeate the BBB. Increasing the value of either physicochemical parameter also risks recognition by efflux transporters, such as P-glycoprotein (P-gp).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a></div><div class="NLM_p">With these guidelines in mind, we sought to determine if mono- and di-<i>N</i>-methylation of the primary amide, as well as its cyclization to form the corresponding isoindolinone analogue, could be tolerated. The effects of these modifications were two-fold. In addition to decreasing the number of HBD, the tPSA was reduced to below 70 Å<sup>2</sup> for <b>18a–b</b> and <b>20a</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> which is in an optimal range for CNS-penetrant drugs.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These structural changes had only moderate effects on the lipophilicity of the three analogues. Unfortunately, these compounds were discovered to be completely inactive against ALK2 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), indicating that the binding affinity of the benzamides may be sensitive to steric effects. Consequently, we decided to incorporate only the primary amide motif in the rest of our analogues.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory and Off-Target Activities of <b>8b–c</b>, <b>18a–b</b>, <b>20a–e</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0008.gif" alt="" id="GRAPHIC-d7e1144-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0009.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Average of duplicate measurements.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Average of triplicate measurements.</p></div></div><div></div></div><div class="NLM_p">To determine if the methoxy group of <b>M4K2149</b> was critical for maintaining potency, compound <b>20b</b> was profiled. Removal of the methoxy substituent reduced inhibitory activity against ALK2 by 28-fold. This result led us to suspect that the methoxy group oriented the amide into a conformation that was ideal for ALK2 binding. The incorporation of intramolecular hydrogen bonds and electrostatic interactions to mask HBD is a technique commonly employed to enhance brain penetration.<a onclick="showRef(event, 'ref1 ref24 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref1 ref24 ref26 ref27 ref28">(1,24,26−28)</a> In an attempt to exploit these interactions and probe for additional ones in the vicinity of the benzamide ring, we profiled compounds <b>20c</b> and <b>20d</b>, which featured a one-carbon homologation of the methoxy group and a bioisosteric replacement of the methoxy for a fluorine atom, respectively. Both modifications, however, failed to improve biochemical potency against ALK2.</div><div class="NLM_p">Incorporation of both a fluorine and methoxy substituent ortho to the amide gave rise to compound <b>8b</b>, which not only had a biochemical ALK2 potency comparable to that of <b>M4K2149</b> (ALK2 IC<sub>50</sub> = 24 nM) but also an improved selectivity profile over ALK5. These results correlated well with those obtained in the NanoBRET and DLA assays (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Exactly how the fluorine substituent contributes to this enhancement in selectivity is yet to be elucidated, although two possible explanations exist. We surmised that the electron-withdrawing nature of the fluorine atom decreases the ability of the carbonyl O to act as a hydrogen bond acceptor,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> thereby reducing the strength of intermolecular interactions that may be more critical for ligand binding to ALK5 than ALK2. The second possible explanation focuses on how the halogen substituent affects the conformation of the amide with respect to the phenyl ring. For anisole and benzamide motifs, which typically adopt planar topologies, ortho substituents can force the methoxy or amide groups out of the plane of the benzene ring in order to reduce allylic strain.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> We postulated that a similar phenomenon could be occurring in the case of <b>8b</b> and that this change in conformation is better tolerated by ALK2 than ALK5.</div><div class="NLM_p last">We decided to introduce a larger substituent ortho to the amide in order to confirm whether the latter hypothesis was correct. Replacing the fluorine atom of <b>8b</b> with a chlorine atom (<b>20e</b>) increased the biochemical selectivity over ALK5 to greater than 200-fold, suggesting that our proposed explanation is a reasonable one. However, NanoBRET ALK2 IC<sub>50</sub> values were similar for both <b>8b</b> and <b>20e</b>, indicating that the modification has little impact on ALK2 potency. To determine if electron-donating groups could be tolerated at this position as well, <b>8c</b> was prepared. This analogue had the greatest structural similarity to our lead compound <b>M4K2009</b>. Although <b>8c</b> was the most potent analogue in our series, it suffered from poor selectivity (biochemical selectivity of 9-fold over ALK5). Additionally, there was a substantial difference in its biochemical and cell-based potencies (biochemical ALK2 IC<sub>50</sub> = 5 nM <i>vs</i> NanoBRET ALK2 IC<sub>50</sub> = 178 nM).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Permeability, Selectivity, and Pharmacokinetic Studies</h3><div class="NLM_p">Having identified several potent analogues, we decided to focus our efforts on improving the pharmacokinetic (PK) profiles of two: <b>8b</b> and <b>8c</b>. In order to assess the permeability of these compounds, they were tested in a Caco-2 assay, which revealed that both analogues were poorly permeable and being recognized by efflux transporters (efflux ratios for both <b>8b</b> and <b>8c</b> were >30) (see Tables 4 and 2 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>). In an attempt to reduce efflux, the terminal piperazine nitrogens of <b>8b</b> and <b>8c</b> were capped with various alkyl groups to generate 1-methyl-, 1-isopropyl-, and 1,2,6-trimethylpiperazine analogues (<b>26a–f</b>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In addition to reducing the number of HBD, methylation of the terminal piperazine nitrogen offered the additional advantage of attenuating p<i>K</i><sub>a</sub>,<a onclick="showRef(event, 'ref25 ref31'); return false;" href="javascript:void(0);" class="ref ref25 ref31">(25,31)</a> which is often associated with a decrease in P-gp-mediated efflux.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The rationale behind incorporating methyl groups at positions 1, 2, and 6 of the piperazine groups was to increase the molecular rigidity of analogues <b>26c</b> and <b>26f</b>. This is a strategy that is commonly employed to enhance brain penetration and oral bioavailability.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As it has been reported that the piperazine motif of <b>LDN-193189</b> is a metabolic liability,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> increasing the steric bulk around this group was also done to improve the inhibitors’ ADME profile <i>in vivo</i>.</div><div class="NLM_p">As anticipated, the permeability (P<sub>app_AB</sub>) of the 2-fluoro-6-methoxybenzamide analogues was increased from 0.3 × 10<sup>–6</sup> cm/s (<b>8b</b>) to around 5.0 × 10<sup>–6</sup> cm/s for <b>26a–c</b>. This was accompanied by a concomitant reduction in the efflux ratio (from >30 for <b>8b</b> to less than 3.0 for <b>26a</b> and <b>26b</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). An enhancement in selectivity over ALK5 was also observed for these compounds. This was more pronounced in the biochemical kinase assay (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Unfortunately, similar results were not obtained for the 2,6-dimethoxybenzamide analogues (<b>26d–f</b>). Piperazine alkylation appeared to have little effect on reducing efflux (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>, Table 2). However, <b>26d–f</b> demonstrated excellent inhibitory activity against ALK2 in the NanoBRET assay. Although <b>M4K2149</b> and <b>8c</b> differ by only one methoxy group, the latter analogue had a significantly higher efflux ratio (8.1 <i>vs</i> >30).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We suspected that the extra electron-donating group was increasing the hydrogen bond acceptor potential of the amide carbonyl, which was being recognized by one of the efflux transporters expressed by the Caco-2 cells. Consequently, these analogues were excluded from further profiling.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory and Off-Target Activity of 2-Fluoro-6-methoxybenzamide and 2,6-Dimethoxybenzamide Analogues, <b>26a–f</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0010.gif" alt="" id="GRAPHIC-d7e1369-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0011.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Average of duplicate measurements.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Average of triplicate measurements.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Average of quadruplicate measurements.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Average of quintuplicate measurements.</p></div></div><div></div></div><div class="NLM_p">Prior to assessing the PK profiles of the 2-fluoro-6-methoxybenzamide analogues <i>in vivo</i>, the metabolic stabilities of <b>8b</b> and <b>26a–c</b> were evaluated in mouse and human liver microsomal (MLM and HLM) stability assays. All four analogues exhibited moderate to high stability in both <i>in vitro</i> assays, with compounds <b>8b</b> and <b>26b</b> demonstrating the highest degree of stability after a 60 min incubation period at 37 °C (>85% remaining) (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>, Table 3). Oral administration of a 10 mg/kg dose of <b>8b</b> in female CB17 SCID mice (<i>n</i> = 3) gave rise to suboptimal values for <i>C</i><sub>max</sub> (97 ng/mL), <i>t</i><sub>1/2</sub> (1.31 h), and AUC<sub>inf</sub> (296 ng·h/mL). Given the poor intrinsic permeability of <b>8b</b>, these results were not surprising. A significant improvement in PK properties was observed for analogues <b>26a</b> and <b>26b</b>, both of which yielded a greater than 17-fold increase in <i>C</i><sub>max</sub>, 13-fold increase in AUC<sub>inf</sub>, and a doubling of <i>t</i><sub>1/2</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The two analogues were also assessed for their ability to penetrate the BBB in the same strain of mice. Oral administration of these compounds at a 100 mg/kg dose gave rise to average total brain concentrations of 777 and 1595 ng/g and total brain-to-plasma ratios (<i>B/P</i>) of 0.178 and 0.132 for <b>26a</b> and <b>26b</b>, respectively. Although these values are moderate, the use of <i>B/P</i> ratios to assess brain permeability is generally not encouraged. The extent of brain penetration is typically evaluated based on the ratio of the unbound brain concentration to the unbound plasma concentration (<i>K</i><sub>p,uu</sub>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Whether these analogues require additional modifications to enhance BBB permeability will ultimately depend on the value of this parameter.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Permeability and Oral <i>In Vivo</i> PK Studies of 2-Fluoro-6-methoxybenzamide Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0012.gif" alt="" id="GRAPHIC-d7e1494-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0013.gif" alt="" id="gr9" /></img><div></div></div><div class="NLM_p">To ensure that a favorable hERG profile had been maintained for the 2-fluoro-6-methoxybenzamide analogues, their potencies against the hERG potassium channel were assessed using a HEK293 cell-based patch-clamp assay. <b>26a</b> and <b>26b</b> had optimal hERG IC<sub>50</sub> values of >30 μM, while <b>26c</b> was slightly more potent against the ion channel (IC<sub>50</sub> = 19 μM) (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>, Table 4). To further investigate the off-target activity of these analogues, we profiled them in a 375-member kinase panel. At a concentration of 1 μM for each of the three compounds, fewer than 5% of the kinases showed a greater than 50% reduction in enzymatic activity. Excluding ALK1, 2, 3, and 6, the kinases ARAF, MAP4K4, MINK, and TNK1 were the most sensitive to inhibition by <b>26a–c</b> (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>, Table 5). We were also encouraged by the results obtained in an <i>in vitro</i> CYP inhibition assay, which showed that these analogues had negligible inhibitory activity (IC<sub>50</sub> > 50 μM) against 7 CYP isoforms (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a>, Table 4). Altogether, these results demonstrate that we were able to meet our objective of designing selective and orally bioavailable inhibitors of ALK2. Furthermore, profiling 7 analogues against 3 ALK2 mutants (R206H, G328V, and R258G) in a radioactive <i>in vitro</i> kinase assay revealed that, similar to <b>M4K2009</b>, the analogues had comparable potencies against both WT and mutant ALK2 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These findings confirm that the benzamide inhibitors developed in this series have the potential to regulate aberrant BMP signaling in patients harboring these mutations.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibitory Activity of Benzamide Analogues against WT and DIPG-Linked Mutant Forms of ALK2</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0014.gif" alt="" id="gr10" /></img><div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Advances in the development of effective chemotherapeutic agents for the treatment of DIPG have been limited. This is in part due to the convoluted genomic signatures of DIPG, which has made our understanding of its pathogenesis difficult. Recent identification of ALK2 as a target for therapeutic intervention has prompted the emergence of several classes of type I kinase inhibitors. In this work, we expanded the SAR of the 3,5-diarylpyridine inhibitor <b>LDN-214117</b>, which led to the discovery of a potent benzamide analogue <b>M4K2149</b> with an attenuated affinity for the hERG potassium channel. We determined that we could tailor the selectivity of our analogues over ALK5 by incorporating halogen substituents at a position ortho to the amide group of <b>M4K2149</b>. We were also able to address issues of permeability by capping the NH of the solvent-exposed piperazine group. The resulting 2-fluoro-6-methoxybenzamide derivatives <b>26a–c</b> demonstrated excellent kinome-wide selectivity and had improved PK properties compared to their parent compound <b>8b</b>. Furthermore, the co-crystal structure of <b>M4K2149</b> with ALK2 helped us rationalize potency differences between analogues in the series and highlighted structural motifs that were crucial for maintaining key interactions with the protein. Despite these optimizations, total brain-to-plasma ratios are inadequate for accurately assessing the pharmacological activity of <b>26a–b</b> in the brain. Measuring the unbound brain concentrations (<i>C</i><sub>b,u</sub>) of these analogues <i>in vivo</i> is therefore warranted. These data would ultimately determine whether additional modifications should be made to reduce efflux/enhance permeability. Nonetheless, these benzamides represent a new chemotype possessing high inhibitory activity against both WT and mutant ALK2. Implementation of an open science model accelerated the development of these analogues by promoting communication between the chemists involved in their design and establishing a pipeline for rapidly generating biological data. Future work will continue to use open science to develop novel classes of ALK2 inhibitors. The analogues presented in this study have the potential to deepen our understanding of the biology of DIPG and will hopefully pave the way for future chemotherapies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p last">All reagents were purchased from commercial vendors and used without further purification. Volatiles were removed under reduced pressure by rotary evaporation or using the V-10 solvent evaporator system by Biotage. Very high boiling point (6000 rpm, 0 mbar, 56 °C), mixed volatile (7000 rpm, 30 mbar, 36 °C), and volatile (6000 rpm, 30 mbar, 36 °C) methods were used to evaporate solvents. The yields given refer to chromatographically purified and spectroscopically pure compounds. Compounds were purified using a Biotage Isolera One system by normal phase chromatography using Biotage SNAP KP-Sil or Sfär Silica D columns (part no.: FSKO-1107/FSRD-0445) or by reverse-phase chromatography using Biotage SNAP KP-C18-HS or Sfär C18 D columns (part no.: FSLO-1118/FSUD-040). If additional purification was required, compounds were purified by solid phase extraction (SPE) using Biotage Isolute Flash SCX-2 cation exchange cartridges (part nos.: 532-0050-C and 456-0200-D). Products were washed with two cartridge volumes of MeOH and eluted with a solution of MeOH and NH<sub>4</sub>OH (9:1 v/v). Preparative chromatography was carried out using a Waters 2767 injector with the collector attached to PDA UV/Vis and SQD mass detectors. An XSelect CSH Prep C18 5 μm OBD 19 mm × 100 mm (part no.: 186005421) or Xselect CSH Prep C18 5 μm 10 mm × 100 mm (part no.: 186005415) column was used for purification. Final compounds were dried using the Labconco Benchtop FreeZone Freeze-Dry System (4.5 L Model). <sup>1</sup>H and proton-decoupled <sup>19</sup>F NMRs were recorded on a Bruker AVANCE-III 500 MHz spectrometer at ambient temperature. Residual protons of CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, and CD<sub>3</sub>OD solvents were used as internal references. Spectral data are reported as follows: chemical shift (δ in ppm), multiplicity (br = broad, s = singlet, d = doublet, dd = doublet of doublets, m = multiplet), coupling constants (<i>J</i> in Hz), and proton integration. Compound purity was determined by UV absorbance at 254 nm during tandem liquid chromatography/mass spectrometry (LCMS) using a Waters Acquity separation module. All final compounds had a purity of ≥95% as determined using this method. Low-resolution mass spectrometry was conducted in the positive ion mode using a Waters Acquity SQD mass spectrometer (electrospray ionization source) fitted with a PDA detector. Mobile phase A consisted of 0.1% formic acid in water, while mobile phase B consisted of 0.1% formic acid in acetonitrile. One of three types of columns were used: column 1: Acquity UPLC CSH C18 (2.1 × 50 mm, 130 Å, 1.7 μm. part no. 186005296), column 2: Acquity UPLC BEH C8 (2.1 × 50 mm, 130 Å, 1.7 μm. part no. 186002877), or column 3: Acquity UPLC HSS T3 (2.1 × 50 mm, 100 Å, 1.8 μm. part no. 186003538). For columns 1 and 2, the gradient went from 90 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, then increased to 90% over 0.2 min for a total run time of 3 min. For column 3, the gradient went from 98 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, then increased to 98% over 0.2 min for a total run time of 3 min, as well. The flow rate was 0.4 mL/min throughout both runs. All columns were used with the temperature maintained at 25 °C. High-resolution mass spectrometry was conducted using a Waters Synapt G2-S quadrupole-time-of-flight (QTOF) hybrid mass spectrometer system coupled with an Acquity ultra-performance liquid chromatography (UPLC) system. Chromatographic separations were carried out on an Acquity UPLC CSH C18 (2.1 × 50 mm, 130 Å, 1.7 μm. part no. 186005296), Acquity UPLC BEH C8 (2.1 × 50 mm, 130 Å, 1.7 μm. part no. 186002877), or Acquity UPLC HSS T3 (2.1 × 50 mm, 100 Å, 1.8 μm. part no. 186003538). The mobile phases were 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). Leucine Enkephalin was used as the lock mass. MassLynx 4.1 was used for data analysis.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>tert</i>-Butyl 4-(4-(5-Bromo-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>3</b>)</h3><div class="NLM_p last">A solution of <i>tert</i>-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate (<b>1</b>) (1.549 g, 3.99 mmol), 3,5-dibromo-4-methylpyridine (<b>2</b>) (0.953 g, 3.80 mmol), [1,12-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·DCM complex (0.310 g, 0.38 mmol), and sodium carbonate monohydrate (1.414 g, 11.40 mmol) in 1,4-dioxane (16.3 mL) and water (2.7 mL) was heated to 85 °C and stirred overnight. The reaction mixture was concentrated under reduced pressure prior to dilution with water (30 mL) and extraction with EtOAc (3 × 30 mL). The combined extracts were dried over MgSO<sub>4</sub> and concentrated to yield brown oil. The crude material was purified by silica gel chromatography (0–50% EtOAc in hexanes) to afford a white solid (0.770 g, 47% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.61 (s, 1H), 8.31 (s, 1H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 6.99 (d, <i>J</i> = 8.8 Hz, 2H), 3.65–3.56 (m, 4H), 3.26–3.18 (m, 4H), 2.36 (s, 3H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i>: 432.31 [M + H]<sup>+</sup>, 434.38 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (5-(4-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)phenyl)-4-methylpyridin-3-yl)boronic Acid (<b>4a</b>)</h3><div class="NLM_p last">A solution of <b>3</b> (171 mg, 0.396 mmol), bis(pinacolato)diboron (201 mg, 0.792 mmol), [1,12-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·DCM complex (32 mg, 0.040 mmol), and potassium acetate (78 mg, 0.792 mmol) in 1,4-dioxane (4 mL) was microwaved at 110 °C for 4 h. The mixture was transferred to a 15 mL Falcon tube and centrifuged for 1 min at 4000 rpm. The dark brown supernatant was used without further purification in subsequent reactions (190 mg, 57% yield). MS (ESI) <i>m</i>/<i>z</i>: 397.90 [M + H]<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5-Chloro-4-methoxythiophene-3-carboxamide (<b>5c</b>)</h3><div class="NLM_p last">The title compound was prepared using a modified literature procedure.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> To a solution of 5-chloro-4-methoxythiophene-3-carboxylic acid (100.0 mg, 0.519 mmol) in DCM (1.5 mL) was added ammonium chloride (33.3 mg, 0.623 mmol), HATU (237.0 mg, 0.623 mmol), and DIPEA (271 μL, 1.558 mmol). The reaction mixture was stirred at room temperature for 3 h. Volatiles were removed under reduced pressure, and the crude product was purified by silica gel chromatography (0–100% EtOAc in hexanes) to afford an off-white solid (71.1 mg, 72% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.91 (s, 1H), 7.21 (br s, 1H), 5.72 (br s, 1H), 4.06 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 192.27 [M + H]<sup>+</sup>, 194.28 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-Bromo-2-fluoro-6-methoxybenzamide (<b>5d</b>)</h3><div class="NLM_p last">The title compound was prepared using modified literature procedures.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> A solution of 4-bromo-2-fluoro-6-methoxybenzonitrile (<b>22a</b>) (5.00 g, 21.74 mmol) in EtOH (100.0 mL) was cooled in an ice bath prior to the addition of an aqueous solution of sodium hydroxide (0.43 M, 65.0 mL). This was followed by the addition of hydrogen peroxide (30 wt % solution in water) (26.6 mL). The solution was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure prior to dilution with water (250 mL) and extraction with EtOAc (3 × 250 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a white crystalline solid (4.63 g, 80% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 7.84 (br s, 1H), 7.58 (br s, 1H), 7.17 (d, <i>J</i> = 8.5 Hz, 1H), 7.13 (s, 1H), 3.82 (s, 3H). <sup>19</sup>F NMR (471 MHz, DMSO): δ −115.38. MS (ESI) <i>m</i>/<i>z</i>: 248.20 [M + H]<sup>+</sup>, 250.27 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-Bromo-2,6-dimethoxybenzamide (<b>5e</b>)</h3><div class="NLM_p">The title compound was synthesized according to the procedure described for <b>5c</b> from 4-bromo-2,6-dimethoxybenzoic acid (157 mg, 0.600 mmol). The final product was a white solid (100 mg, 64% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 7.51 (br s, 1H), 7.23 (br s, 1H), 6.87 (s, 2H), 3.75 (s, 6H). MS (ESI) <i>m</i>/<i>z</i>: 260.35 [M + H]<sup>+</sup>, 262.29 [M + H]<sup>+</sup> + 2.</div><div class="NLM_p last">The title compound was alternatively synthesized according to the procedure described for <b>5d</b> from 4-bromo-2,6-dimethoxybenzonitrile (<b>22b</b>) (968 mg, 4.00 mmol), hydrogen peroxide (30 wt % solution in water) (9.8 mL), and an aqueous solution of sodium hydroxide (2 M, 25.0 mL). The reaction mixture was heated to 110 °C for 8 h. The solvents were evaporated and the crude material was suspended in water, filtered, and dried under high vacuum to afford a white crystalline solid (903 mg, 87% yield).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>tert</i>-Butyl 4-(4-(5-(4-Methoxy-5-(methoxycarbonyl)thiophen-2-yl)-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>6a</b>)</h3><div class="NLM_p last">A solution of <b>4a</b> (80 mg, 0.167 mmol), methyl 5-bromo-3-methoxythiophene-2-carboxylate (42 mg, 0.167 mmol) (<b>5a</b>), [1,12-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·DCM complex (14 mg, 0.017 mmol), and sodium carbonate monohydrate (62 mg, 0.501 mmol) in 1,4-dioxane (2.9 mL) and water (477 μL) was heated to 100 °C for 2 h. The reaction mixture was adsorbed onto Celite, and the volatiles were removed under reduced pressure. The crude product was purified by silica gel chromatography (0–100% EtOAc in hexanes) to afford an off-white powder (45 mg, 50% yield). MS (ESI) <i>m</i>/<i>z</i>: 524.70 [M + H]<sup>+</sup>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>tert</i>-Butyl 4-(4-(5-(4-Methoxy-5-(methoxycarbonyl)thiophen-3-yl)-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>6b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>6a</b> from <b>4a</b> (80 mg, 0.167 mmol) and methyl 4-bromo-3-methoxythiophene-2-carboxylate (<b>5b</b>) (42 mg, 0.167 mmol). The final product was a light yellow powder (47 mg, 52% yield). MS (ESI) <i>m</i>/<i>z</i>: 524.70 [M + H]<sup>+</sup>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-Methoxy-5-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)thiophene-2-carboxamide (<b>7a</b>)</h3><div class="NLM_p last">A 5 mL MW vial was charged with <b>6a</b> (20.0 mg, 0.038 mmol). The material was dissolved in a solution of ammonia in methanol (7 N) (4 mL). The vial was sealed, and the solution was stirred at 90 °C for 3 days. Volatiles were removed under reduced pressure, and the crude material was purified by silica gel chromatography (0–100% EtOAc in hexanes). The purified product was dissolved in DCM (1 mL) and treated with trifluoroacetic acid (88 μL, 1.146 mmol). The solution was stirred overnight. The product was purified by SPE. Drying under high vacuum overnight afforded an off-white powder (7.8 mg, 47% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.37 (s, 1H), 8.36 (s, 1H), 7.76 (s, 1H), 7.66 (br s, 1H), 7.31–7.25 (m, 3H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 3.51 (s, 3H), 3.22–3.20 (m, 4H), 2.98–2.94 (m, 4H), 2.13 (s, 3H). HRMS (ESI) for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 409.1693; found, 409.1691.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-Methoxy-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)thiophene-2-carboxamide (<b>7b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>7a</b> from <b>6b</b> (20.0 mg, 0.038 mmol). The final product was an off-white powder (8.9 mg, 53% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.38 (s, 1H), 8.36 (s, 1H), 7.76 (s, 1H), 7.66 (br s, 1H), 7.30–7.26 (m, 3H), 7.04 (d, <i>J</i> = 8.7 Hz, 2H), 3.52 (s, 3H), 3.19–3.17 (m, 4H), 2.95–2.91 (m, 4H), 2.13 (s, 3H). HRMS (ESI) for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 409.1693; found, 409.1689.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-Methoxy-5-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)thiophene-3-carboxamide (<b>8a</b>)</h3><div class="NLM_p last">A solution of <b>4a</b> (60.0 mg, 0.125 mmol), <b>5c</b> (20.0 mg, 0.104 mmol), XPhos Pd G2 (8.2 mg, 0.010 mmol), and potassium phosphate tribasic (44.3 mg, 0.209 mmol) in 1,4-dioxane (1.8 mL) and water (298 μL) was heated to 100 °C and stirred for 3 h. The reaction mixture was adsorbed onto Celite, and volatiles were removed under reduced pressure. The crude product was purified by silica gel chromatography (0–100% EtOAc in hexanes). Further purification was carried out by reverse-phase chromatography [2–95% ACN (0.1% formic acid) in water (0.1% formic acid)]. The product was dissolved in DCM (1 mL) and treated with trifluoroacetic acid (479 μL, 6.26 mmol). The solution was stirred for 1 h. The product was purified by SPE. Freeze-drying for 3 days afforded an off-white powder (6.5 mg, 15% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.44 (s, 1H), 8.39 (s, 1H), 8.11 (s, 1H), 7.47 (br s, 1H), 7.44 (br s, 1H), 7.30 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 3.57 (s, 3H), 3.24–3.21 (m, 4H), 3.01–2.96 (m, 4H), 2.17 (s, 3H). HRMS (ESI) for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 409.1693; found, 409.1694.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 2-Fluoro-6-methoxy-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>8b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>4a</b> (77 mg, 0.161 mmol) and <b>5d</b> (40 mg, 0.161 mmol). The final product was an off-white powder (20 mg, 29% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.38 (s, 1H), 8.34 (s, 1H), 7.89 (br s, 1H), 7.58 (br s, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.04 (d, <i>J</i> = 8.6 Hz, 2H), 6.98–6.95 (m, 2H), 3.85 (s, 3H), 3.19–3.15 (m, 4H), 2.94–2.89 (m, 4H), 2.19 (s, 3H). <sup>19</sup>F NMR (471 MHz, DMSO): δ −116.73. HRMS (ESI) for C<sub>24</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 421.2034; found, 421.2040.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2,6-Dimethoxy-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>8c</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>4a</b> (190 mg, 0.396 mmol) and <b>5e</b> (82 mg, 0.317 mmol). The final product was an off-white powder (45 mg, 32% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.36 (s, 1H), 8.35 (s, 1H), 7.57 (br s, 1H), 7.31 (d, <i>J</i> = 8.6 Hz, 2H), 7.23 (br s, 1H), 7.04 (d, <i>J</i> = 8.7 Hz, 2H), 6.72 (s, 2H), 3.78 (s, 6H), 3.19–3.15 (m, 4H), 2.93–2.89 (m, 4H), 2.20 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 433.2234; found, 433.2228.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-(5-Chloro-4-methylpyridin-3-yl)-2-methoxybenzoic Acid (<b>11a</b>)</h3><div class="NLM_p">The title compound was synthesized according to the procedure described for <b>6a</b> from 3-bromo-5-chloro-4-methylpyridine (<b>10</b>) (41 mg, 0.200 mmol) and 5-borono-2-methoxybenzoic acid (<b>9a</b>) (39 mg, 0.200 mmol). DMF (1.6 mL) and water (428 μL) were used as the solvents.</div><div class="NLM_p last">The crude material was used without purification in the subsequent cross-coupling reaction (56 mg, 87% yield). MS (ESI) <i>m</i>/<i>z</i>: 278.30 [M + H]<sup>+</sup>, 280.30 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-(5-Chloro-4-methylpyridin-3-yl)-5-methoxybenzoic Acid (<b>11b</b>)</h3><div class="NLM_p">The title compound was synthesized according to the procedure described for <b>6a</b> from 3-bromo-5-chloro-4-methylpyridine (<b>10</b>) (41 mg, 0.200 mmol) and 3-carboxy-5-methoxyphenylboronic acid (<b>9b</b>) (39 mg, 0.200 mmol). DMF (1.6 mL) and water (428 μL) were used as the solvents.</div><div class="NLM_p last">The crude material was used without purification in the subsequent cross-coupling reaction (56 mg, 90% yield). MS (ESI) <i>m</i>/<i>z</i>: 278.23 [M + H]<sup>+</sup>, 280.30 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 5-(5-(4-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-2-methoxybenzoic Acid (<b>13a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>11a</b> (56 mg, 0.200 mmol) and <b>1</b> (140 mg, 0.360 mmol). The crude product was purified by reverse-phase chromatography [2–95% ACN (0.1% formic acid) in water (0.1% formic acid)]. The purified intermediate was used immediately in the subsequent reaction.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-(5-(4-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-5-methoxybenzoic Acid (<b>13b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>11b</b> (56 mg, 0.200 mmol) and <b>1</b> (140 mg, 0.360 mmol). The crude product was purified by reverse-phase chromatography [2–95% ACN (0.1% formic acid) in water (0.1% formic acid)]. The purified intermediate was used immediately in the subsequent reaction.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-Methoxy-5-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>14a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>5c</b> from <b>13a</b>. Deprotection with trifluoroacetic acid (459 μL, 6.00 mmol), purification by SPE, and freeze-drying for 2 days afforded the final product as a yellow powder (5.96 mg, 7% yield over 4 steps). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.32 (s, 1H), 8.29 (s, 1H), 7.81 (d, <i>J</i> = 2.1 Hz, 1H), 7.71 (br s, 1H), 7.59 (br s, 1H), 7.56 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.26 (d, <i>J</i> = 8.6 Hz, 1H), 7.04 (d, <i>J</i> = 8.6 Hz, 2H), 3.95 (s, 3H), 3.21–3.18 (m, 4H), 2.97–2.93 (m, 4H), 2.14 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 403.2129; found, 403.2126.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3-Methoxy-5-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>14b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>5c</b> from <b>13b</b>. Deprotection with trifluoroacetic acid (0.459 mL, 6.00 mmol), purification by reverse-phase chromatography and SPE and freeze drying for 2 days afforded the final product as an off-white powder (4.52 mg, 6% yield over 4 steps). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.36 (s, 1H), 8.35 (s, 1H), 8.02 (br s, 1H), 7.52–7.49 (m, 1H), 7.49–7.47 (m, 1H), 7.44 (br s, 1H), 7.31 (d, <i>J</i> = 8.6 Hz, 2H), 7.17–7.15 (m, 1H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 3.85 (s, 3H), 3.23–3.20 (m, 4H), 2.99–2.95 (m, 4H), 2.15 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 403.2129; found, 403.2137.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>tert</i>-Butyl 4-(4-(5-Chloro-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>15</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>6a</b> from <b>10</b> (320 mg, 1.550 mmol) and <b>1</b> (722 mg, 1.860 mmol). The final product was an off-white crystalline solid (510 mg, 85% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.48 (s, 1H), 8.30 (s, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 2H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 3.63–3.59 (m, 4H), 3.24–3.19 (m, 4H), 2.33 (s, 3H), 1.49 (s, 9H). MS (ESI) <i>m</i>/<i>z</i>: 388.56 [M + H]<sup>+</sup>, 390.57 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>tert</i>-Butyl 4-(4-(5-(3-Methoxy-4-(methoxycarbonyl)phenyl)-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>17</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>15</b> (120 mg, 0.309 mmol) and 3-methoxy-4-methoxycarbonylphenylboronic acid, pinacol ester (<b>16</b>) (90 mg, 0.309 mmol). The solvents used were butan-1-ol (2 mL) and water (476 μL). The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford a light beige solid (160 mg, 99% yield), which was used without further purification in the subsequent reaction. MS (ESI) <i>m</i>/<i>z</i>: 518.57 [M + H]<sup>+</sup>.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>tert</i>-Butyl 4-(4-(5-(4-Carbamoyl-3-methoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>M4K2149</b>)</h3><div class="NLM_p last">To a solution of <b>17</b> (0.160 g, 0.309 mmol) in MeOH (3.0 mL) at room temperature was added a solution of ammonia in MeOH (7 N) (4.4 mL). The resulting mixture was heated to 75 °C for 3 days prior to cooling back down to room temperature, removing all solvents under reduced pressure, and triturating the residue from EtOAc with hexanes. The beige precipitate was collected by filtration and washed with hexanes. The product was subsequently dissolved in MeOH (5.0 mL) and treated with HCl (4.0 M in dioxane, 1.0 mL). The solution was stirred for 30 min prior to the removal of solvents under reduced pressure. The product was purified by SPE. The final compound was dried under vacuum overnight to give an off-white solid (75 mg, 60% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.35 (s, 1H), 8.34 (s, 1H), 8.10 (d, <i>J</i> = 7.9 Hz, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (s, 1H), 7.12 (d, <i>J</i> = 8.3 Hz, 3H), 4.04 (s, 3H), 3.32–3.26 (m, 4H), 3.13–3.07 (m, 4H), 2.24 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 403.2129; found, 403.2128.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>tert</i>-Butyl 4-(4-(5-(3-Methoxy-4-(methylcarbamoyl)phenyl)-4-methylpyridin-3-yl)phenyl)piperazine-1-carboxylate (<b>18a</b>)</h3><div class="NLM_p last">To a solution of <b>17</b> (42 mg, 0.081 mmol) in MeOH (811 μL) was added methylamine, 33 wt % in EtOH (1.0 mL). The solution was stirred at 85 °C for 5h. The solvents were removed under reduced pressure prior to the crude material being triturated from a minimum amount of EtOAc and hexanes. The product was filtered and dried under air, then dissolved in DCM (213 μL), treated with trifluoroacetic acid (100 μL, 1.310 mmol), and stirred for 1 h. The solution was concentrated under reduced pressure prior to purification by reverse-phase chromatography [2–95% ACN (0.1% formic acid) in water (0.1% formic acid)]. The product was purified by SPE. Freeze-drying for 2 days afforded a white powder (7.68 mg, 20% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.32 (s, 1H), 8.30 (s, 1H), 8.01 (d, <i>J</i> = 7.9 Hz, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.15 (s, 1H), 7.12–7.06 (m, 3H), 4.00 (s, 3H), 3.30–3.27 (m, 4H), 3.12–3.08 (m, 4H), 2.98 (s, 3H), 2.21 (s, 3H). HRMS (ESI<sup>+</sup>) for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 417.2285; found, 417.2288.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 4-(5-(4-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-2-methoxybenzoic Acid</h3><div class="NLM_p last">To a suspension of <b>17</b> (54 mg, 0.104 mmol) in THF (695 μL) and water (695 μL) was added potassium hydroxide pellets (12 mg, 0.209 mmol). The suspension was stirred at room temperature for 2 h. The reaction mixture was diluted with water (35 mL) and extracted with Et<sub>2</sub>O (1 × 20 mL). The aqueous layer was carefully acidified to a pH of 5 and extracted with DCM (3 × 20 mL). The Et<sub>2</sub>O and DCM layers were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford an off-white solid (50 mg, 93% yield). MS (ESI) <i>m</i>/<i>z</i>: 504.60 [M + H]<sup>+</sup>.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-Methoxy-<i>N</i>,<i>N</i>-dimethyl-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>18b</b>)</h3><div class="NLM_p last">To a solution of 4-(5-(4-(4-(<i>tert</i>-butoxycarbonyl)piperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-2-methoxybenzoic acid (50 mg, 0.099 mmol), HOBt (16 mg, 0.119 mmol), and EDC (18 mg, 0.119 mmol) in DCM (894 μL) and DMF (99 μL) was added DIPEA (43 μL, 0.248 mmol) and dimethylamine, 2.0 M in THF (50 μL, 0.099 mmol). The solution was stirred at 50 °C overnight. The reaction mixture was diluted with water (5 mL) and DCM (5 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford a sticky yellow solid. The solid was dissolved in DCM (886 μL) and treated with trifluoroacetic acid (339 μL, 4.430 mmol). The solution was stirred for 45 min prior to purification by reverse-phase chromatography [2–95% ACN (0.1% formic acid) in water (0.1% formic acid)]. The product was purified by SPE. Freeze-drying for 2 days afforded a white powder (13 mg, 23% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.33–8.30 (m, 2H), 7.35–7.28 (m, 3H), 7.12–7.04 (m, 4H), 3.90 (s, 3H), 3.28–3.24 (m, 4H), 3.12 (s, 3H), 3.08–3.04 (m, 4H), 2.94 (s, 3H), 2.22 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 431.2442; found, 431.2439.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-Bromo-2-(hydroxymethyl)benzonitrile</h3><div class="NLM_p last">To a solution of 4-bromo-2-formylbenzonitrile (630 mg, 3.00 mmol) in MeOH (7.5 mL) cooled in an ice bath was added sodium borohydride (125 mg, 3.30 mmol). The reaction mixture was stirred for an hour at 0 °C prior to quenching with water (20 mL). Volatiles were removed under reduced pressure, and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic fractions were washed with brine, dried over NaSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford a yellow-brown solid, which was used without further purification in the subsequent reaction (637 mg, 85% yield). MS (ESI) <i>m</i>/<i>z</i>: 212.28 [M + H]<sup>+</sup>, 214.22 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-Bromo-2-(methoxymethyl)benzonitrile</h3><div class="NLM_p last">To a solution of 4-bromo-2-(hydroxymethyl)benzonitrile (400 mg, 1.89 mmol) in THF (6.3 mL) cooled in an ice bath was added sodium hydride, 60% in mineral oil (181 mg, 7.54 mmol). The solution was stirred for 30 min prior to the addition of iodomethane (1.4 mL, 22.63 mmol). The reaction mixture was stirred for an additional 2 h, then quenched with water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure prior to purification by silica gel chromatography (0–80% EtOAc in hexanes) to afford the final product (89 mg, 20% yield).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-Bromo-2-(methoxymethyl)benzamide</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>5d</b> from 4-bromo-2-(methoxymethyl)benzonitrile (80 mg, 0.354 mmol). The reaction mixture was stirred at 90 °C for 2 h and then at room temperature overnight. The crude mixture was diluted with water (10 mL) and extracted with EtOAc (3 × 10 mL). The organic layers were combined and dried over Mg<sub>2</sub>SO<sub>4</sub> to afford an off-white solid (71 mg, 81% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 7.84 (br s, 1H), 7.64 (d, <i>J</i> = 1.9 Hz, 1H), 7.55 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.46 (br s, 1H), 7.42 (d, <i>J</i> = 8.2 Hz, 1H), 4.58 (s, 2H).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(Methoxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (<b>19c</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>4a</b> from 4-bromo-2-(methoxymethyl)benzamide (50 mg, 0.205 mmol). The dark brown supernatant was used without purification in the subsequent reaction (60 mg, 78% yield). MS (ESI) <i>m</i>/<i>z</i>: 292.53 [M + H]<sup>+</sup>.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-Bromo-2-chloro-6-fluorobenzonitrile</h3><div class="NLM_p last">The title compound was prepared using a modified literature procedure.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> To a solution of 4-bromo-2-chloro-6-fluoroaniline (2.00 g, 8.91 mmol) in DCM (17.8 mL) was added nitrosonium tetrafluoroborate (1.14 g, 9.80 mmol). The solution was stirred for 1 h at room temperature and then cooled in an ice bath. Potassium cyanide (1.16 g, 17.82 mmol) was added. A solution of copper (II) sulfate pentahydrate (4.45 g, 17.82 mmol) in water (35.0 mL) was then added gradually. The suspension was stirred for 1 h on ice and then at room temperature for an additional hour. The reaction mixture was diluted with DCM and a saturated sodium bicarbonate solution, and then it filtered through Celite. The organic layer was washed with brine, separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure prior to purification by silica gel chromatography (0–50% EtOAc in hexanes) to give the final product (0.398 g, 10% yield).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-Bromo-2-chloro-6-methoxybenzonitrile</h3><div class="NLM_p last">The title compound was prepared using a modified literature procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> To a solution of 4-bromo-2-chloro-6-fluorobenzonitrile (0.398 g, 1.697 mmol) in 1,4-dioxane (4.6 mL) was added MeOH (178 μL, 4.412 mmol). Sodium hydride, 60% in mineral oil (106 mg, 4.412 mmol) was added gradually over 1 h. The reaction mixture was stirred for 1 h at room temperature. The solvents were removed under reduced pressure, and the crude material was suspended in water and filtered. The filter cake was dissolved in DCM, concentrated, and purified by silica gel chromatography (0–100% DCM in hexanes) to give the final product (223 mg, 49% yield). MS (ESI) <i>m</i>/<i>z</i>: 246.26 [M + H]<sup>+</sup>, 248.26 [M + H]<sup>+</sup> + 2, 250.21 [M + H]<sup>+</sup> + 4. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.27 (d, <i>J</i> = 1.5 Hz, 1H), 7.04 (d, <i>J</i> = 1.4 Hz, 1H), 3.95 (s, 3H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-Bromo-2-chloro-6-methoxybenzamide</h3><div class="NLM_p last">4-bromo-2-chloro-6-methoxybenzamide was synthesized according to the procedure described for <b>5d</b> from 4-bromo-2-chloro-6-methoxybenzonitrile (219 mg, 0.889 mmol). The solution was stirred at 90 °C for 6 h. The crude was diluted with water (50 mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give the final product (219 mg, 77% yield). MS (ESI) <i>m</i>/<i>z</i>: 264.25 [M + H]<sup>+</sup>, 266.26 [M + H]<sup>+</sup> + 2, 268.20 [M + H]<sup>+</sup> + 4. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.20 (d, <i>J</i> = 1.4 Hz, 1H), 6.99 (d, <i>J</i> = 1.3 Hz, 1H), 5.93 (br s, 1H), 5.72 (br s, 1H), 3.85 (s, 3H).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 2-Chloro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (<b>19e</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>4a</b> from 4-bromo-2-chloro-6-methoxybenzamide (100 mg, 0.378 mmol). The dark supernatant was used without purification in the subsequent reaction (113 mg, 36% yield). MS (ESI) <i>m</i>/<i>z</i>: 312.46 [M + H]<sup>+</sup>, 314.41 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 5-(4-Methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)isoindolin-1-one (<b>20a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>15</b> (75 mg, 0.193 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (<b>19a</b>) (50 mg, 0.193 mmol). The final product was a white powder (33 mg, 44% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.62 (br s, 1H), 8.37 (s, 1H), 8.34 (s, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.65 (s, 1H), 7.54 (d, <i>J</i> = 7.7 Hz, 1H), 7.31 (d, <i>J</i> = 8.7 Hz, 2H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 4.44 (s, 2H), 3.19–3.16 (m, 4H), 2.94–2.90 (m, 4H), 2.15 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 385.2023; found, 385.2018.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-(4-Methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>20b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>15</b> (19 mg, 0.048 mmol) and 4-aminocarbonylphenylboronic acid (<b>19b</b>) (8 mg, 0.048 mmol). The final product was a light pink-orange powder (8 mg, 45% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.36 (s, 1H), 8.33 (s, 1H), 8.06 (br s, 1H), 7.98 (d, <i>J</i> = 8.3 Hz, 2H), 7.53 (d, <i>J</i> = 8.2 Hz, 2H), 7.42 (br s, 1H), 7.31 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 3.23–3.19 (m, 4H), 3.02–2.92 (m, 4H), 2.15 (s, 3H). HRMS (ESI) for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 373.2023; found, 373.2014.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 2-(Methoxymethyl)-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>20c</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>15</b> (73 mg, 0.188 mmol) and <b>19c</b> (60 mg, 0.205 mmol). The final compound was an off-white powder (23 mg, 29% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.45 (s, 1H), 8.37 (s, 1H), 7.93 (d, <i>J</i> = 7.9 Hz, 1H), 7.44 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 7.40 (d, <i>J</i> = 1.4 Hz, 1H), 7.28–7.26 (m, 2H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 5.74 (br s, 1H), 4.65 (s, 2H), 3.46 (s, 3H), 3.26–3.22 (m, 4H), 3.10–3.06 (m, 4H), 2.17 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 417.2285; found, 417.2283.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 2-Fluoro-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>20d</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>15</b> (100 mg, 0.258 mmol) and 4-carbamoyl-3-fluorophenylboronic acid (<b>19d</b>) (47 mg, 0.258 mmol). The final compound was a white powder (50 mg, 50% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.37 (s, 1H), 8.32 (s, 1H), 7.96 (t, <i>J</i> = 8.0 Hz, 1H), 7.38–7.30 (m, 4H), 7.11 (d, <i>J</i> = 8.7 Hz, 2H), 3.29–3.23 (m, 4H), 3.08–3.02 (m, 4H), 2.24 (s, 3H). <sup>19</sup>F NMR (471 MHz, MeOD): δ −114.60. HRMS (ESI) for C<sub>23</sub>H<sub>23</sub>FN<sub>4</sub>O [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 391.1929; found, 391.1926.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2-Chloro-6-methoxy-4-(4-methyl-5-(4-(piperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>20e</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>6a</b> from <b>3</b> (66 mg, 0.153 mmol) and <b>19e</b> (59 mg, 0.189 mmol). The material was deprotected with trifluoroacetic acid (350 μL, 4.579 mmol) and purified by SPE. Freeze-drying for a day and a half afforded an off-white powder (24 mg, 36% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.45 (s, 1H), 8.31 (s, 1H), 7.26–7.24 (m, 2H), 7.03 (d, <i>J</i> = 1.1 Hz, 1H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 6.81 (d, <i>J</i> = 1.0 Hz, 1H), 5.94–5.87 (br m, 2H), 3.89 (s, 3H), 3.26–3.22 (m, 4H), 3.10–3.06 (m, 4H), 2.18 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 437.1739; found, 437.1740.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 4-Bromo-2-fluoro-6-methoxybenzonitrile (<b>22a</b>) and 4-Bromo-2,6-dimethoxybenzonitrile (<b>22b</b>)</h3><div class="NLM_p last">The title compounds were prepared according to the procedure described for 4-bromo-2-chloro-6-methoxybenzonitrile from 4-bromo-2,6-difluorobenzonitrile (<b>21</b>) (2.00 g, 9.17 mmol), MeOH (744 μL, 18.34 mmol) and sodium hydride, 60% in mineral oil (0.733 g, 18.34 mmol). 4-Bromo-2-fluoro-6-methoxybenzonitrile was a white crystalline solid (965 mg, 46% yield). 4-Bromo-2,6-dimethoxybenzonitrile was also a white crystalline solid (754 mg, 34% yield). 4-Bromo-2-fluoro-6-methoxybenzonitrile: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.00 (d, <i>J</i> = 8.0 Hz, 1H), 6.94 (s, 1H), 3.95 (s, 3H). <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ −103.78 (s). MS (ESI) <i>m</i>/<i>z</i>: 230.21 [M + H]<sup>+</sup>, 232.21 [M + H]<sup>+</sup> + 2. 4-Bromo-2,6-dimethoxybenzonitrile: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.73 (s, 2H), 3.91 (s, 6H). MS (ESI) <i>m</i>/<i>z</i>: 242.25 [M + H]<sup>+</sup>, 244.19 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (4-Carbamoyl-3-fluoro-5-methoxyphenyl)boronic Acid (<b>23a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>4a</b> from <b>5d</b> (2.48 g, 10.0 mmol). The dark brown supernatant was used without further purification in subsequent reactions (2.46 g, 84% yield). MS (ESI) <i>m</i>/<i>z</i>: 214.34 [M + H]<sup>+</sup>.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2,6-Dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (<b>23b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>4a</b> from <b>5e</b> (800 mg, 3.08 mmol). The dark brown supernatant was used without further purification in subsequent reactions (945 mg, 70% yield). MS (ESI) <i>m</i>/<i>z</i>: 308.26 [M + H]<sup>+</sup>.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-(5-Chloro-4-methylpyridin-3-yl)-2-fluoro-6-methoxybenzamide (<b>24a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>6a</b> from <b>10</b> (2.06 g, 10.0 mmol) and <b>23a</b> (2.95 g, 10.0 mmol). The final compound was an off-white crystalline solid (1.67 g, 56% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.63 (s, 1H), 8.38 (s, 1H), 7.90 (br s, 1H), 7.60 (br s, 1H), 6.97–6.94 (m, 2H), 3.83 (s, 3H), 2.33 (s, 3H). <sup>19</sup>F NMR (471 MHz, DMSO): δ −116.46. MS (ESI) <i>m</i>/<i>z</i>: 294.97 [M + H]<sup>+</sup>, 297.10 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-(5-Chloro-4-methylpyridin-3-yl)-2,6-dimethoxybenzamide (<b>24b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>6a</b> from <b>10</b> (954 mg, 4.62 mmol) and <b>23b</b> (946 mg, 3.08 mmol). The final compound was an off-white crystalline solid (747 mg, 79% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.61 (s, 1H), 8.38 (s, 1H), 7.58 (br s, 1H), 7.26 (br s, 1H), 6.70 (s, 2H), 3.77 (s, 6H), 2.34 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 307.26 [M + H]<sup>+</sup>.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (2<i>R</i>,6<i>S</i>)-4-(4-Bromophenyl)-1,2,6-trimethylpiperazine</h3><div class="NLM_p last">The title compound was prepared using modified literature procedures.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> A solution of (2<i>R</i>,6<i>S</i>)-1,2,6-trimethylpiperazine (100 mg, 0.780 mmol), 1-bromo-4-iodobenzene (221 mg, 0.780 mmol), bis(dibenzylideneacetone)palladium(0) (22 mg, 0.039 mmol), xantphos (68 mg, 0.117 mmol), and lithium <i>tert</i>-butoxide 1.0 M in THF (2.34 mL, 2.340 mmol) in 1,4-dioxane (3.12 mL) was heated to 110 °C and stirred overnight. Volatiles were removed under reduced pressure, and the crude material was purified by silica gel chromatography (0–10% MeOH in EtOAc). <sup>1</sup>H NMR (500 MHz, MeOD): δ 7.32 (d, <i>J</i> = 9.0 Hz, 2H), 6.87 (d, <i>J</i> = 9.0 Hz, 2H), 3.55–3.49 (m, <i>J</i> = 11.5 Hz, 2H), 2.52–2.46 (m, <i>J</i> = 11.4 Hz, 2H), 2.44–2.38 (m, 2H), 2.33 (s, 3H), 1.19 (d, <i>J</i> = 6.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 283.37 [M + H]<sup>+</sup>, 285.32 [M + H]<sup>+</sup> + 2.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (2<i>R</i>,6<i>S</i>)-1,2,6-Trimethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (<b>25c</b>)</h3><div class="NLM_p last">The title compound was prepared according to the procedure described for <b>4a</b> from (2<i>R</i>,6<i>S</i>)-4-(4-bromophenyl)-1,2,6-trimethylpiperazine (100 mg, 0.353 mmol). The dark brown reaction mixture was used without purification in subsequent reactions (117 mg, 91% yield). MS (ESI) <i>m</i>/<i>z</i>: 331.46 [M + H]<sup>+</sup>.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-Fluoro-6-methoxy-4-(4-methyl-5-(4-(4-methylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>26a</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>8a</b> from <b>24a</b> (150 mg, 0.509 mmol) and 4-(4-methylpiperazin-1-yl)phenylboronic acid (<b>25a</b>) (134 mg, 0.611 mmol). XPhos Pd G3 (21.54 mg, 0.025 mmol) was used as the catalyst. The reaction mixture was adsorbed onto Celite, and the solvents were removed under reduced pressure. The crude material was purified by silica gel chromatography (0–15% MeOH in EtOAc). Freeze-drying for 1 day afforded white powder (183 mg, 83% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.37 (s, 1H), 8.34 (s, 1H), 7.89 (br s, 1H), 7.58 (br s, 1H), 7.30 (d, <i>J</i> = 8.7 Hz, 2H), 7.05 (d, <i>J</i> = 8.8 Hz, 2H), 6.98–6.94 (m, 2H), 3.85 (s, 3H), 3.23–3.19 (m, 4H), 2.48–2.45 (m, 4H), 2.23 (s, 3H), 2.19 (s, 3H). <sup>19</sup>F NMR (471 MHz, DMSO): δ −116.74. HRMS (ESI) for C<sub>25</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 435.2191; found, 435.2191.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-Fluoro-4-(5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-6-methoxybenzamide (<b>26b</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>26a</b> from <b>24a</b> (150 mg, 0.509 mmol) and 4-(4-isopropylpiperazinyl)phenylboronic acid, pinacol ester (<b>25b</b>) (202 mg, 0.611 mmol). The final compound was white powder (142 mg, 60% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.38 (s, 1H), 8.34 (s, 1H), 7.89 (br s, 1H), 7.58 (br s, 1H), 7.30 (d, <i>J</i> = 8.7 Hz, 2H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 6.98–6.95 (m, 2H), 3.85 (s, 3H), 3.23–3.17 (m, 4H), 2.72–2.66 (m, 1H), 2.63–2.57 (m, 4H), 2.19 (s, 3H), 1.02 (d, <i>J</i> = 6.5 Hz, 6H). <sup>19</sup>F NMR (471 MHz, DMSO): δ −116.74. HRMS (ESI) for C<sub>27</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 463.2504; found, 463.2506.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 2-Fluoro-6-methoxy-4-(4-methyl-5-(4-((3<i>R</i>,5<i>S</i>)-3,4,5-trimethylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>26c</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>26a</b> from <b>24a</b> (156 mg, 0.531 mmol) and (2<i>R</i>,6<i>S</i>)-1,2,6-trimethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (<b>25c</b>) (58.5 mg, 0.177 mmol). The final compound was light yellow powder (36 mg, 43% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.43 (s, 1H), 8.30 (s, 1H), 7.24 (d, <i>J</i> = 8.6 Hz, 2H), 6.99 (d, <i>J</i> = 8.6 Hz, 2H), 6.77 (dd, <i>J</i> = 9.7, 0.5 Hz, 1H), 6.71 (s, 1H), 6.32 (br s, 1H), 6.09 (br s, 1H), 3.91 (s, 3H), 3.57 (d, <i>J</i> = 11.5 Hz, 2H), 2.86–2.67 (m, 2H), 2.60–2.45 (m, 2H), 2.40 (s, 3H), 2.16 (s, 3H), 1.26 (d, <i>J</i> = 5.8 Hz, 6H). <sup>19</sup>F NMR (471 MHz, MeOD): δ −117.13. HRMS (ESI) for C<sub>27</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 463.2504; found, 463.2510.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2,6-Dimethoxy-4-(4-methyl-5-(4-(4-methylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>26d</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>26a</b> from <b>24b</b> (150 mg, 0.489 mmol) and <b>25a</b> (129 mg, 0.587 mmol). The final compound was white powder (189 mg, 87% yield). <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.35 (s, 1H), 8.35 (s, 1H), 7.57 (br s, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.23 (br s, 1H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 6.72 (s, 2H), 3.78 (s, 6H), 3.23–3.19 (m, 4H), 2.48–2.46 (m, 4H), 2.24 (s, 3H), 2.20 (s, 3H). HRMS (ESI) for C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 477.2391; found, 447.2394.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 4-(5-(4-(4-Isopropylpiperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-2,6-dimethoxybenzamide (<b>26e</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>26a</b> from <b>24b</b> (150 mg, 0.489 mmol) and <b>25b</b> (194 mg, 0.587 mmol). The final compound was an off-white powder (179 mg, 75% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.31 (s, 1H), 8.30 (s, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.13 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (s, 2H), 3.86 (s, 6H), 3.47–3.36 (m, 4H), 3.15–3.01 (m, 5H), 2.22 (s, 3H), 1.27 (d, <i>J</i> = 6.6 Hz, 6H). HRMS (ESI) for C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 475.2704; found, 475.2705.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2,6-Dimethoxy-4-(4-methyl-5-(4-((3<i>R</i>,5<i>S</i>)-3,4,5-trimethylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide (<b>26f</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the procedure described for <b>26a</b> from <b>24b</b> (109 mg, 0.354 mmol) and <b>25c</b> (58 mg, 0.177 mmol). The final compound was white powder (22 mg, 26% yield). <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.31 (s, 1H), 8.29 (s, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 2H), 7.09 (d, <i>J</i> = 8.5 Hz, 2H), 6.69 (s, 2H), 3.86 (s, 6H), 3.65 (d, <i>J</i> = 11.8 Hz, 2H), 2.62–2.55 (m, 2H), 2.51–2.44 (m, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 2.16 (s, 2H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H). HRMS (ESI) for C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 475.2704; found, 475.2699.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Kinase Assay</h3><div class="NLM_p last">The biochemical potencies of all compounds were measured by Reaction Biology Corporation (RBC) (Malvern, Pennsylvania, United States). Compounds were tested against ALK2/ACVR1 and ALK5/TGFβ-R1 in a 10-dose IC<sub>50</sub> mode with a 2-fold serial dilution starting at 1 or 5 μM. Reactions were conducted at an ATP concentration of 10 μM and Casein concentration of 1 mg/mL. <b>LDN-193189</b> was tested as a control in a 10-dose IC<sub>50</sub> mode with a threefold serial dilution starting at 10 μM. Reductions in enzymatic activity were determined relative to DMSO controls.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Cell Culture and Transfection</h3><div class="NLM_p last">HEK-293 cells were maintained in Dulbecco’s modified Eagle medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher) and penicillin/streptomycin (Thermo Fisher). HEK-293 cells were transfected with the protein expression or reporter constructs using FuGENE HD (Promega) according to the manufacturer’s instructions. Briefly, DNA was diluted into phenol red-free Opti-MEM (Gibco) at a concentration of 10 μg/mL. Without coming in contact with the sides of the container, 3 μL of FuGENE HD was added for each μg of DNA used. After thorough mixing by inversion, FuGENE HD/DNA complexes were allowed to form by incubation at room temperature for 20 min. Transfection mixture (1 part) was added to 20 parts of HEK-293 cell suspension with a density of 200,000 cells per mL (volume/volume). HEK-293 cells were incubated in a humidified, 37 °C incubator with 5% carbon dioxide for 24 h before they are used in the NanoBRET target engagement assay or dual luciferase reporter assay.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> NanoBRET Target Engagement Assay</h3><div class="NLM_p last">ALK2-C-terminal nanoluciferase fusion with the GSSG linker was encoded by the pFC32K vector (Promega). ALK2-nanoluciferase fusion construct (1 part) was mixed with 9 parts of Transfection Carrier DNA (mass/mass) (Promega). Transfected cells were trypsinized and resuspended in Opti-MEM at a density of 200,000 cells per mL. Cells (17 μL) were dispensed into each well of 384-well flat-bottom polypropylene plate (Greiner). Working solution (20×) of target engagement tracer PBI-6908 (Promega) was prepared by diluting DMSO stock in tracer dilution buffer (12.5 mM HEPES pH 7.5, 31.25% PEG-400). Stocks (1000×) of test compounds in DMSO (Cell Signaling Technology) were diluted further in Opti-MEM for 10× working solutions. After the addition of 1 μL of 20× target engagement tracer and 2 μL of 10× working solutions, contents of the wells were thoroughly mixed by agitating the plate at 500 rpm for 1 min. Cells were incubated in a humidified, 37 °C incubator with 5% carbon dioxide for 2 h prior to BRET measurement. For bioluminiscence resonance energy transfer (BRET) measurement, the NanoBRET NanoGlo Substrate and Extracellular NanoLuc Inhibitor (Promega) were diluted 166× and 500×, respectively, in Opti-MEM to produce 3× working stock. A PHERAstar FSX microplate reader (BMG Labtech) with the LUM 610-LP 460-80 optical module was used to measure the intensity of dual emission. A measurement interval of 1 s and gain settings of 3600 and 1879 for 610 and 460 nm, respectively, were used. Milli-BRET units (mBU) were calculated by dividing the signal measured at 610 nm with the signal measured at 460 nm and multiplying by 1000. The apparent EC<sub>50</sub> values of test compounds were estimated using the [Inhibitor] <i>versus</i> response (three parameters) nonlinear regression curve fitting function of GraphPad Prism 7.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Dual Luciferase Reporter Assay</h3><div class="NLM_p last">CAGA-Luc and Renilla-luciferase constructs (a gift of Dr Petra Knaus, Free University of Berlin) were used as the reporter for ALK5 signaling and loading control, respectively. CAGA-Luc construct (4 parts) was mixed with 1 part of Renilla-luciferase construct (mass/mass). Ten thousand transfected cells were seeded into each well of 96-well plate (Corning). Twenty four hours after transfection, the cells were incubated with 10 ng/mL TGF-β1 (Peprotech, 100-21-10) and test compounds simultaneously at the concentrations indicated in a humidified, 37 °C incubator with 5% carbon dioxide. Twenty-four hours later, the cells were harvested, lysed, and processed for the measurement of luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s instructions. Briefly, the culture medium was aspirated completely, and cells were lysed in 50 μL of 1× PLB with 300 rpm agitation for 30 min. Cell lysate (10 μL) was dispensed into each well of a 384-well flat-bottom polypropylene plate (Greiner). The luminescent signal of firefly and Renilla luciferase activity were measured sequentially using a PHERAstar FS microplate reader (BMG Labtech) after the addition of 25 μL of LARII and Stop & Glo, respectively. A measurement interval of 2 s and gain setting of 3600 were used. The firefly luciferase signal was normalized to the cell number by division with Renilla luciferase signal. The relative luciferase unit (RLU) was obtained by further division with the signal from cells without TGF-β stimulation. The apparent EC50 values of test compounds were estimated using the [Inhibitor] <i>versus</i> response (three parameters) nonlinear regression curve fitting function of GraphPad Prism 7.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Caco-2 Permeability Assay</h3><div class="NLM_p">Caco-2 cells (C2BBe1) were purchased from American Type Culture Collection, ATCC. Caco-2 cell cultures were routinely maintained in T-75 tissue culture flasks in DMEM containing 20% FBS, 0.1 mg/mL normocin, and 0.05 mg/mL gentamicin. These cells were seeded at a density of 40,000 cells/well on the 24-well polyethylene terephthalate (PET) membrane (1.0 μm pore size, 0.31 cm<sup>2</sup> surface area) insert plates. Cell monolayers were grown for 21 or 22 days at 37 °C with 5% CO<sub>2</sub> in a humidified incubator. The cell culture medium was replaced twice weekly during the cell growth period. Prior to beginning the permeability assay, cell monolayers were rinsed with Hank’s balanced salt solution (HBSS) twice to remove the residual cell culture medium.</div><div class="NLM_p">The assay buffer comprised HBSS containing 10 mM HEPES and 15 mM glucose at a pH of 7.4. The dosing buffer contained 5 μM metoprolol (positive control), 5 μM atenolol (negative control), and 100 μM Lucifer yellow in the assay buffer. The receiving buffer contained 1% bovine serum albumin (BSA) in the assay buffer. The concentration of the test compound was 5 μM in the dosing buffer (final DMSO concentration was 0.1%). Digoxin at 10 μM was utilized as a Pgp substrate control.</div><div class="NLM_p">For apical to basolateral (A to B) permeability experiment, 0.25 mL of the dosing buffer was added to the apical chambers, and 1.0 mL of the receiving buffer was added to the basolateral chambers of the assay plate. For the basolateral to apical (B to A) permeability experiment, 0.25 mL of the receiving buffer was added to the apical chambers, and 1.0 mL of dosing buffer was added to the basolateral chambers of the assay plates. The assay plates were then incubated at 37 °C for 120 min on an orbital shaker at 65 rpm. Sample solutions were taken from the donor chambers (10 μL) and receiver chambers (100 μL) after the incubation period. For each sample, there were two technical replicates. The sample solutions from donor chambers were diluted ten times with the receiving buffer. In order to extract test compounds and precipitate BSA from sample solutions, three volumes of acetonitrile (containing 0.5% formic acid and an internal standard) were added, and the plate was vigorously mixed. Sample solutions were then centrifuged at 4000 rpm for 10 min to remove debris and precipitated BSA. Approximately, 150 μL of the supernatant was subsequently transferred to a new 96-well microplate for LC/MS analysis. Narrow-window mass extraction LC/MS analysis was performed for all samples from this study using a Waters Xevo quadrupole time-of-flight (QTof) mass spectrometer to determine relative peak areas of parent compounds. The co-dosed positive and negative controls were also measured for each well to monitor integrity of cell monolayers and well-to-well variability. The apparent permeability coefficient (<i>P</i><sub>app</sub>) and post-assay recovery are calculated using the following equations<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_m001.gif" alt="" id="_i73" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_m002.gif" alt="" id="_i74" /></img></span>where d<i>C</i>/d<i>t</i> is the slope of cumulative concentration in the receiver compartment <i>versus</i> time, <i>V</i><sub>r</sub> is the volume of the receiver compartment, <i>V</i><sub>d</sub> is the volume of the donor compartment, <i>A</i> is the membrane surface area, <i>C</i><sub>0</sub> is the compound initial concentration in the donor chamber, <i>C</i><sub class="stack">r</sub><sup class="stack">final</sup> is the cumulative receiver concentration at the end of the incubation period, and <i>C</i><sub class="stack">d</sub><sup class="stack">final</sup> is the concentration of the donor at the end of the incubation period.</div><div class="NLM_p last">Efflux ratio (ER) is defined as <i>P</i><sub>app</sub> (B-to-A)/<i>P</i><sub>app</sub> (A-to-B).</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Liver Microsomal Metabolic Stability Assay</h3><div class="NLM_p">For this assay, stock solutions of test compounds in DMSO (1 mM) were initially diluted to a concentration of 40.0 μM using 0.1 M potassium phosphate buffer (pH 7.4). Test compounds were then added to reaction wells at a final concentration of 1 μM which was assumed to be well below <i>K</i><sub>m</sub> values to ensure linear reaction conditions (<i>i.e.,</i> avoid saturation). The final DMSO concentration was kept constant at 0.1%. Each compound was tested in duplicate for both time points (0 and 60 min). CD-1 mouse (male) or pooled human liver microsomes (Corning Gentest) were added to the reaction wells at a final concentration of 0.5 mg/mL (protein). The final volume for each reaction was 100 μL, which included the NADPH-regeneration solution (NRS) mix (Corning Gentest). This NRS mix comprised glucose 6-phosphate dehydrogenase, NADP<sup>+</sup>, MgCl<sub>2</sub>, and glucose 6-phosphate. Reactions were carried out at 37 °C in an orbital shaker at 175 rpm. Upon completion of the 60 min time point, reactions were terminated by the addition of two volumes (200 μL) of ice-cold acetonitrile containing 0.5% formic acid and an internal standard. Samples were then centrifuged at 4000 rpm for 10 min to remove debris and precipitated proteins. Approximately, 150 μL of supernatant was subsequently transferred to a new 96-well microplate for LC/MS analysis.</div><div class="NLM_p last">Narrow-window mass extraction LC/MS analysis was performed for all samples in this study using a Waters Xevo quadrupole time-of-flight (QTof) mass spectrometer to determine relative peak areas of test compounds. The percentage remaining values were calculated using the following equations<span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_m003.gif" alt="" id="_i76" /></img></span>where <i>A</i> is area response after incubation, <i>A</i><sub>0</sub> is area response at initial time point.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> hERG Inhibition Assay</h3><div class="NLM_p">hERG IC<sub>50</sub> values were generated by Charles River Laboratories (Cleveland, Ohio, United States). Their protocol is described below:</div><div class="NLM_p last">Compounds were tested against cloned hERG potassium channels expressed in HEK293 cells. Chemicals used in solution preparation were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted and were of ACS reagent-grade purity or higher. Stock solutions of test articles and the positive control were prepared in dimethyl sulfoxide (DMSO) and stored frozen. Reference compound concentrations were prepared fresh daily by diluting stock solutions into a Charles River proprietary HEPES-buffered physiological saline (HB-PS) solution which was prepared weekly and refrigerated until use. Because previous results have shown that ≤0.3% DMSO did not affect channels currents, all test and control solutions contained 0.3% DMSO. Each test article formulation was sonicated (model 2510/5510, Branson Ultrasonics, Danbury, CT) at ambient room temperature for 20 min to facilitate dissolution. Cells were cultured in DMEM/nutrient mixture F-12 (D-MEM/F-12) supplemented with 10% FBS, 100 U/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and 500 μg/mL G418. Before testing, cells in culture dishes were washed twice with HBSS and detached with accutase. Immediately before use in the IonWorks Barracuda system, the cells were washed twice in HB-PS to remove the accutase and resuspended in 5 mL of HB-PS. The test article effects were evaluated using IonWorks Barracuda systems (Molecular Devices Corporation, Union City, CA). HEPES-buffered intracellular solution (Charles River proprietary) for whole cell recordings was loaded into the intracellular compartment of the Population Patch Clamp (PPC) planar electrode. Extracellular buffer (HB-PS) was loaded into PPC planar electrode plate wells (11 μL per well). The cell suspension was pipetted into the wells of the PPC planar electrode (9 μL per well). After establishment of a whole-cell configuration (the perforated patch), membrane currents were recorded using a patch clamp amplifier in the IonWorks Barracuda system. The current recordings were performed one (1) time before test article application to the cells (baseline) and one (1) time after application of the test article. Test article concentrations were applied to naïve cells (<i>n</i> = 4, where <i>n</i> = replicates/concentration). Each application consisted of addition of 20 μL of 2× concentrated test article solution to the total 40 μL of final volume of the extracellular well of the PPC plate. The duration of exposure to each compound concentration was five (5) minutes. The hERG current was measured using a pulse pattern with fixed amplitudes (conditioning pre-pulse: −80 mV for 25 ms; test pulse: +40 mV for 80 ms) from a holding potential of 0 mV (“zero holding” procedure). The hERG current was measured as a difference between the peak current at 1 ms after the test step to +40 mV and the steady-state current at the end of the step to +40 mV.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> CYP Inhibition Assay</h3><div class="NLM_p">CYP IC<sub>50</sub> values were generated by Pharmaron. Their protocol is described below:</div><div class="NLM_p last">Multiple concentrations (1 μL) of the test compound or positive control compound (CYP1A2: furafylline, CYP2B6: ketoconazole, CYP2C8: quercetin, CYP2C9: sulfaphenazole, CYP2C19: N-3-benzylnirvanol, CYP2D6: quinidine, and CYP3A4: ketoconazole) were transferred to the “Compound Plate”. The concentrations of test compounds and positive control compounds were 0, 0.2, 1, 2, 10, 50, 200, 2000, and 10,000 μM. The master solution was prepared with MgCl<sub>2</sub> solution (20 μL of 50 mM solution), phosphate buffer (100 μL of 200 mM solution), ultrapure water (56 μL), human liver microsomes [2 μL of 20 mg/mL stock concentration (Corning UltraPool HLM 150, Mixed Gender Cat. no.: 452117)], and 1 μL of substrate [CYP1A2: phenacetin (8 mM stock concentration), CYP2B6: bupropion (10 mM stock concentration), CYP2C8: paclitaxel (1 mM stock concentration), CYP2C9: tolbutamide (40 mM stock concentration), CYP2C19: mephenytoin (10 mM stock concentration), CYP2D6: dextromethorphan (2 mM stock concentration) and CYP3A4: midazolam (1 mM stock concentration), and testosterone (10 mM stock concentration)]. The master solution was prewarmed in a water bath at 37 °C for 5 min. The incubated master solution (179 μL) was transferred to the compound plate. In the mixed system, the final concentrations of the test compounds and positive control compounds were 0, 0.001, 0.005, 0.01, 0.05, 0.25, 1, 10, and 50 μM. All experiments were performed in duplicate. The reaction was started with the addition of 20 μL of 10 mM NADPH solution at the final concentration of 1 mM. The reaction was stopped by the addition of 1.5 volumes of methanol with IS (100 nM alprazolam, 200 nM imipramine, 200 nM labetalol, and 2 μM ketoprofen) to the “Incubation Plate” at the designated time points (20 min for CYP1A2, 2B6, 2C9, 2C19, and 2D6, 5 min for midazolam-mediated 3A4, and 10 min for testosterone-mediated 3A4). The “Incubation Plate” was centrifuged at 3220 g for 40 min to precipitate the protein. An aliquot of 100 μL of the supernatant was diluted using 100 μL ultrapure H<sub>2</sub>O, and the mixture was used for LC/MS/MS analysis. The formation of metabolites was analyzed using LC/MS/MS. A decrease in the formation of the metabolites in the peak area to vehicle control was used to calculate an IC<sub>50</sub> value (test compound concentration which produces 50% inhibition) using Excel XLfit.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>In Vivo</i> Pharmacokinetic Studies</h3><div class="NLM_p">The pharmacokinetic profiles of <b>8b</b>, <b>26a</b>, and <b>26b</b> were assessed by Pharmaron. Their protocol is described below:</div><div class="NLM_p">Test compounds were dissolved first in DMSO, then mixed with 47.5% PEG400 and 47.5% DI water with 10% Tween80. The solutions were thoroughly vortexed after each step and stored at room temperature. Solutions were freshly prepared on the day of dosing. Female CB17 SCID mice (<i>n</i> = 3) (6–8 weeks old, 17–20 g weight) were orally administered a 10 mg/kg dose (10 mL/kg dose volume, 1 mg/mL concentration) of the test compound. Blood samples were taken <i>via</i> the dorsal metatarsal vein at 0.25, 0.5, 1, 2, 4, 8, and 24 h post-dosage. Blood samples were transferred into plastic microcentrifuge tubes containing the anticoagulant Heparin-Na and centrifuged at 4000 g for 5 min at 4 °C to obtain plasma. The samples were stored in a freezer at −75 ± 15 °C prior to analysis.</div><div class="NLM_p">To determine brain concentrations, female CB17 SCID mice (<i>n</i> = 3) (6–8 weeks old, 17–20 g weight) were orally administered a 100 mg/kg dose (10 mL/kg dose volume, 10 mg/mL concentration) of the test compound. 4 h post-dose, the animals were terminally anaesthetized by an increasing concentration of CO<sub>2</sub>. Their chest cavities were opened to expose the heart and an incision at the right auricle using surgical scissors was done. A syringe full of gentle saline was pushed into the heart slowly <i>via</i> the left ventricle (saline volume: ∼10 mL). The animal was placed head down at a 45° angle to facilitate blood removal. Brain samples were collected and kept frozen at −75 ± 15 °C. All brain samples were weighed and homogenized with phosphate buffered saline by brain weight (g) to buffer volume (mL) ratio 1:3 before analysis. The actual concentrations were the detected value multiplied using the dilution factor.</div><div class="NLM_p">Concentrations of the test compound in the plasma samples were analyzed using a LC/MS/MS method. WinNonlin (Phoenix, version 8.0) or other similar software was used for pharmacokinetic calculations. The following pharmacokinetic parameters were calculated, whenever possible from the plasma concentration <i>versus</i> time data:</div><div class="NLM_p">PO administration: <i>T</i><sub>1/2</sub>, <i>C</i><sub>max</sub>, <i>T</i><sub>max</sub>, AUC<sub>last</sub>, AUC<sub>inf</sub>, and <i>F</i>.</div><div class="NLM_p last">All animal procedures were in accordance with the regulations of Institutional Animal Care and Use Committee (IACUC) at Pharmaron Inc.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Cocrystallization of ALK2 with <b>M4K2149</b></h3><div id="sec4_61_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Protein Expression and Purification</h4><div class="NLM_p last">Constructs were prepared by ligation-independent cloning. The kinase domain of ALK2 (residues 201–499; Uniprot ID, <a href="https://Q04771" class="ext-link">Q04771</a>) was cloned into pFB-LIC-Bse for the baculoviral expression. The construct was verified by sequencing. ALK2 was expressed in Sf9 insect cells grown at 27 °C. Some 72 h postinfection, cells were harvested and lysed using ultrasonication. ALK2 was initially purified by nickel affinity chromatography before subsequent purification by size exclusion chromatography (Superdex 200 16/600). The eluted protein was stored in 50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM DTT. The hexahistidine tag of ALK2 was cleaved using tobacco etch virus protease after initial nickel purification.</div></div><div id="sec4_61_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Crystallization</h4><div class="NLM_p last">Crystallization was achieved at 4 °C using the sitting-drop vapor diffusion method. ALK2 was preincubated with 1 mM <b>M4K2149</b> at a protein concentration of 11 mg/mL and crystallized using a precipitant containing 0.1 M citrate pH 4.9, 1 M ammonium sulfate, and 0.2 M sodium/potassium tartrate. Viable crystals were obtained when the protein solution was mixed with the reservoir solution at 2:1 volume ratio. Crystals were cryoprotected with mother liquor plus 25% ethylene glycol, prior to vitrification in liquid nitrogen.</div></div><div id="sec4_61_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Data Collection</h4><div class="NLM_p last">Diffraction data were collected at the Diamond Light Source, station I03 using monochromatic radiation at a wavelength 0.9763 Å.</div></div><div id="sec4_61_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Phasing, Model Building, Refinement, and Validation</h4><div class="NLM_p">Data were processed with Xia2 and subsequently scaled using the program AIMLESS from the CCP4 suite.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Initial phases were obtained by molecular replacement using the program PHASER and the structure of ALK2 (Protein Data Bank code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SRH">6SRH</a>) as a search model.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The resulting structure solution was refined using Phenix Refine and manually rebuilt with COOT.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The complete structure was verified for geometric correctness with MolProbity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Data collection and refinement statistics can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">Supporting Information</a> Table 1.</div><div class="NLM_p last">Cocrystal images in the article were processed using Molsoft MolBrowser 3.8.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00395" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00395?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00395</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H and <sup>19</sup>F NMR spectra of select compounds, crystallization methods, Caco-2 and HLM and MLM data, CYP and hERG inhibition data, and kinase selectivity panel (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf">jm0c00395_si_001.pdf (1.46 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_002.csv">jm0c00395_si_002.csv (1.61 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: ALK2-<b>M4K2149</b>, 6T6D; ALK2-<b>LDN-213844</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00395" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rima Al-awar</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, University
of Toronto, Medical Sciences Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4185-055X" title="Orcid link">http://orcid.org/0000-0002-4185-055X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c193a8aca0ef80ada0b6a0b381aea8a2b3efaeafefa2a0"><span class="__cf_email__" data-cfemail="7e2c17131f503f121f091f0c3e11171d0c501110501d1f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deeba Ensan</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, University
of Toronto, Medical Sciences Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3251-1521" title="Orcid link">http://orcid.org/0000-0002-3251-1521</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Smil</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6232-6087" title="Orcid link">http://orcid.org/0000-0002-6232-6087</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos A. Zepeda-Velázquez</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8130-2232" title="Orcid link">http://orcid.org/0000-0002-8130-2232</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dimitrios Panagopoulos</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre,
South Tower, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jong Fu Wong</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eleanor P. Williams</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roslin Adamson</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alex N. Bullock</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taira Kiyota</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed Aman</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Leslie Dan
Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Owen G. Roberts</span> - <span class="hlFld-Affiliation affiliation">M4K
Pharma Inc., 101 College
Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aled M. Edwards</span> - <span class="hlFld-Affiliation affiliation">M4K
Pharma Inc., 101 College
Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre,
South Tower, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff A. O’Meara</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span>Present Address:
                        Dalriada Therapeutics Inc., 3252 Respond Road, Mississauga, Ontario L5M 7X4, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Methvin B. Isaac</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Analogues were synthesized by D.E., D.S., and D.P. The compounds were designed and their syntheses devised by D.S., M.B.I., C.A.Z.-V., and D.E. All NanoBRET data was generated by J.F.W. and A.H. Crystallography experiments were performed by E.P.W. and R.A. Caco-2 and microsomal stability studies were conducted by T.K. HRMS were also generated by T.K. A.N.B., A.A., J.A.O., M.B.I., and R.A.-a. were involved in the experimental design, the interpretation of data, and they monitored project progress. O.G.R. and A.M.E. initiated the project and edited the paper. The manuscript was written by D.E. and revised by D.S., C.A.Z.-V., M.B.I., and R.A.-a.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded by the Cancer Therapeutics Innovation Pipeline program at the Ontario Institute for Cancer Research (OICR). The OICR is funded by the Government of Ontario. Funding from The Brain Tumour Charity was used to support the cellular and crystallographic research conducted at the University of Oxford. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. We thank Reaction Biology Corporation for their pro bono contributions in testing the biological activity of our compounds. D.P. is grateful to NSERC for the Collaborative Research and Training Experience 432008-2013 grant. We would like to thank Dr. Gennady Poda for generating the Oracle database where the compound data were stored and for providing his expertise on molecular modeling. We would also like to thank Mehakpreet Saini for contributing to the writing and editing of ADME protocols.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ALK2</td><td class="NLM_def"><p class="first last">activin receptor-like kinase-2</p></td></tr><tr><td class="NLM_term">ALK5</td><td class="NLM_def"><p class="first last">activin receptor-like kinase-5</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC<sub>inf</sub></td><td class="NLM_def"><p class="first last">area under the curve (extrapolated to infinity)</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BMP</td><td class="NLM_def"><p class="first last">bone morphogenetic protein</p></td></tr><tr><td class="NLM_term">B/P</td><td class="NLM_def"><p class="first last">total brain-to-plasma ratio</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>b,u</sub></td><td class="NLM_def"><p class="first last">unbound brain concentration</p></td></tr><tr><td class="NLM_term">cLogP</td><td class="NLM_def"><p class="first last">calculated lipophilicity</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DIPG</td><td class="NLM_def"><p class="first last">diffuse intrinsic pontine glioma</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">FOP</td><td class="NLM_def"><p class="first last">fibrodysplasia ossificans progressiva</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">glycine–serine-rich domain</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether a-go-go related gene</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">STKR</td><td class="NLM_def"><p class="first last">serine/threonine kinase receptor</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TGFβ-R1</td><td class="NLM_def"><p class="first last">transforming growth factor beta receptor 1</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77601" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77601" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0lgZNUw8jjiqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lhT_9cpyDugYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.cytogfr.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=26776312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=93-104&author=M.+Pacificiauthor=E.+M.+Shore&title=Common+mutations+in+ALK2%2FACVR1%2C+a+multi-faceted+receptor%2C+have+roles+in+distinct+pediatric+musculoskeletal+and+neural+orphan+disorders&doi=10.1016%2Fj.cytogfr.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span></div><div class="casAuthors">Pacifici, Maurizio; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptor family.  ALK2 exerts key and non-redundant roles in numerous developmental processes, including the specification, growth and morphogenesis of endochondral skeletal elements.  There is also strong evidence that BMP signaling plays important roles in detn., differentiation and function of neural cells and tissues.  Here we focus on the intriguing discovery that common activating mutations in ALK2 occur in Fibrodysplasia Ossificans Progressiva (FOP) and Diffuse Intrinsic Pontine Gliomas (DIPGs), distinct pediatric disorders of significant severity that are assocd. with premature death.  Pathogenesis and treatment remain elusive for both.  We consider recent studies on the nature of the ACVR1 mutations, possible modes of action and targets, and plausible therapeutic measures.  Comparisons of the diverse - but genetically interrelated - pathologies of FOP and DIPG will continue to be of major mutual benefit with broad biomedical and clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwM08RQn6m7LVg90H21EOLACvtfcHk0lhT_9cpyDugYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D&md5=1b6f732518596d155f46178c2743d841</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DPacifici%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DCommon%2520mutations%2520in%2520ALK2%252FACVR1%252C%2520a%2520multi-faceted%2520receptor%252C%2520have%2520roles%2520in%2520distinct%2520pediatric%2520musculoskeletal%2520and%2520neural%2520orphan%2520disorders%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D27%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.cytogfr.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmierer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span> <span> </span><span class="NLM_article-title">TGFβ-SMAD signal transduction: molecular specificity and functional flexibility</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1038/nrm2297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fnrm2297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=18000526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=970-982&author=B.+Schmiererauthor=C.+S.+Hill&title=TGF%CE%B2-SMAD+signal+transduction%3A+molecular+specificity+and+functional+flexibility&doi=10.1038%2Fnrm2297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">TGFβ-SMAD signal transduction: molecular specificity and functional flexibility</span></div><div class="casAuthors">Schmierer, Bernhard; Hill, Caroline S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">970-982</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Transforming growth factor-β (TGFβ)-induced signaling converges on a limited no. of SMAD complexes.  These complexes effect a plethora of specific and functional responses in both embryos and adult organisms.  How are these complex cellular responses elicited.  Ligands of the transforming growth factor-β (TGFβ) superfamily of growth factors initiate signal transduction through a bewildering complexity of ligand-receptor interactions.  Signaling then converges to nuclear accumulation of transcriptionally active SMAD complexes and gives rise to a plethora of specific functional responses in both embryos and adult organisms.  Current research is focused on the mechanisms that regulate SMAD activity to evoke cell-type-specific and context-dependent transcriptional programs.  An equally important challenge is understanding the functional role of signal strength and duration.  How are these quant. aspects of the extracellular signal regulated.  How are they then sensed and interpreted, and how do they affect responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS8aBln1hVMbVg90H21EOLACvtfcHk0lhT_9cpyDugYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsb3K&md5=0c60dcd2275bb22d0f555381264d1aef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2297%26sid%3Dliteratum%253Aachs%26aulast%3DSchmierer%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26atitle%3DTGF%25CE%25B2-SMAD%2520signal%2520transduction%253A%2520molecular%2520specificity%2520and%2520functional%2520flexibility%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D970%26epage%3D982%26doi%3D10.1038%2Fnrm2297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massagué, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">TGFβ signaling in growth control, cancer, and heritable disorders</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)00121-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2FS0092-8674%2800%2900121-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=11057902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Clt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=295-309&author=J.+Massagu%C3%A9author=S.+W.+Blainauthor=R.+S.+Lo&title=TGF%CE%B2+signaling+in+growth+control%2C+cancer%2C+and+heritable+disorders&doi=10.1016%2Fs0092-8674%2800%2900121-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">TGFβ signaling in growth control, cancer, and heritable disorders</span></div><div class="casAuthors">Massague, Joan; Blain, Stacy W.; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 141 refs. refs.  The control of cell growth and differentiation by the TGFβ family in relation to pathogenesis of human disorders and tumors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8n-oZyDANtLVg90H21EOLACvtfcHk0ljJ1yOmn83dQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Clt7w%253D&md5=0ecc3149cea49379e6d7e4760504abf5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900121-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900121-5%26sid%3Dliteratum%253Aachs%26aulast%3DMassagu%25C3%25A9%26aufirst%3DJ.%26aulast%3DBlain%26aufirst%3DS.%2BW.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTGF%25CE%25B2%2520signaling%2520in%2520growth%2520control%252C%2520cancer%252C%2520and%2520heritable%2520disorders%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D295%26epage%3D309%26doi%3D10.1016%2Fs0092-8674%2800%2900121-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ACVR1 mutations in DIPG: lessons learned from FOP</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4565</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1158%2F0008-5472.CAN-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=25136070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=4565-4570&author=K.+R.+Taylorauthor=M.+Vinciauthor=A.+N.+Bullockauthor=C.+Jones&title=ACVR1+mutations+in+DIPG%3A+lessons+learned+from+FOP&doi=10.1158%2F0008-5472.can-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 mutations in DIPG: Lessons learned from FOP</span></div><div class="casAuthors">Taylor, Kathryn R.; Vinci, Maria; Bullock, Alex N.; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4565-4570</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Whole-genome sequencing studies have recently identified a quarter of cases of the rare childhood brainstem tumor diffuse intrinsic pontine glioma to harbor somatic mutations in ACVR1.  This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.  This unexpected link points toward the importance of developmental biol. processes in tumorigenesis and provides an extensive experience in mechanistic understanding and drug development hard-won by FOP researchers to pediatric neurooncol.  Here, we review the literature in both fields and identify potential areas for collaboration and rapid advancement for patients of both diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEL1hRMgcHVLVg90H21EOLACvtfcHk0ljJ1yOmn83dQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I&md5=6954694896e9f71ad21eec835247b1cd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DACVR1%2520mutations%2520in%2520DIPG%253A%2520lessons%2520learned%2520from%2520FOP%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D4565%26epage%3D4570%26doi%3D10.1158%2F0008-5472.can-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span> <span> </span><span class="NLM_article-title">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/ng.2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fng.2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=24705252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=457-461&author=K.+R.+Taylorauthor=A.+Mackayauthor=N.+Truffauxauthor=Y.+S.+Butterfieldauthor=O.+Morozovaauthor=C.+Philippeauthor=D.+Castelauthor=C.+S.+Grassoauthor=M.+Vinciauthor=D.+Carvalhoauthor=A.+M.+Carcabosoauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=N.+Entz-Werleauthor=W.+J.+Ingramauthor=M.+Monjeauthor=D.+Hargraveauthor=A.+N.+Bullockauthor=S.+Pugetauthor=S.+Yipauthor=C.+Jonesauthor=J.+Grill&title=Recurrent+activating+ACVR1+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fng.2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Taylor, Kathryn R.; Mackay, Alan; Truffaux, Nathalene; Butterfield, Yaron S.; Morozova, Olena; Philippe, Cathy; Castel, David; Grasso, Catherine S.; Vinci, Maria; Carvalho, Diana; Carcaboso, Angel M.; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Entz-Werle, Natacha; Ingram, Wendy J.; Monje, Michelle; Hargrave, Darren; Bullock, Alex N.; Puget, Stephanie; Yip, Stephen; Jones, Chris; Grill, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clin. outcome.  The median survival time is 9-12 mo, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clin. trials in children with these tumors.  We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples.  Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) and have been shown to constitutively activate the BMP-TGF-β signaling pathway.  These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRfkuGtWYWLVg90H21EOLACvtfcHk0ljJ1yOmn83dQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D&md5=69fb86fc99975a0f0dbaa060141788a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fng.2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2925%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DTruffaux%26aufirst%3DN.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DPhilippe%26aufirst%3DC.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrasso%26aufirst%3DC.%2BS.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DGrill%26aufirst%3DJ.%26atitle%3DRecurrent%2520activating%2520ACVR1%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D457%26epage%3D461%26doi%3D10.1038%2Fng.2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutka, J. T.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics</span>. <i>J. Korean Neurosurg. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.3340/jkns.2018.0008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.3340%2Fjkns.2018.0008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=29742880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=343-351&author=R.+K.+Mathewauthor=J.+T.+Rutka&title=Diffuse+intrinsic+pontine+glioma%3A+clinical+features%2C+molecular+genetics%2C+and+novel+targeted+therapeutics&doi=10.3340%2Fjkns.2018.0008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma : clinical features, molecular genetics, and novel targeted therapeutics</span></div><div class="casAuthors">Mathew, Ryan K.; Rutka, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Neurosurgical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-351</span>CODEN:
                <span class="NLM_cas:coden">JKNSAI</span>;
        ISSN:<span class="NLM_cas:issn">1598-7876</span>.
    
            (<span class="NLM_cas:orgname">Korean Neurosurgical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer.  Transient response to radiation, ineffective chemotherapeutic agents and aggressive biol. result in rapid progression of symptoms and a dismal prognosis.  Increased availability of tumor tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which have resulted in mol. and phenotypic subgrouping.  However, many of the underlying mechanisms of DIPG oncogenesis remain unexplained.  It is hoped that more representative in vitro and preclin. models-using both xenografted material and genetically engineered mice-will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery.  This review provides a clin. overview of DIPG, the barriers to progress in developing effective treatment, updates on drug development and preclin. models, and an introduction to new technologies aimed at enhancing drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohREcp3C8kCLVg90H21EOLACvtfcHk0lg6DNPg0vVnxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ&md5=0f37c4371f752f813af3014085c0dca3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3340%2Fjkns.2018.0008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3340%252Fjkns.2018.0008%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DR.%2BK.%26aulast%3DRutka%26aufirst%3DJ.%2BT.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520clinical%2520features%252C%2520molecular%2520genetics%252C%2520and%2520novel%2520targeted%2520therapeutics%26jtitle%3DJ.%2520Korean%2520Neurosurg.%2520Soc.%26date%3D2018%26volume%3D61%26spage%3D343%26epage%3D351%26doi%3D10.3340%2Fjkns.2018.0008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: poised for progress</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fonc.2012.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.3389%2Ffonc.2012.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=23293772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=205&author=K.+E.+Warren&title=Diffuse+intrinsic+pontine+glioma%3A+poised+for+progress&doi=10.3389%2Ffonc.2012.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma: poised for progress</span></div><div class="casAuthors">Warren Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat.  Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy.  Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success.  The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care.  The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar.  However, recent pivotal studies demonstrate that DIPGs appear to be their own entity.  Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments.  This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREW6_X20GCz7YtC3U5jeOifW6udTcc2eZ4Q0HuBBalMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D&md5=d51f614b4d5e8bfa9b7bb755cdf736e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2012.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2012.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DK.%2BE.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520poised%2520for%2520progress%26jtitle%3DFront.%2520Oncol.%26date%3D2012%26volume%3D2%26spage%3D205%26doi%3D10.3389%2Ffonc.2012.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lg6DNPg0vVnxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaciregui, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">156</span>, <span class="refDoi"> DOI: 10.1038/s42003-019-0420-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fs42003-019-0420-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=31098401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=156&author=D.+Carvalhoauthor=K.+R.+Taylorauthor=N.+G.+Olacireguiauthor=V.+Molinariauthor=M.+Clarkeauthor=A.+Mackayauthor=R.+Ruddleauthor=A.+Henleyauthor=M.+Valentiauthor=A.+Hayesauthor=A.+D.+H.+Brandonauthor=S.+A.+Ecclesauthor=F.+Raynaudauthor=A.+Boudharauthor=M.+Monjeauthor=S.+Popovauthor=A.+S.+Mooreauthor=J.+Moraauthor=O.+Cruzauthor=M.+Vinciauthor=P.+E.+Brennanauthor=A.+N.+Bullockauthor=A.+M.+Carcabosoauthor=C.+Jones&title=ALK2+inhibitors+display+beneficial+effects+in+preclinical+models+of+ACVR1+mutant+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fs42003-019-0420-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Popov Sergey; Vinci Mara; Jones Chris; Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Ruddle Ruth; Henley Alan; Valenti Melanie; Hayes Angela; Brandon Alexis De Haven; Eccles Suzanne A; Raynaud Florence; Popov Sergey; Vinci Mara; Jones Chris; Taylor Kathryn R; Monje Michelle; Olaciregui Nagore Gene; Mora Jaume; Cruz Ofelia; Carcaboso Angel Montero; Boudhar Aicha; Brennan Paul E; Bullock Alex N; Boudhar Aicha; Brennan Paul E; Popov Sergey; Moore Andrew S; Moore Andrew S; Vinci Mara</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2.  Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models.  Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo.  We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration.  Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls.  Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZQ93BSEDMxWZyxfu64m4ffW6udTcc2eZxmcUcBELpLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D&md5=bc5f88aabf7d4d758e1288df1e70d5cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0420-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0420-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DOlaciregui%26aufirst%3DN.%2BG.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBrandon%26aufirst%3DA.%2BD.%2BH.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DBoudhar%26aufirst%3DA.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DALK2%2520inhibitors%2520display%2520beneficial%2520effects%2520in%2520preclinical%2520models%2520of%2520ACVR1%2520mutant%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26spage%3D156%26doi%3D10.1038%2Fs42003-019-0420-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastas, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zee, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrescu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nocco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filbin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.ccell.2019.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=31631026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=528-544&author=J.+N.+Anastasauthor=B.+M.+Zeeauthor=J.+H.+Kalinauthor=M.+Kimauthor=R.+Guoauthor=S.+Alexandrescuauthor=M.+A.+Blancoauthor=S.+Gieraauthor=S.+M.+Gillespieauthor=J.+Dasauthor=M.+Wuauthor=S.+Noccoauthor=D.+M.+Bonalauthor=Q.-D.+Nguyenauthor=M.+L.+Suvaauthor=B.+E.+Bernsteinauthor=R.+Alaniauthor=T.+R.+Golubauthor=P.+A.+Coleauthor=M.+G.+Filbinauthor=Y.+Shi&title=Re-programing+chromatin+with+a+bifunctional+LSD1%2FHDAC+inhibitor+induces+therapeutic+differentiation+in+DIPG&doi=10.1016%2Fj.ccell.2019.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG</span></div><div class="casAuthors">Anastas, Jamie N.; Zee, Barry M.; Kalin, Jay H.; Kim, Mirhee; Guo, Robyn; Alexandrescu, Sanda; Blanco, Mario Andres; Giera, Stefanie; Gillespie, Shawn M.; Das, Jayanta; Wu, Muzhou; Nocco, Sarah; Bonal, Dennis M.; Nguyen, Quang-De; Suva, Mario L.; Bernstein, Bradley E.; Alani, Rhoda; Golub, Todd R.; Cole, Philip A.; Filbin, Mariella G.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-544.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">H3K27M mutations resulting in epigenetic dysfunction are frequently obsd. in diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer.  We conduct a CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors.  Consistently, Corin, a bifunctional inhibitor of HDACs and LSD1, potently inhibits DIPG growth in vitro and in xenografts.  Mechanistically, Corin increases H3K27me3 levels suppressed by H3K27M histones, and simultaneously increases HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-assocd. genes.  Corin treatment induces cell death, cell-cycle arrest, and a cellular differentiation phenotype and drives transcriptional changes correlating with increased survival time in DIPG patients.  These data suggest a strategy for treating DIPG by simultaneously inhibiting LSD1 and HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHX1Q6HDJoobVg90H21EOLACvtfcHk0ljskG8sCo5rnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsr%252FL&md5=32c4c2c7f032812a95d424b19ca7039e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAnastas%26aufirst%3DJ.%2BN.%26aulast%3DZee%26aufirst%3DB.%2BM.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DAlexandrescu%26aufirst%3DS.%26aulast%3DBlanco%26aufirst%3DM.%2BA.%26aulast%3DGiera%26aufirst%3DS.%26aulast%3DGillespie%26aufirst%3DS.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNocco%26aufirst%3DS.%26aulast%3DBonal%26aufirst%3DD.%2BM.%26aulast%3DNguyen%26aufirst%3DQ.-D.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DAlani%26aufirst%3DR.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DFilbin%26aufirst%3DM.%2BG.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DRe-programing%2520chromatin%2520with%2520a%2520bifunctional%2520LSD1%252FHDAC%2520inhibitor%2520induces%2520therapeutic%2520differentiation%2520in%2520DIPG%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D528%26epage%3D544%26doi%3D10.1016%2Fj.ccell.2019.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1217330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1080%2F13543776.2016.1217330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=27476794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1115-1128&author=C.+R.+Hopkins&title=Inhibitors+of+the+bone+morphogenetic+protein+%28BMP%29+signaling+pathway%3A+a+patent+review+%282008-2015%29&doi=10.1080%2F13543776.2016.1217330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1128</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The bone morphogenetic protein (BMP) is a crit. signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others.  Areas covered: This review covers small mol. inhibitors/antagonists of BMP in patent applications between 2008 - 2015, along with brief synopses of the disclosed inhibitors in the primary literature.  Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile.  Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP).  Recently, however, there has been increased interest in their use in a no. of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few.  Although the primary participants in the early work were from academic labs., recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications.  Due to this, expect a no. of new approaches such as repurposing of other kinase inhibitors to be brought into clin. trials in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShe2EZoRM8LVg90H21EOLACvtfcHk0lieUvIDNASr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO&md5=e71e2ed75369d31a3835aaed4cf65de6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1217330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1217330%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DInhibitors%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520pathway%253A%2520a%2520patent%2520review%2520%25282008-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1115%26epage%3D1128%26doi%3D10.1080%2F13543776.2016.1217330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.bmcl.2008.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=18621530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4388-4392&author=G.+D.+Cunyauthor=P.+B.+Yuauthor=J.+K.+Lahaauthor=X.+Xingauthor=J.-F.+Liuauthor=C.+S.+Laiauthor=D.+Y.+Dengauthor=C.+Sachidanandanauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Structure-activity+relationship+study+of+bone+morphogenetic+protein+%28BMP%29+signaling+inhibitors&doi=10.1016%2Fj.bmcl.2008.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span></div><div class="casAuthors">Cuny, Gregory D.; Yu, Paul B.; Laha, Joydev K.; Xing, Xuechao; Liu, Ji-Feng; Lai, Carol S.; Deng, Donna Y.; Sachidanandan, Chetana; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4388-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline.  The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examd. by prepg. and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivs.  In addn., increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent Ph ring with piperazine.  Finally, an optimized compd. 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t 1/2 = 1.6 h) following i.p. administration in mice.  These studies provide useful mol. probes for examg. the in vivo pharmacol. of BMP signaling inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxlj03oLBHLVg90H21EOLACvtfcHk0lieUvIDNASr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D&md5=227395181629474e47aee6163492c4bc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DLaha%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4388%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2008.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span>; <span class="NLM_string-name">Cuny, G. D.</span>; <span class="NLM_string-name">Mohedas, A. H.</span>; <span class="NLM_string-name">Bloch, K. D.</span>; <span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">BMP Inhibitors and Methods of Use Thereof</span>. <span class="NLM_patent">WO2014138088A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+B.+Yu&author=G.+D.+Cuny&author=A.+H.+Mohedas&author=K.+D.+Bloch&author=R.+T.+Peterson&title=BMP+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DBMP%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">A new class of small molecule inhibitor of BMP signaling</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e62721</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0062721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1371%2Fjournal.pone.0062721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=23646137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=C.+E.+Sanvitaleauthor=G.+Kerrauthor=A.+Chaikuadauthor=M.-C.+Ramelauthor=A.+H.+Mohedasauthor=S.+Reichertauthor=Y.+Wangauthor=J.+T.+Triffittauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=C.+S.+Hillauthor=A.+N.+Bullock&title=A+new+class+of+small+molecule+inhibitor+of+BMP+signaling&doi=10.1371%2Fjournal.pone.0062721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of small molecule inhibitor of BMP signaling</span></div><div class="casAuthors">Sanvitale, Caroline E.; Kerr, Georgina; Chaikuad, Apirat; Ramel, Marie-Christine; Mohedas, Agustin H.; Reichert, Sabine; Wang, You; Triffitt, James T.; Cuny, Gregory D.; Yu, Paul B.; Hill, Caroline S.; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e62721</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of interest for drug discovery.  Small mol. inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).  Dorsomorphin analogs, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.  By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concns. similar to the current lead compd. LDN-193189.  K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos.  Comparison of the crystal structures of ALK2 with K02288 and LDN-193189 revealed addnl. contacts in the K02288 complex affording improved shape complementarity and identified the exposed phenol group for further optimization of pharmacokinetics.  The discovery of a new chem. series provides an independent pharmacol. tool to investigate BMP signaling and offers multiple opportunities for pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMygI9eYjlbVg90H21EOLACvtfcHk0liu9pf-8ype6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D&md5=d00f0fddc871eb1a92fa90f36c7d54dc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0062721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0062721%26sid%3Dliteratum%253Aachs%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DRamel%26aufirst%3DM.-C.%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DReichert%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DA%2520new%2520class%2520of%2520small%2520molecule%2520inhibitor%2520of%2520BMP%2520signaling%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0062721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7915</span>, <span class="refDoi"> DOI: 10.1021/jm501177w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501177w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7900-7915&author=A.+H.+Mohedasauthor=Y.+Wangauthor=C.+E.+Sanvitaleauthor=P.+Canningauthor=S.+Choiauthor=X.+Xingauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Structure-activity+relationship+of+3%2C5-diaryl-2-aminopyridine+ALK2+inhibitors+reveals+unaltered+binding+affinity+for+fibrodysplasia+ossificans+progressiva+causing+mutants&doi=10.1021%2Fjm501177w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants</span></div><div class="casAuthors">Mohedas, Agustin H.; Wang, You; Sanvitale, Caroline E.; Canning, Peter; Choi, Sungwoon; Xing, Xuechao; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7900-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2.  Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors.  Here the authors describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compd. K02288.  Several modifications increased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as well as selectivity for ALK2 vs. closely related BMP and TGF-β type I receptor kinases.  Compds. in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or selectivity, suggesting mechanisms independent of BMP or TGF-β inhibition.  The study also highlights a potent 2-methylpyridine deriv. I (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclin. development.  Contrary to the notion that activating mutations of ALK2 might alter inhibitor efficacy due to potential conformational changes in the ATP-binding site, the compds. demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins.  Thus, BMP inhibitors identified via activity against wild-type ALK2 signaling are likely to be of clin. relevance for the diverse ALK2 mutant proteins assocd. with FOP and DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKhBWuwrqjLVg90H21EOLACvtfcHk0liu9pf-8ype6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP&md5=c5efce9b3d06bbb126aa8a197d3d2b40</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm501177w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501177w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DStructure-activity%2520relationship%2520of%25203%252C5-diaryl-2-aminopyridine%2520ALK2%2520inhibitors%2520reveals%2520unaltered%2520binding%2520affinity%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%2520causing%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7900%26epage%3D7915%26doi%3D10.1021%2Fjm501177w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span>; <span class="NLM_string-name">Cuny, G. D.</span>; <span class="NLM_string-name">Mohedas, A. H.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Inhibiting BMP</span>. <span class="NLM_patent">WO2015148654A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+B.+Yu&author=G.+D.+Cuny&author=A.+H.+Mohedas&title=Compositions+and+Methods+for+Inhibiting+BMP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Inhibiting%2520BMP%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinecke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruprecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiechmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzlmeir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=655-664&author=M.+Reineckeauthor=B.+Ruprechtauthor=S.+Poserauthor=S.+Wiechmannauthor=M.+Wilhelmauthor=S.+Heinzlmeirauthor=B.+Kusterauthor=G.+M%C3%A9dard&title=Chemoproteomic+selectivity+profiling+of+PIKK+and+PI3K+kinase+inhibitors&doi=10.1021%2Facschembio.8b01020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors</span></div><div class="casAuthors">Reinecke, Maria; Ruprecht, Benjamin; Poser, Sandra; Wiechmann, Svenja; Wilhelm, Mathias; Heinzlmeir, Stephanie; Kuster, Bernhard; Medard, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-664</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. proteomic approaches utilizing immobilized, broad-selective kinase inhibitors (Kinobeads) have proven valuable for the elucidation of a compd.'s target profile under close-to-physiol. conditions and often revealed potentially synergistic or toxic off-targets.  Current Kinobeads enrich more than 300 native protein kinases from cell line or tissue lysates but do not systematically cover phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related kinases (PIKKs).  Some PIKKs and PI3Ks show aberrant activation in many human diseases and are indeed validated drug targets.  Here, we report the development of a novel version of Kinobeads that extends kinome coverage to these proteins.  This is achieved by inclusion of two affinity probes derived from the clin. PI3K/MTOR inhibitors Omipalisib and BGT226.  We demonstrate the utility of the new affinity matrix by the profiling of 13 clin. and preclin. PIKK/PI3K inhibitors.  The large discrepancies between the PI3K affinity values obtained and reported results from recombinant assays led us to perform a phosphoproteomic expt. showing that the chemoproteomic assay is the better approxn. of PI3K inhibitor action in cellulo.  The results further show that NVP-BEZ235 is not a PI3K inhibitor.  Surprisingly, the designated ATM inhibitor CP466722 was found to bind strongly to ALK2, identifying a new chemotype for drug discovery to treat fibrodysplasia ossificans progressiva.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqA0YbOfmxobVg90H21EOLACvtfcHk0liu9pf-8ype6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aksrs%253D&md5=180dc2ef468b01067faceb69e399c8d4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01020%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%26aulast%3DRuprecht%26aufirst%3DB.%26aulast%3DPoser%26aufirst%3DS.%26aulast%3DWiechmann%26aufirst%3DS.%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DHeinzlmeir%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26atitle%3DChemoproteomic%2520selectivity%2520profiling%2520of%2520PIKK%2520and%2520PI3K%2520kinase%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D655%26epage%3D664%26doi%3D10.1021%2Facschembio.8b01020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrem, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleverly, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaiah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slapak, C. A.</span></span> <span> </span><span class="NLM_article-title">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4479</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.2147/dddt.s86621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.2147%2FDDDT.S86621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=26309397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4479-4499&author=M.+Lahnauthor=S.+Herbertzauthor=J.+S.+Sawyerauthor=A.+J.+Stauberauthor=I.+Gueorguievaauthor=K.+E.+Driscollauthor=S.+T.+Estremauthor=A.+L.+Cleverlyauthor=D.+Desaiahauthor=S.+C.+Gubaauthor=K.+A.+Benhadjiauthor=C.+A.+Slapak&title=Clinical+development+of+galunisertib+%28LY2157299+monohydrate%29%2C+a+small+molecule+inhibitor+of+transforming+growth+factor-beta+signaling+pathway&doi=10.2147%2Fdddt.s86621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span></div><div class="casAuthors">Herbertz, Stephan; Sawyer, J. Scott; Stauber, Anja J.; Gueorguieva, Ivelina; Driscoll, Kyla E.; Estrem, Shawn T.; Cleverly, Ann L.; Desaiah, Durisala; Guba, Susan C.; Benhadji, Karim A.; Slapak, Christopher A.; Lahn, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4479-4499</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biol. processes.  TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance.  There are several pharmacol. approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small mol. inhibitors.  Galunisertib (LY2157299 monohydrate) is an oral small mol. inhibitor of the TGF-β receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.  Furthermore, galunisertib has antitumor activity in tumor-bearing animal models such as breast, colon, lung cancers, and hepatocellular carcinoma.  Continuous long-term exposure to galunisertib caused cardiac toxicities in animals requiring adoption of a pharmacokinetic/pharmacodynamic-based dosing strategy to allow further development.  The use of such a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clin. investigation of galunisertib.  These efforts resulted in an intermittent dosing regimen (14 days on/14 days off, on a 28-day cycle) of galunisertib for all ongoing trials.  Galunisertib is being investigated either as monotherapy or in combination with std. antitumor regimens (including nivolumab) in patients with cancer with high unmet medical needs such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma.  The present review summarizes the past and current experiences with different pharmacol. treatments that enabled galunisertib to be investigated in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYOwgVYb7M2bVg90H21EOLACvtfcHk0liLZLYpTAq_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D&md5=f896505ddcd4dbc54bd59863588c4268</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86621%26sid%3Dliteratum%253Aachs%26aulast%3DLahn%26aufirst%3DM.%26aulast%3DHerbertz%26aufirst%3DS.%26aulast%3DSawyer%26aufirst%3DJ.%2BS.%26aulast%3DStauber%26aufirst%3DA.%2BJ.%26aulast%3DGueorguieva%26aufirst%3DI.%26aulast%3DDriscoll%26aufirst%3DK.%2BE.%26aulast%3DEstrem%26aufirst%3DS.%2BT.%26aulast%3DCleverly%26aufirst%3DA.%2BL.%26aulast%3DDesaiah%26aufirst%3DD.%26aulast%3DGuba%26aufirst%3DS.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%2BA.%26aulast%3DSlapak%26aufirst%3DC.%2BA.%26atitle%3DClinical%2520development%2520of%2520galunisertib%2520%2528LY2157299%2520monohydrate%2529%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520transforming%2520growth%2520factor-beta%2520signaling%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4479%26epage%3D4499%26doi%3D10.2147%2Fdddt.s86621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span>Unpublished
results. Data can be viewed in presentations archived at <a href="https://m4kpharma.com/blog/" class="extLink">https://m4kpharma.com/blog/</a> (accessed Apr. 1, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Unpublished%0Aresults.+Data+can+be+viewed+in+presentations+archived+at+https%3A%2F%2Fm4kpharma.com%2Fblog%2F+%28accessed+Apr.+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span>. <i>Wellcome Open Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.12688/wellcomeopenres.14947.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.12688%2Fwellcomeopenres.14947.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30705971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=154&author=M.+R.+Morganauthor=O.+G.+Robertsauthor=A.+M.+Edwards&title=Ideation+and+implementation+of+an+open+science+drug+discovery+business+model+-+M4K+Pharma&doi=10.12688%2Fwellcomeopenres.14947.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span></div><div class="casAuthors">Morgan Maxwell Robert; Edwards Aled Morgan; Morgan Maxwell Robert; Roberts Owen Gwilym; Edwards Aled Morgan; Morgan Maxwell Robert; Edwards Aled Morgan</div><div class="citationInfo"><span class="NLM_cas:title">Wellcome open research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn">2398-502X</span>.
    </div><div class="casAbstract">M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science.  The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5e8MVHlijOLZpSb_XWfMrfW6udTcc2eZ1v-y2RCV5u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D&md5=375dea208c308eb3199d178e4b1977a3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.12688%2Fwellcomeopenres.14947.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Fwellcomeopenres.14947.1%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DM.%2BR.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DIdeation%2520and%2520implementation%2520of%2520an%2520open%2520science%2520drug%2520discovery%2520business%2520model%2520-%2520M4K%2520Pharma%26jtitle%3DWellcome%2520Open%2520Res.%26date%3D2018%26volume%3D3%26spage%3D154%26doi%3D10.12688%2Fwellcomeopenres.14947.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boergermann, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">36990</span>– <span class="NLM_lpage">36998</span>, <span class="refDoi"> DOI: 10.1074/jbc.m112.365932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1074%2Fjbc.M112.365932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=22977237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=36990-36998&author=A.+Chaikuadauthor=I.+Alfanoauthor=G.+Kerrauthor=C.+E.+Sanvitaleauthor=J.+H.+Boergermannauthor=J.+T.+Triffittauthor=F.+von+Delftauthor=S.+Knappauthor=P.+Knausauthor=A.+N.+Bullock&title=Structure+of+the+bone+morphogenetic+protein+receptor+ALK2+and+implications+for+fibrodysplasia+ossificans+progressiva&doi=10.1074%2Fjbc.m112.365932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva</span></div><div class="casAuthors">Chaikuad, Apirat; Alfano, Ivan; Kerr, Georgina; Sanvitale, Caroline E.; Boergermann, Jan H.; Triffitt, James T.; von Delft, Frank; Knapp, Stefan; Knaus, Petra; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">36990-36998</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) receptor kinases are tightly regulated to control development and tissue homeostasis.  Mutant receptor kinase domains escape regulation leading to severely degenerative diseases and represent an important therapeutic target.  Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating disorder of extraskeletal bone formation.  FOP-assocd. mutations in the BMP receptor ALK2 reduce binding of the inhibitor FKBP12 and promote leaky signaling in the absence of ligand.  To establish structural mechanisms of receptor regulation and to address the effects of FOP mutation, we detd. the crystal structure of the cytoplasmic domain of ALK2 in complex with the inhibitors FKBP12 and dorsomorphin.  FOP mutations break crit. interactions that stabilize the inactive state of the kinase, thereby facilitating structural rearrangements that diminish FKBP12 binding and promote the correct positioning of the glycine-serine-rich loop and αC helix for kinase activation.  The balance of these effects accounts for the comparable activity of R206H and L196P.  Kinase activation in the clin. benign mutant L196P is far weaker than R206H but yields equiv. signals due to the stronger interaction of FKBP12 with R206H.  The presented ALK2 structure offers a valuable template for the further design of specific inhibitors of BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEuij-Kpil0bVg90H21EOLACvtfcHk0liiFFDMfs_DXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfK&md5=3c6d294d209dd85602a01a321831c503</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.365932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.365932%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DBoergermann%26aufirst%3DJ.%2BH.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKnaus%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DStructure%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520receptor%2520ALK2%2520and%2520implications%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D36990%26epage%3D36998%26doi%3D10.1074%2Fjbc.m112.365932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0liiFFDMfs_DXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">tPSA, p<i>K</i><sub>a</sub> and cLogP values were calculated using ChemDraw Professional 19.0.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0liUzE57xP3_ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2611</span>, <span class="refDoi"> DOI: 10.1021/jm100087s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100087s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2601-2611&author=B.+Kuhnauthor=P.+Mohrauthor=M.+Stahl&title=Intramolecular+hydrogen+bonding+in+medicinal+chemistry&doi=10.1021%2Fjm100087s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span></div><div class="casAuthors">Kuhn, Bernd; Mohr, Peter; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2601-2611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of intramol. hydrogen bonds has a very pronounced effect on mol. structure and properties.  We study both aspects in detail with the aim of enabling a more rational use of this class of interactions in medicinal chem.  On the basis of exhaustive searches in crystal structure databases, we derive propensities for intramol. hydrogen bond formation of five- to eight-membered ring systems of relevance in drug discovery.  A no. of motifs, several of which are clearly underutilized in drug discovery, are analyzed in more detail by comparing small mol. and protein-ligand X-ray structures.  To investigate effects on physicochem. properties, sets of closely related structures with and without the ability to form intramol. hydrogen bonds were designed, synthesized, and characterized with respect to membrane permeability, water soly., and lipophilicity.  We find that changes in these properties depend on a subtle balance between the strength of the hydrogen bond interaction, geometry of the newly formed ring system, and the relative energies of the open and closed conformations in polar and unpolar environments.  A no. of general guidelines for medicinal chemists emerge from this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaV7tFRU4k7Vg90H21EOLACvtfcHk0liUzE57xP3_ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D&md5=b9b6865dfcc9bdf7796d15218f6e8ff2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm100087s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100087s%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2601%26epage%3D2611%26doi%3D10.1021%2Fjm100087s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0liUzE57xP3_ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lg0Jl5ebsOIbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekimata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima-Tsumagari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1248%2Fcpb.c18-00598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30828000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeju7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=224-235&author=K.+Sekimataauthor=T.+Satoauthor=N.+Sakaiauthor=H.+Watanabeauthor=C.+Mishima-Tsumagariauthor=T.+Taguriauthor=T.+Matsumotoauthor=Y.+Fujiiauthor=N.+Handaauthor=T.+Honmaauthor=A.+Tanakaauthor=M.+Shirouzuauthor=S.+Yokoyamaauthor=K.+Miyazonoauthor=Y.+Hashizumeauthor=H.+Koyama&title=Bis-heteroaryl+pyrazoles%3A+identification+of+orally+bioavailable+inhibitors+of+activin+receptor-like+kinase-2+%28R206H%29&doi=10.1248%2Fcpb.c18-00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span></div><div class="casAuthors">Sekimata, Katsuhiko; Sato, Tomohiro; Sakai, Naoki; Watanabe, Hisami; Mishima-Tsumagari, Chiemi; Taguri, Tomonori; Matsumoto, Takehisa; Fujii, Yoshifumi; Handa, Noriko; Honma, Teruki; Tanaka, Akiko; Shirouzu, Mikako; Yokoyama, Shigeyuki; Miyazono, Kohei; Hashizume, Yoshinobu; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Mutant activin receptor-like kinase-2 (ALK2) was reported to be closely assocd. with the pathogenesis of fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG), and therefore presents an attractive target for therapeutic intervention.  Through in silico virtual screenings and structure-activity relationship studies assisted by X-ray crystallog. analyses, a novel series of bis-heteroaryl pyrazole was identified as potent inhibitors of ALK2 (R206H).  Derived from in silico hit compd. RK-59638 (6a), compd. 18p was identified as a potent inhibitor of ALK2 (R206H) with good aq. soly., liver microsomal stability, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3_X7yj3rTv7Vg90H21EOLACvtfcHk0lg0Jl5ebsOIbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeju7jE&md5=edb5753df77bc0bf1546de7f70a900ac</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00598%26sid%3Dliteratum%253Aachs%26aulast%3DSekimata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMishima-Tsumagari%26aufirst%3DC.%26aulast%3DTaguri%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DMiyazono%26aufirst%3DK.%26aulast%3DHashizume%26aufirst%3DY.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DBis-heteroaryl%2520pyrazoles%253A%2520identification%2520of%2520orally%2520bioavailable%2520inhibitors%2520of%2520activin%2520receptor-like%2520kinase-2%2520%2528R206H%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D67%26spage%3D224%26epage%3D235%26doi%3D10.1248%2Fcpb.c18-00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khalili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, A. L. L.</span></span> <span> </span><span class="NLM_article-title">pK<sub>a</sub> values of some piperazines at (298, 303, 313, and 323) K</span>. <i>J. Chem. Eng. Data</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2914</span>– <span class="NLM_lpage">2917</span>, <span class="refDoi"> DOI: 10.1021/je900005c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/je900005c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=2914-2917&author=F.+Khaliliauthor=A.+Henniauthor=A.+L.+L.+East&title=pKa+values+of+some+piperazines+at+%28298%2C+303%2C+313%2C+and+323%29+K&doi=10.1021%2Fje900005c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">pKa Values of Some Piperazines at (298, 303, 313, and 323) K</span></div><div class="casAuthors">Khalili, Farhad; Henni, Amr; East, Allan L. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical & Engineering Data</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2914-2917</span>CODEN:
                <span class="NLM_cas:coden">JCEAAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9568</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dissocn. consts. of the conjugate acids of six cyclic diamines [piperazine, 1-methylpiperazine, 2-methylpiperazine, 1-ethylpiperazine, 1-(2-hydroxyethyl)piperazine, and 1,4-dimethylpiperazine] were calcd. using the potentiometric titrn. method at (298, 303, 313, and 323) K.  The pKa values of piperazine were compared with published data to validate the procedure used.  The thermodn. quantities (ΔH° and ΔS°) for the dissocn. processes were detd. using the van't Hoff equation.  A trend is proposed related to the variation of the pKa with the addn. of different radical groups to the base piperazine mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfe3zSGzoq1rVg90H21EOLACvtfcHk0lg0Jl5ebsOIbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCltrw%253D&md5=9fdc3aba92e3c5a4745baa70aa721af6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fje900005c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fje900005c%26sid%3Dliteratum%253Aachs%26aulast%3DKhalili%26aufirst%3DF.%26aulast%3DHenni%26aufirst%3DA.%26aulast%3DEast%26aufirst%3DA.%2BL.%2BL.%26atitle%3DpKa%2520values%2520of%2520some%2520piperazines%2520at%2520%2528298%252C%2520303%252C%2520313%252C%2520and%2520323%2529%2520K%26jtitle%3DJ.%2520Chem.%2520Eng.%2520Data%26date%3D2009%26volume%3D54%26spage%3D2914%26epage%3D2917%26doi%3D10.1021%2Fje900005c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3356</span>– <span class="NLM_lpage">3362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.bmcl.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30227946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3356-3362&author=J.-k.+Jiangauthor=X.+Huangauthor=K.+Shamimauthor=P.+R.+Patelauthor=A.+Leeauthor=A.+Q.+Wangauthor=K.+Nguyenauthor=G.+Tawaauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=W.+Zhengauthor=X.+Xuauthor=P.+Sandersonauthor=W.+Huang&title=Discovery+of+3-%284-sulfamoylnaphthyl%29pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+ALK2+inhibitors&doi=10.1016%2Fj.bmcl.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span></div><div class="casAuthors">Jiang, Jian-kang; Huang, Xiuli; Shamim, Khalida; Patel, Paresma R.; Lee, Arthur; Wang, Amy Q.; Nguyen, Kimloan; Tawa, Gregory; Cuny, Gregory D.; Yu, Paul B.; Zheng, Wei; Xu, Xin; Sanderson, Philip; Huang, Wenwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3356-3362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity.  Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination vs. ALK3 but also high kinome selectivity.  In addn., the optimized compd. 23 demonstrates good ADME and in vivo pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotGqzp6yONDLVg90H21EOLACvtfcHk0licktFMyKQbaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP&md5=c612015c66df5b0bebaaf43b67f55970</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-k.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShamim%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25284-sulfamoylnaphthyl%2529pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520ALK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3356%26epage%3D3362%26doi%3D10.1016%2Fj.bmcl.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Fauber, B.</span>; <span class="NLM_string-name">Gao, Z.</span>; <span class="NLM_string-name">Labadie, S.</span>; <span class="NLM_string-name">Lai, K. W.</span>; <span class="NLM_string-name">Purkey, H. E.</span>; <span class="NLM_string-name">Robarge, K.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Zhou, A.</span></span> <span> </span><span class="NLM_article-title">Piperidine-dione Derivatives</span>. <span class="NLM_patent">WO2015140133A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Chen&author=C.+Z.+Ding&author=P.+Dragovich&author=B.+Fauber&author=Z.+Gao&author=S.+Labadie&author=K.+W.+Lai&author=H.+E.+Purkey&author=K.+Robarge&author=B.+Wei&author=A.+Zhou&title=Piperidine-dione+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DPiperidine-dione%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">McClure, K. F.</span>; <span class="NLM_string-name">Munchhof, M. J.</span>; <span class="NLM_string-name">Robinson, R. P.,  Jr.</span></span> <span> </span><span class="NLM_article-title">4-(5-Cyano-pyrazol-1-yl)-piperidine Derivatives as GPR 119 Modulators</span>. <span class="NLM_patent">WO2012069948A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=V.+Mascitti&author=K.+F.+McClure&author=M.+J.+Munchhof&author=R.+P.+Robinson&title=4-%285-Cyano-pyrazol-1-yl%29-piperidine+Derivatives+as+GPR+119+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26atitle%3D4-%25285-Cyano-pyrazol-1-yl%2529-piperidine%2520Derivatives%2520as%2520GPR%2520119%2520Modulators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.-t.</span></span> <span> </span><span class="NLM_article-title">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2018.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.tet.2018.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVajs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=1527-1532&author=W.+Zhanauthor=L.+Jiauthor=Z.-m.+Geauthor=X.+Wangauthor=R.-t.+Li&title=A+continuous-flow+synthesis+of+primary+amides+from+hydrolysis+of+nitriles+using+hydrogen+peroxide+as+oxidant&doi=10.1016%2Fj.tet.2018.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant</span></div><div class="casAuthors">Zhan, Wei; Ji, Ling; Ge, Ze-mei; Wang, Xin; Li, Run-tao</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1527-1532</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant has been developed.  Using this procedure, a variety of nitriles could be smoothly transformed into the desired primary amides in good to excellent yields.  The mild reaction conditions and the flowing reaction system greatly improved the safety and make the reaction easy to scale up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2BdppGocGfLVg90H21EOLACvtfcHk0licktFMyKQbaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVajs7s%253D&md5=f93a2f9214afb4852bcb8d607da3c343</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2018.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2018.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DZ.-m.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DR.-t.%26atitle%3DA%2520continuous-flow%2520synthesis%2520of%2520primary%2520amides%2520from%2520hydrolysis%2520of%2520nitriles%2520using%2520hydrogen%2520peroxide%2520as%2520oxidant%26jtitle%3DTetrahedron%26date%3D2018%26volume%3D74%26spage%3D1527%26epage%3D1532%26doi%3D10.1016%2Fj.tet.2018.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, A.</span>; <span class="NLM_string-name">Ornoski, O.</span>; <span class="NLM_string-name">Raghavan, S.</span>; <span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Garfunkle, J.</span>; <span class="NLM_string-name">Yang, Z.</span>; <span class="NLM_string-name">Ji, G.</span>; <span class="NLM_string-name">Jiang, F.</span>; <span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Fused Pyrazine Derivatives Useful as Soluble Guanylate Cyclase Stimulators</span>. <span class="NLM_patent">WO2017200825A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Whitehead&author=O.+Ornoski&author=S.+Raghavan&author=R.+Berger&author=J.+Garfunkle&author=Z.+Yang&author=G.+Ji&author=F.+Jiang&author=J.+Fu&title=Fused+Pyrazine+Derivatives+Useful+as+Soluble+Guanylate+Cyclase+Stimulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWhitehead%26aufirst%3DA.%26atitle%3DFused%2520Pyrazine%2520Derivatives%2520Useful%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Stimulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span>; <span class="NLM_string-name">Bensen, D. C.</span>; <span class="NLM_string-name">Borchardt, A.</span>; <span class="NLM_string-name">Brady, T. P.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Lam, T.</span>; <span class="NLM_string-name">Tari, L. W.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Dihydrofolate Reductase</span>. <span class="NLM_patent">WO2016201219A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+M.+Balkovec&author=D.+C.+Bensen&author=A.+Borchardt&author=T.+P.+Brady&author=Z.+Chen&author=T.+Lam&author=L.+W.+Tari&title=Small+Molecule+Inhibitors+of+Dihydrofolate+Reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouzet, P.</span>; <span class="NLM_string-name">Hoenke, C.</span>; <span class="NLM_string-name">Nickolaus, P.</span>; <span class="NLM_string-name">Goeggel, R.</span>; <span class="NLM_string-name">Fox, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Klinder, K.</span></span> <span> </span><span class="NLM_article-title">Novel Piperazino-dihydrothienopyrimidine Derivatives</span>. <span class="NLM_patent">WO2009050236A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+Pouzet&author=C.+Hoenke&author=P.+Nickolaus&author=R.+Goeggel&author=T.+Fox&author=D.+Fiegen&author=K.+Klinder&title=Novel+Piperazino-dihydrothienopyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPouzet%26aufirst%3DP.%26atitle%3DNovel%2520Piperazino-dihydrothienopyrimidine%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, D. J.</span>; <span class="NLM_string-name">Bair, K. W.</span>; <span class="NLM_string-name">Caravella, J. A.</span>; <span class="NLM_string-name">Ioannidis, S.</span>; <span class="NLM_string-name">Lancia, D. R.,  Jr</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Mischke, S.</span>; <span class="NLM_string-name">Ng, P. Y.</span>; <span class="NLM_string-name">Richard, D.</span>; <span class="NLM_string-name">Schiller, S. E. R.</span>; <span class="NLM_string-name">Shelekhin, T.</span>; <span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Thienopyridine Carboxamides as Ubiquitin-specific Protease Inhibitors</span>. <span class="NLM_patent">WO2017139778A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+J.+Guerin&author=K.+W.+Bair&author=J.+A.+Caravella&author=S.+Ioannidis&author=D.+R.+Lancia&author=H.+Li&author=S.+Mischke&author=P.+Y.+Ng&author=D.+Richard&author=S.+E.+R.+Schiller&author=T.+Shelekhin&author=Z.+Wang&title=Thienopyridine+Carboxamides+as+Ubiquitin-specific+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26atitle%3DThienopyridine%2520Carboxamides%2520as%2520Ubiquitin-specific%2520Protease%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">xia2: an expert system for macromolecular crystallography data reduction</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1107/s0021889809045701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0021889809045701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=186-190&author=G.+Winter&title=xia2%3A+an+expert+system+for+macromolecular+crystallography+data+reduction&doi=10.1107%2Fs0021889809045701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">xia2: An expert system for macromolecular crystallography data reduction</span></div><div class="casAuthors">Winter, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190, S186/1-S186/5</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An expert system for macromol. crystallog. data redn. is presented, which builds on existing software to automate the complete data redn. process from images to merged structure factor amplitudes.  This can automatically identify multi-wedge, multi-pass and multiwavelength data sets and includes explicit procedures to test for crystallog. special cases.  With the push towards high-throughput crystallog. at synchrotron beamlines and automation of structure soln., the ability to reduce data with no user input fills an important gap in the pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOi3u0ydXbSrVg90H21EOLACvtfcHk0lgQzyDtXhxUgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D&md5=27771caa813f3e828abdf2a331ae55e3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0021889809045701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809045701%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26atitle%3Dxia2%253A%2520an%2520expert%2520system%2520for%2520macromolecular%2520crystallography%2520data%2520reduction%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2010%26volume%3D43%26spage%3D186%26epage%3D190%26doi%3D10.1107%2Fs0021889809045701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/s0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2Fs0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lgQzyDtXhxUgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2Fs0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/s0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2Fs0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0ljN7-tFhhHDKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2Fs0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/s0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2Fs0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0ljN7-tFhhHDKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2Fs0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/s0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2Fs0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lg6IkMyf3JDdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2Fs0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaver-Fay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeyink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">W375</span>– <span class="NLM_lpage">W383</span>, <span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2eb4AhjE085Rsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Emily Murrell, Junchao Tong, David Smil, Taira Kiyota, Ahmed M. Aman, Methvin B. Isaac, Iain D. G. Watson, <span class="NLM_string-name hlFld-ContribAuthor">Neil Vasdev</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 846-850. <a href="https://doi.org/10.1021/acsmedchemlett.1c00127" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00127%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLeveraging%252BOpen%252BScience%252BDrug%252BDevelopment%252Bfor%252BPET%25253A%252BPreliminary%252BNeuroimaging%252Bof%252B11C-Labeled%252BALK2%252BInhibitors%26aulast%3DMurrell%26aufirst%3DEmily%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02032021%26date%3D21042021%26date%3D23042021%26volume%3D12%26issue%3D5%26spage%3D846%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David Smil, Jong Fu Wong, Eleanor P. Williams, Roslin J. Adamson, Alison Howarth, David A. McLeod, Ahmed Mamai, Soyoung Kim, Brian J. Wilson, Taira Kiyota, Ahmed Aman, Julie Owen, Gennady Poda, Kurumi Y. Horiuchi, Ekaterina Kuznetsova, Haiching Ma, J. Nicole Hamblin, Sue Cramp, Owen G. Roberts, Aled M. Edwards, David Uehling, Rima Al-awar, Alex N. Bullock, Jeff A. O’Meara, <span class="NLM_string-name hlFld-ContribAuthor">Methvin B. Isaac</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 10061-10085. <a href="https://doi.org/10.1021/acs.jmedchem.0c01199" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01199%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLeveraging%252Ban%252BOpen%252BScience%252BDrug%252BDiscovery%252BModel%252Bto%252BDevelop%252BCNS-Penetrant%252BALK2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BDiffuse%252BIntrinsic%252BPontine%252BGlioma%26aulast%3DSmil%26aufirst%3DDavid%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10072020%26date%3D26082020%26date%3D11082020%26volume%3D63%26issue%3D17%26spage%3D10061%26epage%3D10085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sophie M.  Peeters</span>, <span class="hlFld-ContribAuthor ">Yagmur  Muftuoglu</span>, <span class="hlFld-ContribAuthor ">Brian  Na</span>, <span class="hlFld-ContribAuthor ">David J.  Daniels</span>, <span class="hlFld-ContribAuthor ">Anthony C.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Pediatric Gliomas. </span><span class="cited-content_cbyCitation_journal-name">Neurosurgery Clinics of North America</span><span> <strong>2021,</strong> <em>32 </em>
                                    (2)
                                     , 181-190. <a href="https://doi.org/10.1016/j.nec.2020.12.001" title="DOI URL">https://doi.org/10.1016/j.nec.2020.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nec.2020.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nec.2020.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurosurgery%2520Clinics%2520of%2520North%2520America%26atitle%3DPediatric%252BGliomas%26aulast%3DPeeters%26aufirst%3DSophie%2BM.%26date%3D2021%26volume%3D32%26issue%3D2%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory R.  Gipson</span>, <span class="hlFld-ContribAuthor ">Erich J.  Goebel</span>, <span class="hlFld-ContribAuthor ">Kaitlin N.  Hart</span>, <span class="hlFld-ContribAuthor ">Emily C.  Kappes</span>, <span class="hlFld-ContribAuthor ">Chandramohan  Kattamuri</span>, <span class="hlFld-ContribAuthor ">Jason C.  McCoy</span>, <span class="hlFld-ContribAuthor ">Thomas B.  Thompson</span>. </span><span class="cited-content_cbyCitation_article-title">Structural perspective of BMP ligands and signaling. </span><span class="cited-content_cbyCitation_journal-name">Bone</span><span> <strong>2020,</strong> <em>140 </em>, 115549. <a href="https://doi.org/10.1016/j.bone.2020.115549" title="DOI URL">https://doi.org/10.1016/j.bone.2020.115549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bone.2020.115549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bone.2020.115549%26sid%3Dliteratum%253Aachs%26jtitle%3DBone%26atitle%3DStructural%252Bperspective%252Bof%252BBMP%252Bligands%252Band%252Bsignaling%26aulast%3DGipson%26aufirst%3DGregory%2BR.%26date%3D2020%26volume%3D140%26spage%3D115549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Darren W.  Engers</span>, <span class="hlFld-ContribAuthor ">Sean R.  Bollinger</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Felts</span>, <span class="hlFld-ContribAuthor ">Anish K.  Vadukoot</span>, <span class="hlFld-ContribAuthor ">Charles H.  Williams</span>, <span class="hlFld-ContribAuthor ">Anna L.  Blobaum</span>, <span class="hlFld-ContribAuthor ">Craig W.  Lindsley</span>, <span class="hlFld-ContribAuthor ">Charles C.  Hong</span>, <span class="hlFld-ContribAuthor ">Corey R.  Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (18)
                                     , 127418. <a href="https://doi.org/10.1016/j.bmcl.2020.127418" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127418%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%25252C%252Bsynthesis%252Band%252Bcharacterization%252Bof%252Ba%252Bseries%252Bof%252B7-aryl-imidazo%25255B1%25252C2-a%25255Dpyridine-3-ylquinolines%252Bas%252Bactivin-like%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DEngers%26aufirst%3DDarren%2BW.%26date%3D2020%26volume%3D30%26issue%3D18%26spage%3D127418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibitory and off-target activity of previously reported ALK2 inhibitors and novel analogues. Reported values were obtained from the corresponding references.<a onclick="showRef(event, 'ref15 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref17 ref18">(15,17,18)</a> Measured values were determined utilizing a radioactive biochemical kinase assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7a–b</b> and <b>8a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 85 °C, overnight; (b) B<sub>2</sub>pin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 110 °C, 4 h; (c) aryl halide (<b>5a–b</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 2 h; (d) 7 N NH<sub>3</sub> in MeOH, 90 °C, 3 d; (e) TFA, DCM, rt, overnight; (f) aryl halide (<b>5c–e</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>14a–b</b>, <b>M4K2149</b>, <b>18a–b</b>, and <b>20a–e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (b) XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (c) NH<sub>4</sub>Cl, HATU, DIPEA, DCM, rt, 3 h; (d) TFA, DCM, rt, 1 h; (e) 7 N NH<sub>3</sub> in MeOH, 75 °C, 3 d; (f) methylamine, MeOH, 85 °C, 5 h; (g) KOH, THF/H<sub>2</sub>O, rt, 2 h; (h) dimethylamine, HOBt, EDC, DIPEA, DCM/DMF, 50 °C, overnight; (i) 4 M HCl in dioxane, MeOH, rt, 30 min.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>26a–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, MeOH, dioxane, rt, overnight; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/H<sub>2</sub>O, overnight; (c) B<sub>2</sub>pin<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 110 °C, 4 h; (d) Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h; (e) XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 100 °C, 3 h.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/medium/jm0c00395_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>M4K2149</b> (light yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T6D">6T6D</a>). Hydrogen bonds are established with H286 and K235. The benzamide moiety of <b>M4K2149</b> occupies a hydrophobic pocket (green) of ALK2 and is flanked by several hydrogen bond-donating (blue; K235) and hydrogen bond-accepting residues (red; D354 and E248). The protonated piperazine motif is in close proximity to D293, indicative of an electrostatic interaction. (B) Cocrystal structure of <b>LDN-213844</b> (light yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>). <b>M4K2149</b> and <b>LDN-213844</b> have similar modes of binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00395/20200602/images/large/jm0c00395_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00395&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0lhHInmcdu96Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lhHInmcdu96Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.cytogfr.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=26776312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=93-104&author=M.+Pacificiauthor=E.+M.+Shore&title=Common+mutations+in+ALK2%2FACVR1%2C+a+multi-faceted+receptor%2C+have+roles+in+distinct+pediatric+musculoskeletal+and+neural+orphan+disorders&doi=10.1016%2Fj.cytogfr.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span></div><div class="casAuthors">Pacifici, Maurizio; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptor family.  ALK2 exerts key and non-redundant roles in numerous developmental processes, including the specification, growth and morphogenesis of endochondral skeletal elements.  There is also strong evidence that BMP signaling plays important roles in detn., differentiation and function of neural cells and tissues.  Here we focus on the intriguing discovery that common activating mutations in ALK2 occur in Fibrodysplasia Ossificans Progressiva (FOP) and Diffuse Intrinsic Pontine Gliomas (DIPGs), distinct pediatric disorders of significant severity that are assocd. with premature death.  Pathogenesis and treatment remain elusive for both.  We consider recent studies on the nature of the ACVR1 mutations, possible modes of action and targets, and plausible therapeutic measures.  Comparisons of the diverse - but genetically interrelated - pathologies of FOP and DIPG will continue to be of major mutual benefit with broad biomedical and clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwM08RQn6m7LVg90H21EOLACvtfcHk0ljbTAOz_-YMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D&md5=1b6f732518596d155f46178c2743d841</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DPacifici%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DCommon%2520mutations%2520in%2520ALK2%252FACVR1%252C%2520a%2520multi-faceted%2520receptor%252C%2520have%2520roles%2520in%2520distinct%2520pediatric%2520musculoskeletal%2520and%2520neural%2520orphan%2520disorders%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D27%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.cytogfr.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmierer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span> <span> </span><span class="NLM_article-title">TGFβ-SMAD signal transduction: molecular specificity and functional flexibility</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1038/nrm2297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fnrm2297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=18000526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=970-982&author=B.+Schmiererauthor=C.+S.+Hill&title=TGF%CE%B2-SMAD+signal+transduction%3A+molecular+specificity+and+functional+flexibility&doi=10.1038%2Fnrm2297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">TGFβ-SMAD signal transduction: molecular specificity and functional flexibility</span></div><div class="casAuthors">Schmierer, Bernhard; Hill, Caroline S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">970-982</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Transforming growth factor-β (TGFβ)-induced signaling converges on a limited no. of SMAD complexes.  These complexes effect a plethora of specific and functional responses in both embryos and adult organisms.  How are these complex cellular responses elicited.  Ligands of the transforming growth factor-β (TGFβ) superfamily of growth factors initiate signal transduction through a bewildering complexity of ligand-receptor interactions.  Signaling then converges to nuclear accumulation of transcriptionally active SMAD complexes and gives rise to a plethora of specific functional responses in both embryos and adult organisms.  Current research is focused on the mechanisms that regulate SMAD activity to evoke cell-type-specific and context-dependent transcriptional programs.  An equally important challenge is understanding the functional role of signal strength and duration.  How are these quant. aspects of the extracellular signal regulated.  How are they then sensed and interpreted, and how do they affect responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS8aBln1hVMbVg90H21EOLACvtfcHk0ljbTAOz_-YMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsb3K&md5=0c60dcd2275bb22d0f555381264d1aef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2297%26sid%3Dliteratum%253Aachs%26aulast%3DSchmierer%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26atitle%3DTGF%25CE%25B2-SMAD%2520signal%2520transduction%253A%2520molecular%2520specificity%2520and%2520functional%2520flexibility%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D970%26epage%3D982%26doi%3D10.1038%2Fnrm2297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massagué, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">TGFβ signaling in growth control, cancer, and heritable disorders</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)00121-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2FS0092-8674%2800%2900121-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=11057902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Clt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=295-309&author=J.+Massagu%C3%A9author=S.+W.+Blainauthor=R.+S.+Lo&title=TGF%CE%B2+signaling+in+growth+control%2C+cancer%2C+and+heritable+disorders&doi=10.1016%2Fs0092-8674%2800%2900121-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">TGFβ signaling in growth control, cancer, and heritable disorders</span></div><div class="casAuthors">Massague, Joan; Blain, Stacy W.; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 141 refs. refs.  The control of cell growth and differentiation by the TGFβ family in relation to pathogenesis of human disorders and tumors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8n-oZyDANtLVg90H21EOLACvtfcHk0ljbTAOz_-YMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Clt7w%253D&md5=0ecc3149cea49379e6d7e4760504abf5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900121-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900121-5%26sid%3Dliteratum%253Aachs%26aulast%3DMassagu%25C3%25A9%26aufirst%3DJ.%26aulast%3DBlain%26aufirst%3DS.%2BW.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTGF%25CE%25B2%2520signaling%2520in%2520growth%2520control%252C%2520cancer%252C%2520and%2520heritable%2520disorders%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D295%26epage%3D309%26doi%3D10.1016%2Fs0092-8674%2800%2900121-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ACVR1 mutations in DIPG: lessons learned from FOP</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4565</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1158%2F0008-5472.CAN-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=25136070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=4565-4570&author=K.+R.+Taylorauthor=M.+Vinciauthor=A.+N.+Bullockauthor=C.+Jones&title=ACVR1+mutations+in+DIPG%3A+lessons+learned+from+FOP&doi=10.1158%2F0008-5472.can-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 mutations in DIPG: Lessons learned from FOP</span></div><div class="casAuthors">Taylor, Kathryn R.; Vinci, Maria; Bullock, Alex N.; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4565-4570</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Whole-genome sequencing studies have recently identified a quarter of cases of the rare childhood brainstem tumor diffuse intrinsic pontine glioma to harbor somatic mutations in ACVR1.  This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.  This unexpected link points toward the importance of developmental biol. processes in tumorigenesis and provides an extensive experience in mechanistic understanding and drug development hard-won by FOP researchers to pediatric neurooncol.  Here, we review the literature in both fields and identify potential areas for collaboration and rapid advancement for patients of both diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEL1hRMgcHVLVg90H21EOLACvtfcHk0ljWj7i2R539AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I&md5=6954694896e9f71ad21eec835247b1cd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DACVR1%2520mutations%2520in%2520DIPG%253A%2520lessons%2520learned%2520from%2520FOP%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D4565%26epage%3D4570%26doi%3D10.1158%2F0008-5472.can-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span> <span> </span><span class="NLM_article-title">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/ng.2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fng.2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=24705252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=457-461&author=K.+R.+Taylorauthor=A.+Mackayauthor=N.+Truffauxauthor=Y.+S.+Butterfieldauthor=O.+Morozovaauthor=C.+Philippeauthor=D.+Castelauthor=C.+S.+Grassoauthor=M.+Vinciauthor=D.+Carvalhoauthor=A.+M.+Carcabosoauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=N.+Entz-Werleauthor=W.+J.+Ingramauthor=M.+Monjeauthor=D.+Hargraveauthor=A.+N.+Bullockauthor=S.+Pugetauthor=S.+Yipauthor=C.+Jonesauthor=J.+Grill&title=Recurrent+activating+ACVR1+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fng.2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Taylor, Kathryn R.; Mackay, Alan; Truffaux, Nathalene; Butterfield, Yaron S.; Morozova, Olena; Philippe, Cathy; Castel, David; Grasso, Catherine S.; Vinci, Maria; Carvalho, Diana; Carcaboso, Angel M.; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Entz-Werle, Natacha; Ingram, Wendy J.; Monje, Michelle; Hargrave, Darren; Bullock, Alex N.; Puget, Stephanie; Yip, Stephen; Jones, Chris; Grill, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clin. outcome.  The median survival time is 9-12 mo, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clin. trials in children with these tumors.  We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples.  Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) and have been shown to constitutively activate the BMP-TGF-β signaling pathway.  These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRfkuGtWYWLVg90H21EOLACvtfcHk0ljWj7i2R539AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D&md5=69fb86fc99975a0f0dbaa060141788a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fng.2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2925%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DTruffaux%26aufirst%3DN.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DPhilippe%26aufirst%3DC.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrasso%26aufirst%3DC.%2BS.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DGrill%26aufirst%3DJ.%26atitle%3DRecurrent%2520activating%2520ACVR1%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D457%26epage%3D461%26doi%3D10.1038%2Fng.2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutka, J. T.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics</span>. <i>J. Korean Neurosurg. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.3340/jkns.2018.0008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.3340%2Fjkns.2018.0008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=29742880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=343-351&author=R.+K.+Mathewauthor=J.+T.+Rutka&title=Diffuse+intrinsic+pontine+glioma%3A+clinical+features%2C+molecular+genetics%2C+and+novel+targeted+therapeutics&doi=10.3340%2Fjkns.2018.0008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma : clinical features, molecular genetics, and novel targeted therapeutics</span></div><div class="casAuthors">Mathew, Ryan K.; Rutka, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Neurosurgical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-351</span>CODEN:
                <span class="NLM_cas:coden">JKNSAI</span>;
        ISSN:<span class="NLM_cas:issn">1598-7876</span>.
    
            (<span class="NLM_cas:orgname">Korean Neurosurgical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer.  Transient response to radiation, ineffective chemotherapeutic agents and aggressive biol. result in rapid progression of symptoms and a dismal prognosis.  Increased availability of tumor tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which have resulted in mol. and phenotypic subgrouping.  However, many of the underlying mechanisms of DIPG oncogenesis remain unexplained.  It is hoped that more representative in vitro and preclin. models-using both xenografted material and genetically engineered mice-will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery.  This review provides a clin. overview of DIPG, the barriers to progress in developing effective treatment, updates on drug development and preclin. models, and an introduction to new technologies aimed at enhancing drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohREcp3C8kCLVg90H21EOLACvtfcHk0ljWj7i2R539AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ&md5=0f37c4371f752f813af3014085c0dca3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3340%2Fjkns.2018.0008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3340%252Fjkns.2018.0008%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DR.%2BK.%26aulast%3DRutka%26aufirst%3DJ.%2BT.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520clinical%2520features%252C%2520molecular%2520genetics%252C%2520and%2520novel%2520targeted%2520therapeutics%26jtitle%3DJ.%2520Korean%2520Neurosurg.%2520Soc.%26date%3D2018%26volume%3D61%26spage%3D343%26epage%3D351%26doi%3D10.3340%2Fjkns.2018.0008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: poised for progress</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fonc.2012.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.3389%2Ffonc.2012.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=23293772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=205&author=K.+E.+Warren&title=Diffuse+intrinsic+pontine+glioma%3A+poised+for+progress&doi=10.3389%2Ffonc.2012.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma: poised for progress</span></div><div class="casAuthors">Warren Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat.  Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy.  Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success.  The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care.  The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar.  However, recent pivotal studies demonstrate that DIPGs appear to be their own entity.  Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments.  This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREW6_X20GCz7YtC3U5jeOifW6udTcc2eZmQ0jtxaSqfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D&md5=d51f614b4d5e8bfa9b7bb755cdf736e6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2012.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2012.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DK.%2BE.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520poised%2520for%2520progress%26jtitle%3DFront.%2520Oncol.%26date%3D2012%26volume%3D2%26spage%3D205%26doi%3D10.3389%2Ffonc.2012.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0ljldzvPpO2yWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaciregui, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">156</span>, <span class="refDoi"> DOI: 10.1038/s42003-019-0420-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1038%2Fs42003-019-0420-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=31098401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=156&author=D.+Carvalhoauthor=K.+R.+Taylorauthor=N.+G.+Olacireguiauthor=V.+Molinariauthor=M.+Clarkeauthor=A.+Mackayauthor=R.+Ruddleauthor=A.+Henleyauthor=M.+Valentiauthor=A.+Hayesauthor=A.+D.+H.+Brandonauthor=S.+A.+Ecclesauthor=F.+Raynaudauthor=A.+Boudharauthor=M.+Monjeauthor=S.+Popovauthor=A.+S.+Mooreauthor=J.+Moraauthor=O.+Cruzauthor=M.+Vinciauthor=P.+E.+Brennanauthor=A.+N.+Bullockauthor=A.+M.+Carcabosoauthor=C.+Jones&title=ALK2+inhibitors+display+beneficial+effects+in+preclinical+models+of+ACVR1+mutant+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fs42003-019-0420-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Popov Sergey; Vinci Mara; Jones Chris; Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Ruddle Ruth; Henley Alan; Valenti Melanie; Hayes Angela; Brandon Alexis De Haven; Eccles Suzanne A; Raynaud Florence; Popov Sergey; Vinci Mara; Jones Chris; Taylor Kathryn R; Monje Michelle; Olaciregui Nagore Gene; Mora Jaume; Cruz Ofelia; Carcaboso Angel Montero; Boudhar Aicha; Brennan Paul E; Bullock Alex N; Boudhar Aicha; Brennan Paul E; Popov Sergey; Moore Andrew S; Moore Andrew S; Vinci Mara</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2.  Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models.  Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo.  We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration.  Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls.  Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZQ93BSEDMxWZyxfu64m4ffW6udTcc2eaSwUx1OM4SH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D&md5=bc5f88aabf7d4d758e1288df1e70d5cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0420-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0420-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DOlaciregui%26aufirst%3DN.%2BG.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBrandon%26aufirst%3DA.%2BD.%2BH.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DBoudhar%26aufirst%3DA.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DALK2%2520inhibitors%2520display%2520beneficial%2520effects%2520in%2520preclinical%2520models%2520of%2520ACVR1%2520mutant%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26spage%3D156%26doi%3D10.1038%2Fs42003-019-0420-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastas, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zee, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrescu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nocco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filbin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.ccell.2019.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=31631026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=528-544&author=J.+N.+Anastasauthor=B.+M.+Zeeauthor=J.+H.+Kalinauthor=M.+Kimauthor=R.+Guoauthor=S.+Alexandrescuauthor=M.+A.+Blancoauthor=S.+Gieraauthor=S.+M.+Gillespieauthor=J.+Dasauthor=M.+Wuauthor=S.+Noccoauthor=D.+M.+Bonalauthor=Q.-D.+Nguyenauthor=M.+L.+Suvaauthor=B.+E.+Bernsteinauthor=R.+Alaniauthor=T.+R.+Golubauthor=P.+A.+Coleauthor=M.+G.+Filbinauthor=Y.+Shi&title=Re-programing+chromatin+with+a+bifunctional+LSD1%2FHDAC+inhibitor+induces+therapeutic+differentiation+in+DIPG&doi=10.1016%2Fj.ccell.2019.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG</span></div><div class="casAuthors">Anastas, Jamie N.; Zee, Barry M.; Kalin, Jay H.; Kim, Mirhee; Guo, Robyn; Alexandrescu, Sanda; Blanco, Mario Andres; Giera, Stefanie; Gillespie, Shawn M.; Das, Jayanta; Wu, Muzhou; Nocco, Sarah; Bonal, Dennis M.; Nguyen, Quang-De; Suva, Mario L.; Bernstein, Bradley E.; Alani, Rhoda; Golub, Todd R.; Cole, Philip A.; Filbin, Mariella G.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-544.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">H3K27M mutations resulting in epigenetic dysfunction are frequently obsd. in diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer.  We conduct a CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors.  Consistently, Corin, a bifunctional inhibitor of HDACs and LSD1, potently inhibits DIPG growth in vitro and in xenografts.  Mechanistically, Corin increases H3K27me3 levels suppressed by H3K27M histones, and simultaneously increases HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-assocd. genes.  Corin treatment induces cell death, cell-cycle arrest, and a cellular differentiation phenotype and drives transcriptional changes correlating with increased survival time in DIPG patients.  These data suggest a strategy for treating DIPG by simultaneously inhibiting LSD1 and HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHX1Q6HDJoobVg90H21EOLACvtfcHk0lgdIU94uQUIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsr%252FL&md5=32c4c2c7f032812a95d424b19ca7039e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAnastas%26aufirst%3DJ.%2BN.%26aulast%3DZee%26aufirst%3DB.%2BM.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DAlexandrescu%26aufirst%3DS.%26aulast%3DBlanco%26aufirst%3DM.%2BA.%26aulast%3DGiera%26aufirst%3DS.%26aulast%3DGillespie%26aufirst%3DS.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNocco%26aufirst%3DS.%26aulast%3DBonal%26aufirst%3DD.%2BM.%26aulast%3DNguyen%26aufirst%3DQ.-D.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DAlani%26aufirst%3DR.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DFilbin%26aufirst%3DM.%2BG.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DRe-programing%2520chromatin%2520with%2520a%2520bifunctional%2520LSD1%252FHDAC%2520inhibitor%2520induces%2520therapeutic%2520differentiation%2520in%2520DIPG%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D528%26epage%3D544%26doi%3D10.1016%2Fj.ccell.2019.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1217330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1080%2F13543776.2016.1217330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=27476794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1115-1128&author=C.+R.+Hopkins&title=Inhibitors+of+the+bone+morphogenetic+protein+%28BMP%29+signaling+pathway%3A+a+patent+review+%282008-2015%29&doi=10.1080%2F13543776.2016.1217330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1128</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The bone morphogenetic protein (BMP) is a crit. signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others.  Areas covered: This review covers small mol. inhibitors/antagonists of BMP in patent applications between 2008 - 2015, along with brief synopses of the disclosed inhibitors in the primary literature.  Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile.  Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP).  Recently, however, there has been increased interest in their use in a no. of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few.  Although the primary participants in the early work were from academic labs., recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications.  Due to this, expect a no. of new approaches such as repurposing of other kinase inhibitors to be brought into clin. trials in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShe2EZoRM8LVg90H21EOLACvtfcHk0ljLUhfRDw0nhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO&md5=e71e2ed75369d31a3835aaed4cf65de6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1217330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1217330%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DInhibitors%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520pathway%253A%2520a%2520patent%2520review%2520%25282008-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1115%26epage%3D1128%26doi%3D10.1080%2F13543776.2016.1217330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.bmcl.2008.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=18621530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4388-4392&author=G.+D.+Cunyauthor=P.+B.+Yuauthor=J.+K.+Lahaauthor=X.+Xingauthor=J.-F.+Liuauthor=C.+S.+Laiauthor=D.+Y.+Dengauthor=C.+Sachidanandanauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Structure-activity+relationship+study+of+bone+morphogenetic+protein+%28BMP%29+signaling+inhibitors&doi=10.1016%2Fj.bmcl.2008.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span></div><div class="casAuthors">Cuny, Gregory D.; Yu, Paul B.; Laha, Joydev K.; Xing, Xuechao; Liu, Ji-Feng; Lai, Carol S.; Deng, Donna Y.; Sachidanandan, Chetana; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4388-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline.  The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examd. by prepg. and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivs.  In addn., increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent Ph ring with piperazine.  Finally, an optimized compd. 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t 1/2 = 1.6 h) following i.p. administration in mice.  These studies provide useful mol. probes for examg. the in vivo pharmacol. of BMP signaling inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxlj03oLBHLVg90H21EOLACvtfcHk0ljLUhfRDw0nhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D&md5=227395181629474e47aee6163492c4bc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DLaha%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4388%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2008.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span>; <span class="NLM_string-name">Cuny, G. D.</span>; <span class="NLM_string-name">Mohedas, A. H.</span>; <span class="NLM_string-name">Bloch, K. D.</span>; <span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">BMP Inhibitors and Methods of Use Thereof</span>. <span class="NLM_patent">WO2014138088A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+B.+Yu&author=G.+D.+Cuny&author=A.+H.+Mohedas&author=K.+D.+Bloch&author=R.+T.+Peterson&title=BMP+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DBMP%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">A new class of small molecule inhibitor of BMP signaling</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e62721</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0062721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1371%2Fjournal.pone.0062721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=23646137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=C.+E.+Sanvitaleauthor=G.+Kerrauthor=A.+Chaikuadauthor=M.-C.+Ramelauthor=A.+H.+Mohedasauthor=S.+Reichertauthor=Y.+Wangauthor=J.+T.+Triffittauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=C.+S.+Hillauthor=A.+N.+Bullock&title=A+new+class+of+small+molecule+inhibitor+of+BMP+signaling&doi=10.1371%2Fjournal.pone.0062721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of small molecule inhibitor of BMP signaling</span></div><div class="casAuthors">Sanvitale, Caroline E.; Kerr, Georgina; Chaikuad, Apirat; Ramel, Marie-Christine; Mohedas, Agustin H.; Reichert, Sabine; Wang, You; Triffitt, James T.; Cuny, Gregory D.; Yu, Paul B.; Hill, Caroline S.; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e62721</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of interest for drug discovery.  Small mol. inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).  Dorsomorphin analogs, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.  By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concns. similar to the current lead compd. LDN-193189.  K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos.  Comparison of the crystal structures of ALK2 with K02288 and LDN-193189 revealed addnl. contacts in the K02288 complex affording improved shape complementarity and identified the exposed phenol group for further optimization of pharmacokinetics.  The discovery of a new chem. series provides an independent pharmacol. tool to investigate BMP signaling and offers multiple opportunities for pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMygI9eYjlbVg90H21EOLACvtfcHk0ljLUhfRDw0nhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D&md5=d00f0fddc871eb1a92fa90f36c7d54dc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0062721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0062721%26sid%3Dliteratum%253Aachs%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DRamel%26aufirst%3DM.-C.%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DReichert%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DA%2520new%2520class%2520of%2520small%2520molecule%2520inhibitor%2520of%2520BMP%2520signaling%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0062721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7915</span>, <span class="refDoi"> DOI: 10.1021/jm501177w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501177w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7900-7915&author=A.+H.+Mohedasauthor=Y.+Wangauthor=C.+E.+Sanvitaleauthor=P.+Canningauthor=S.+Choiauthor=X.+Xingauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Structure-activity+relationship+of+3%2C5-diaryl-2-aminopyridine+ALK2+inhibitors+reveals+unaltered+binding+affinity+for+fibrodysplasia+ossificans+progressiva+causing+mutants&doi=10.1021%2Fjm501177w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants</span></div><div class="casAuthors">Mohedas, Agustin H.; Wang, You; Sanvitale, Caroline E.; Canning, Peter; Choi, Sungwoon; Xing, Xuechao; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7900-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2.  Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors.  Here the authors describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compd. K02288.  Several modifications increased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as well as selectivity for ALK2 vs. closely related BMP and TGF-β type I receptor kinases.  Compds. in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or selectivity, suggesting mechanisms independent of BMP or TGF-β inhibition.  The study also highlights a potent 2-methylpyridine deriv. I (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclin. development.  Contrary to the notion that activating mutations of ALK2 might alter inhibitor efficacy due to potential conformational changes in the ATP-binding site, the compds. demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins.  Thus, BMP inhibitors identified via activity against wild-type ALK2 signaling are likely to be of clin. relevance for the diverse ALK2 mutant proteins assocd. with FOP and DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKhBWuwrqjLVg90H21EOLACvtfcHk0lgAJWdltANY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP&md5=c5efce9b3d06bbb126aa8a197d3d2b40</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm501177w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501177w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DStructure-activity%2520relationship%2520of%25203%252C5-diaryl-2-aminopyridine%2520ALK2%2520inhibitors%2520reveals%2520unaltered%2520binding%2520affinity%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%2520causing%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7900%26epage%3D7915%26doi%3D10.1021%2Fjm501177w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span>; <span class="NLM_string-name">Cuny, G. D.</span>; <span class="NLM_string-name">Mohedas, A. H.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Inhibiting BMP</span>. <span class="NLM_patent">WO2015148654A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+B.+Yu&author=G.+D.+Cuny&author=A.+H.+Mohedas&title=Compositions+and+Methods+for+Inhibiting+BMP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Inhibiting%2520BMP%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinecke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruprecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiechmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzlmeir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=655-664&author=M.+Reineckeauthor=B.+Ruprechtauthor=S.+Poserauthor=S.+Wiechmannauthor=M.+Wilhelmauthor=S.+Heinzlmeirauthor=B.+Kusterauthor=G.+M%C3%A9dard&title=Chemoproteomic+selectivity+profiling+of+PIKK+and+PI3K+kinase+inhibitors&doi=10.1021%2Facschembio.8b01020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors</span></div><div class="casAuthors">Reinecke, Maria; Ruprecht, Benjamin; Poser, Sandra; Wiechmann, Svenja; Wilhelm, Mathias; Heinzlmeir, Stephanie; Kuster, Bernhard; Medard, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-664</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. proteomic approaches utilizing immobilized, broad-selective kinase inhibitors (Kinobeads) have proven valuable for the elucidation of a compd.'s target profile under close-to-physiol. conditions and often revealed potentially synergistic or toxic off-targets.  Current Kinobeads enrich more than 300 native protein kinases from cell line or tissue lysates but do not systematically cover phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related kinases (PIKKs).  Some PIKKs and PI3Ks show aberrant activation in many human diseases and are indeed validated drug targets.  Here, we report the development of a novel version of Kinobeads that extends kinome coverage to these proteins.  This is achieved by inclusion of two affinity probes derived from the clin. PI3K/MTOR inhibitors Omipalisib and BGT226.  We demonstrate the utility of the new affinity matrix by the profiling of 13 clin. and preclin. PIKK/PI3K inhibitors.  The large discrepancies between the PI3K affinity values obtained and reported results from recombinant assays led us to perform a phosphoproteomic expt. showing that the chemoproteomic assay is the better approxn. of PI3K inhibitor action in cellulo.  The results further show that NVP-BEZ235 is not a PI3K inhibitor.  Surprisingly, the designated ATM inhibitor CP466722 was found to bind strongly to ALK2, identifying a new chemotype for drug discovery to treat fibrodysplasia ossificans progressiva.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqA0YbOfmxobVg90H21EOLACvtfcHk0lgAJWdltANY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aksrs%253D&md5=180dc2ef468b01067faceb69e399c8d4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01020%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%26aulast%3DRuprecht%26aufirst%3DB.%26aulast%3DPoser%26aufirst%3DS.%26aulast%3DWiechmann%26aufirst%3DS.%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DHeinzlmeir%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26atitle%3DChemoproteomic%2520selectivity%2520profiling%2520of%2520PIKK%2520and%2520PI3K%2520kinase%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D655%26epage%3D664%26doi%3D10.1021%2Facschembio.8b01020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrem, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleverly, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaiah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slapak, C. A.</span></span> <span> </span><span class="NLM_article-title">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4479</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.2147/dddt.s86621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.2147%2FDDDT.S86621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=26309397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4479-4499&author=M.+Lahnauthor=S.+Herbertzauthor=J.+S.+Sawyerauthor=A.+J.+Stauberauthor=I.+Gueorguievaauthor=K.+E.+Driscollauthor=S.+T.+Estremauthor=A.+L.+Cleverlyauthor=D.+Desaiahauthor=S.+C.+Gubaauthor=K.+A.+Benhadjiauthor=C.+A.+Slapak&title=Clinical+development+of+galunisertib+%28LY2157299+monohydrate%29%2C+a+small+molecule+inhibitor+of+transforming+growth+factor-beta+signaling+pathway&doi=10.2147%2Fdddt.s86621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span></div><div class="casAuthors">Herbertz, Stephan; Sawyer, J. Scott; Stauber, Anja J.; Gueorguieva, Ivelina; Driscoll, Kyla E.; Estrem, Shawn T.; Cleverly, Ann L.; Desaiah, Durisala; Guba, Susan C.; Benhadji, Karim A.; Slapak, Christopher A.; Lahn, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4479-4499</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biol. processes.  TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance.  There are several pharmacol. approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small mol. inhibitors.  Galunisertib (LY2157299 monohydrate) is an oral small mol. inhibitor of the TGF-β receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.  Furthermore, galunisertib has antitumor activity in tumor-bearing animal models such as breast, colon, lung cancers, and hepatocellular carcinoma.  Continuous long-term exposure to galunisertib caused cardiac toxicities in animals requiring adoption of a pharmacokinetic/pharmacodynamic-based dosing strategy to allow further development.  The use of such a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clin. investigation of galunisertib.  These efforts resulted in an intermittent dosing regimen (14 days on/14 days off, on a 28-day cycle) of galunisertib for all ongoing trials.  Galunisertib is being investigated either as monotherapy or in combination with std. antitumor regimens (including nivolumab) in patients with cancer with high unmet medical needs such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma.  The present review summarizes the past and current experiences with different pharmacol. treatments that enabled galunisertib to be investigated in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYOwgVYb7M2bVg90H21EOLACvtfcHk0ljCb4jBLQCuhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D&md5=f896505ddcd4dbc54bd59863588c4268</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86621%26sid%3Dliteratum%253Aachs%26aulast%3DLahn%26aufirst%3DM.%26aulast%3DHerbertz%26aufirst%3DS.%26aulast%3DSawyer%26aufirst%3DJ.%2BS.%26aulast%3DStauber%26aufirst%3DA.%2BJ.%26aulast%3DGueorguieva%26aufirst%3DI.%26aulast%3DDriscoll%26aufirst%3DK.%2BE.%26aulast%3DEstrem%26aufirst%3DS.%2BT.%26aulast%3DCleverly%26aufirst%3DA.%2BL.%26aulast%3DDesaiah%26aufirst%3DD.%26aulast%3DGuba%26aufirst%3DS.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%2BA.%26aulast%3DSlapak%26aufirst%3DC.%2BA.%26atitle%3DClinical%2520development%2520of%2520galunisertib%2520%2528LY2157299%2520monohydrate%2529%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520transforming%2520growth%2520factor-beta%2520signaling%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4479%26epage%3D4499%26doi%3D10.2147%2Fdddt.s86621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span>Unpublished
results. Data can be viewed in presentations archived at <a href="https://m4kpharma.com/blog/" class="extLink">https://m4kpharma.com/blog/</a> (accessed Apr. 1, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Unpublished%0Aresults.+Data+can+be+viewed+in+presentations+archived+at+https%3A%2F%2Fm4kpharma.com%2Fblog%2F+%28accessed+Apr.+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span>. <i>Wellcome Open Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.12688/wellcomeopenres.14947.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.12688%2Fwellcomeopenres.14947.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30705971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=154&author=M.+R.+Morganauthor=O.+G.+Robertsauthor=A.+M.+Edwards&title=Ideation+and+implementation+of+an+open+science+drug+discovery+business+model+-+M4K+Pharma&doi=10.12688%2Fwellcomeopenres.14947.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span></div><div class="casAuthors">Morgan Maxwell Robert; Edwards Aled Morgan; Morgan Maxwell Robert; Roberts Owen Gwilym; Edwards Aled Morgan; Morgan Maxwell Robert; Edwards Aled Morgan</div><div class="citationInfo"><span class="NLM_cas:title">Wellcome open research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn">2398-502X</span>.
    </div><div class="casAbstract">M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science.  The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5e8MVHlijOLZpSb_XWfMrfW6udTcc2ebzEU5sucuNOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D&md5=375dea208c308eb3199d178e4b1977a3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.12688%2Fwellcomeopenres.14947.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Fwellcomeopenres.14947.1%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DM.%2BR.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DIdeation%2520and%2520implementation%2520of%2520an%2520open%2520science%2520drug%2520discovery%2520business%2520model%2520-%2520M4K%2520Pharma%26jtitle%3DWellcome%2520Open%2520Res.%26date%3D2018%26volume%3D3%26spage%3D154%26doi%3D10.12688%2Fwellcomeopenres.14947.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boergermann, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">36990</span>– <span class="NLM_lpage">36998</span>, <span class="refDoi"> DOI: 10.1074/jbc.m112.365932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1074%2Fjbc.M112.365932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=22977237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=36990-36998&author=A.+Chaikuadauthor=I.+Alfanoauthor=G.+Kerrauthor=C.+E.+Sanvitaleauthor=J.+H.+Boergermannauthor=J.+T.+Triffittauthor=F.+von+Delftauthor=S.+Knappauthor=P.+Knausauthor=A.+N.+Bullock&title=Structure+of+the+bone+morphogenetic+protein+receptor+ALK2+and+implications+for+fibrodysplasia+ossificans+progressiva&doi=10.1074%2Fjbc.m112.365932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva</span></div><div class="casAuthors">Chaikuad, Apirat; Alfano, Ivan; Kerr, Georgina; Sanvitale, Caroline E.; Boergermann, Jan H.; Triffitt, James T.; von Delft, Frank; Knapp, Stefan; Knaus, Petra; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">36990-36998</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) receptor kinases are tightly regulated to control development and tissue homeostasis.  Mutant receptor kinase domains escape regulation leading to severely degenerative diseases and represent an important therapeutic target.  Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating disorder of extraskeletal bone formation.  FOP-assocd. mutations in the BMP receptor ALK2 reduce binding of the inhibitor FKBP12 and promote leaky signaling in the absence of ligand.  To establish structural mechanisms of receptor regulation and to address the effects of FOP mutation, we detd. the crystal structure of the cytoplasmic domain of ALK2 in complex with the inhibitors FKBP12 and dorsomorphin.  FOP mutations break crit. interactions that stabilize the inactive state of the kinase, thereby facilitating structural rearrangements that diminish FKBP12 binding and promote the correct positioning of the glycine-serine-rich loop and αC helix for kinase activation.  The balance of these effects accounts for the comparable activity of R206H and L196P.  Kinase activation in the clin. benign mutant L196P is far weaker than R206H but yields equiv. signals due to the stronger interaction of FKBP12 with R206H.  The presented ALK2 structure offers a valuable template for the further design of specific inhibitors of BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEuij-Kpil0bVg90H21EOLACvtfcHk0ljCb4jBLQCuhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqsrfK&md5=3c6d294d209dd85602a01a321831c503</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.365932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.365932%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DBoergermann%26aufirst%3DJ.%2BH.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKnaus%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DStructure%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520receptor%2520ALK2%2520and%2520implications%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D36990%26epage%3D36998%26doi%3D10.1074%2Fjbc.m112.365932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0lgdMO30Hnkf4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">tPSA, p<i>K</i><sub>a</sub> and cLogP values were calculated using ChemDraw Professional 19.0.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhVhePXHZFFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2611</span>, <span class="refDoi"> DOI: 10.1021/jm100087s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100087s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2601-2611&author=B.+Kuhnauthor=P.+Mohrauthor=M.+Stahl&title=Intramolecular+hydrogen+bonding+in+medicinal+chemistry&doi=10.1021%2Fjm100087s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Hydrogen Bonding in Medicinal Chemistry</span></div><div class="casAuthors">Kuhn, Bernd; Mohr, Peter; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2601-2611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The formation of intramol. hydrogen bonds has a very pronounced effect on mol. structure and properties.  We study both aspects in detail with the aim of enabling a more rational use of this class of interactions in medicinal chem.  On the basis of exhaustive searches in crystal structure databases, we derive propensities for intramol. hydrogen bond formation of five- to eight-membered ring systems of relevance in drug discovery.  A no. of motifs, several of which are clearly underutilized in drug discovery, are analyzed in more detail by comparing small mol. and protein-ligand X-ray structures.  To investigate effects on physicochem. properties, sets of closely related structures with and without the ability to form intramol. hydrogen bonds were designed, synthesized, and characterized with respect to membrane permeability, water soly., and lipophilicity.  We find that changes in these properties depend on a subtle balance between the strength of the hydrogen bond interaction, geometry of the newly formed ring system, and the relative energies of the open and closed conformations in polar and unpolar environments.  A no. of general guidelines for medicinal chemists emerge from this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaV7tFRU4k7Vg90H21EOLACvtfcHk0lhVhePXHZFFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Clur8%253D&md5=b9b6865dfcc9bdf7796d15218f6e8ff2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm100087s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100087s%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2601%26epage%3D2611%26doi%3D10.1021%2Fjm100087s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lhLmck68Y0-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lhLmck68Y0-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekimata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima-Tsumagari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1248%2Fcpb.c18-00598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30828000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeju7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=224-235&author=K.+Sekimataauthor=T.+Satoauthor=N.+Sakaiauthor=H.+Watanabeauthor=C.+Mishima-Tsumagariauthor=T.+Taguriauthor=T.+Matsumotoauthor=Y.+Fujiiauthor=N.+Handaauthor=T.+Honmaauthor=A.+Tanakaauthor=M.+Shirouzuauthor=S.+Yokoyamaauthor=K.+Miyazonoauthor=Y.+Hashizumeauthor=H.+Koyama&title=Bis-heteroaryl+pyrazoles%3A+identification+of+orally+bioavailable+inhibitors+of+activin+receptor-like+kinase-2+%28R206H%29&doi=10.1248%2Fcpb.c18-00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span></div><div class="casAuthors">Sekimata, Katsuhiko; Sato, Tomohiro; Sakai, Naoki; Watanabe, Hisami; Mishima-Tsumagari, Chiemi; Taguri, Tomonori; Matsumoto, Takehisa; Fujii, Yoshifumi; Handa, Noriko; Honma, Teruki; Tanaka, Akiko; Shirouzu, Mikako; Yokoyama, Shigeyuki; Miyazono, Kohei; Hashizume, Yoshinobu; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Mutant activin receptor-like kinase-2 (ALK2) was reported to be closely assocd. with the pathogenesis of fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG), and therefore presents an attractive target for therapeutic intervention.  Through in silico virtual screenings and structure-activity relationship studies assisted by X-ray crystallog. analyses, a novel series of bis-heteroaryl pyrazole was identified as potent inhibitors of ALK2 (R206H).  Derived from in silico hit compd. RK-59638 (6a), compd. 18p was identified as a potent inhibitor of ALK2 (R206H) with good aq. soly., liver microsomal stability, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3_X7yj3rTv7Vg90H21EOLACvtfcHk0lhLmck68Y0-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeju7jE&md5=edb5753df77bc0bf1546de7f70a900ac</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00598%26sid%3Dliteratum%253Aachs%26aulast%3DSekimata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMishima-Tsumagari%26aufirst%3DC.%26aulast%3DTaguri%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DMiyazono%26aufirst%3DK.%26aulast%3DHashizume%26aufirst%3DY.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DBis-heteroaryl%2520pyrazoles%253A%2520identification%2520of%2520orally%2520bioavailable%2520inhibitors%2520of%2520activin%2520receptor-like%2520kinase-2%2520%2528R206H%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D67%26spage%3D224%26epage%3D235%26doi%3D10.1248%2Fcpb.c18-00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khalili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, A. L. L.</span></span> <span> </span><span class="NLM_article-title">pK<sub>a</sub> values of some piperazines at (298, 303, 313, and 323) K</span>. <i>J. Chem. Eng. Data</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2914</span>– <span class="NLM_lpage">2917</span>, <span class="refDoi"> DOI: 10.1021/je900005c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/je900005c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=2914-2917&author=F.+Khaliliauthor=A.+Henniauthor=A.+L.+L.+East&title=pKa+values+of+some+piperazines+at+%28298%2C+303%2C+313%2C+and+323%29+K&doi=10.1021%2Fje900005c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">pKa Values of Some Piperazines at (298, 303, 313, and 323) K</span></div><div class="casAuthors">Khalili, Farhad; Henni, Amr; East, Allan L. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical & Engineering Data</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2914-2917</span>CODEN:
                <span class="NLM_cas:coden">JCEAAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9568</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dissocn. consts. of the conjugate acids of six cyclic diamines [piperazine, 1-methylpiperazine, 2-methylpiperazine, 1-ethylpiperazine, 1-(2-hydroxyethyl)piperazine, and 1,4-dimethylpiperazine] were calcd. using the potentiometric titrn. method at (298, 303, 313, and 323) K.  The pKa values of piperazine were compared with published data to validate the procedure used.  The thermodn. quantities (ΔH° and ΔS°) for the dissocn. processes were detd. using the van't Hoff equation.  A trend is proposed related to the variation of the pKa with the addn. of different radical groups to the base piperazine mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfe3zSGzoq1rVg90H21EOLACvtfcHk0lh4Gm8yz4T5kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCltrw%253D&md5=9fdc3aba92e3c5a4745baa70aa721af6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fje900005c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fje900005c%26sid%3Dliteratum%253Aachs%26aulast%3DKhalili%26aufirst%3DF.%26aulast%3DHenni%26aufirst%3DA.%26aulast%3DEast%26aufirst%3DA.%2BL.%2BL.%26atitle%3DpKa%2520values%2520of%2520some%2520piperazines%2520at%2520%2528298%252C%2520303%252C%2520313%252C%2520and%2520323%2529%2520K%26jtitle%3DJ.%2520Chem.%2520Eng.%2520Data%26date%3D2009%26volume%3D54%26spage%3D2914%26epage%3D2917%26doi%3D10.1021%2Fje900005c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3356</span>– <span class="NLM_lpage">3362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.bmcl.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=30227946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3356-3362&author=J.-k.+Jiangauthor=X.+Huangauthor=K.+Shamimauthor=P.+R.+Patelauthor=A.+Leeauthor=A.+Q.+Wangauthor=K.+Nguyenauthor=G.+Tawaauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=W.+Zhengauthor=X.+Xuauthor=P.+Sandersonauthor=W.+Huang&title=Discovery+of+3-%284-sulfamoylnaphthyl%29pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+ALK2+inhibitors&doi=10.1016%2Fj.bmcl.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span></div><div class="casAuthors">Jiang, Jian-kang; Huang, Xiuli; Shamim, Khalida; Patel, Paresma R.; Lee, Arthur; Wang, Amy Q.; Nguyen, Kimloan; Tawa, Gregory; Cuny, Gregory D.; Yu, Paul B.; Zheng, Wei; Xu, Xin; Sanderson, Philip; Huang, Wenwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3356-3362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity.  Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination vs. ALK3 but also high kinome selectivity.  In addn., the optimized compd. 23 demonstrates good ADME and in vivo pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotGqzp6yONDLVg90H21EOLACvtfcHk0lh4Gm8yz4T5kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP&md5=c612015c66df5b0bebaaf43b67f55970</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-k.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShamim%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25284-sulfamoylnaphthyl%2529pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520ALK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3356%26epage%3D3362%26doi%3D10.1016%2Fj.bmcl.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Ding, C. Z.</span>; <span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Fauber, B.</span>; <span class="NLM_string-name">Gao, Z.</span>; <span class="NLM_string-name">Labadie, S.</span>; <span class="NLM_string-name">Lai, K. W.</span>; <span class="NLM_string-name">Purkey, H. E.</span>; <span class="NLM_string-name">Robarge, K.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Zhou, A.</span></span> <span> </span><span class="NLM_article-title">Piperidine-dione Derivatives</span>. <span class="NLM_patent">WO2015140133A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Chen&author=C.+Z.+Ding&author=P.+Dragovich&author=B.+Fauber&author=Z.+Gao&author=S.+Labadie&author=K.+W.+Lai&author=H.+E.+Purkey&author=K.+Robarge&author=B.+Wei&author=A.+Zhou&title=Piperidine-dione+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DPiperidine-dione%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">McClure, K. F.</span>; <span class="NLM_string-name">Munchhof, M. J.</span>; <span class="NLM_string-name">Robinson, R. P.,  Jr.</span></span> <span> </span><span class="NLM_article-title">4-(5-Cyano-pyrazol-1-yl)-piperidine Derivatives as GPR 119 Modulators</span>. <span class="NLM_patent">WO2012069948A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=V.+Mascitti&author=K.+F.+McClure&author=M.+J.+Munchhof&author=R.+P.+Robinson&title=4-%285-Cyano-pyrazol-1-yl%29-piperidine+Derivatives+as+GPR+119+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26atitle%3D4-%25285-Cyano-pyrazol-1-yl%2529-piperidine%2520Derivatives%2520as%2520GPR%2520119%2520Modulators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.-t.</span></span> <span> </span><span class="NLM_article-title">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2018.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1016%2Fj.tet.2018.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVajs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=1527-1532&author=W.+Zhanauthor=L.+Jiauthor=Z.-m.+Geauthor=X.+Wangauthor=R.-t.+Li&title=A+continuous-flow+synthesis+of+primary+amides+from+hydrolysis+of+nitriles+using+hydrogen+peroxide+as+oxidant&doi=10.1016%2Fj.tet.2018.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant</span></div><div class="casAuthors">Zhan, Wei; Ji, Ling; Ge, Ze-mei; Wang, Xin; Li, Run-tao</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1527-1532</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A continuous-flow synthesis of primary amides from hydrolysis of nitriles using hydrogen peroxide as oxidant has been developed.  Using this procedure, a variety of nitriles could be smoothly transformed into the desired primary amides in good to excellent yields.  The mild reaction conditions and the flowing reaction system greatly improved the safety and make the reaction easy to scale up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2BdppGocGfLVg90H21EOLACvtfcHk0lgUhfRN_MrhUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVajs7s%253D&md5=f93a2f9214afb4852bcb8d607da3c343</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2018.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2018.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DZ.-m.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DR.-t.%26atitle%3DA%2520continuous-flow%2520synthesis%2520of%2520primary%2520amides%2520from%2520hydrolysis%2520of%2520nitriles%2520using%2520hydrogen%2520peroxide%2520as%2520oxidant%26jtitle%3DTetrahedron%26date%3D2018%26volume%3D74%26spage%3D1527%26epage%3D1532%26doi%3D10.1016%2Fj.tet.2018.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, A.</span>; <span class="NLM_string-name">Ornoski, O.</span>; <span class="NLM_string-name">Raghavan, S.</span>; <span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Garfunkle, J.</span>; <span class="NLM_string-name">Yang, Z.</span>; <span class="NLM_string-name">Ji, G.</span>; <span class="NLM_string-name">Jiang, F.</span>; <span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Fused Pyrazine Derivatives Useful as Soluble Guanylate Cyclase Stimulators</span>. <span class="NLM_patent">WO2017200825A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Whitehead&author=O.+Ornoski&author=S.+Raghavan&author=R.+Berger&author=J.+Garfunkle&author=Z.+Yang&author=G.+Ji&author=F.+Jiang&author=J.+Fu&title=Fused+Pyrazine+Derivatives+Useful+as+Soluble+Guanylate+Cyclase+Stimulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWhitehead%26aufirst%3DA.%26atitle%3DFused%2520Pyrazine%2520Derivatives%2520Useful%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Stimulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balkovec, J. M.</span>; <span class="NLM_string-name">Bensen, D. C.</span>; <span class="NLM_string-name">Borchardt, A.</span>; <span class="NLM_string-name">Brady, T. P.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Lam, T.</span>; <span class="NLM_string-name">Tari, L. W.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Dihydrofolate Reductase</span>. <span class="NLM_patent">WO2016201219A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+M.+Balkovec&author=D.+C.+Bensen&author=A.+Borchardt&author=T.+P.+Brady&author=Z.+Chen&author=T.+Lam&author=L.+W.+Tari&title=Small+Molecule+Inhibitors+of+Dihydrofolate+Reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouzet, P.</span>; <span class="NLM_string-name">Hoenke, C.</span>; <span class="NLM_string-name">Nickolaus, P.</span>; <span class="NLM_string-name">Goeggel, R.</span>; <span class="NLM_string-name">Fox, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Klinder, K.</span></span> <span> </span><span class="NLM_article-title">Novel Piperazino-dihydrothienopyrimidine Derivatives</span>. <span class="NLM_patent">WO2009050236A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+Pouzet&author=C.+Hoenke&author=P.+Nickolaus&author=R.+Goeggel&author=T.+Fox&author=D.+Fiegen&author=K.+Klinder&title=Novel+Piperazino-dihydrothienopyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPouzet%26aufirst%3DP.%26atitle%3DNovel%2520Piperazino-dihydrothienopyrimidine%2520Derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, D. J.</span>; <span class="NLM_string-name">Bair, K. W.</span>; <span class="NLM_string-name">Caravella, J. A.</span>; <span class="NLM_string-name">Ioannidis, S.</span>; <span class="NLM_string-name">Lancia, D. R.,  Jr</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Mischke, S.</span>; <span class="NLM_string-name">Ng, P. Y.</span>; <span class="NLM_string-name">Richard, D.</span>; <span class="NLM_string-name">Schiller, S. E. R.</span>; <span class="NLM_string-name">Shelekhin, T.</span>; <span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Thienopyridine Carboxamides as Ubiquitin-specific Protease Inhibitors</span>. <span class="NLM_patent">WO2017139778A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+J.+Guerin&author=K.+W.+Bair&author=J.+A.+Caravella&author=S.+Ioannidis&author=D.+R.+Lancia&author=H.+Li&author=S.+Mischke&author=P.+Y.+Ng&author=D.+Richard&author=S.+E.+R.+Schiller&author=T.+Shelekhin&author=Z.+Wang&title=Thienopyridine+Carboxamides+as+Ubiquitin-specific+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26atitle%3DThienopyridine%2520Carboxamides%2520as%2520Ubiquitin-specific%2520Protease%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">xia2: an expert system for macromolecular crystallography data reduction</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1107/s0021889809045701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0021889809045701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=186-190&author=G.+Winter&title=xia2%3A+an+expert+system+for+macromolecular+crystallography+data+reduction&doi=10.1107%2Fs0021889809045701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">xia2: An expert system for macromolecular crystallography data reduction</span></div><div class="casAuthors">Winter, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190, S186/1-S186/5</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An expert system for macromol. crystallog. data redn. is presented, which builds on existing software to automate the complete data redn. process from images to merged structure factor amplitudes.  This can automatically identify multi-wedge, multi-pass and multiwavelength data sets and includes explicit procedures to test for crystallog. special cases.  With the push towards high-throughput crystallog. at synchrotron beamlines and automation of structure soln., the ability to reduce data with no user input fills an important gap in the pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOi3u0ydXbSrVg90H21EOLACvtfcHk0lgUhfRN_MrhUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D&md5=27771caa813f3e828abdf2a331ae55e3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0021889809045701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809045701%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26atitle%3Dxia2%253A%2520an%2520expert%2520system%2520for%2520macromolecular%2520crystallography%2520data%2520reduction%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2010%26volume%3D43%26spage%3D186%26epage%3D190%26doi%3D10.1107%2Fs0021889809045701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/s0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2Fs0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lj77MegToOMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2Fs0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/s0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2Fs0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lj77MegToOMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2Fs0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/s0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2Fs0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lh1Dz91DXM9jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2Fs0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/s0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2Fs0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lh1Dz91DXM9jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2Fs0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaver-Fay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeyink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">W375</span>– <span class="NLM_lpage">W383</span>, <span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2eb0JpkTV2zhdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T6D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T6D','PDB','6T6D'); return false;">PDB: 6T6D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG','PDB','4BGG'); return false;">PDB: 4BGG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SRH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SRH','PDB','6SRH'); return false;">PDB: 6SRH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i85"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00395">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_15551"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00395?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00395</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H and <sup>19</sup>F NMR spectra of select compounds, crystallization methods, Caco-2 and HLM and MLM data, CYP and hERG inhibition data, and kinase selectivity panel (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_001.pdf">jm0c00395_si_001.pdf (1.46 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00395/suppl_file/jm0c00395_si_002.csv">jm0c00395_si_002.csv (1.61 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: ALK2-<b>M4K2149</b>, 6T6D; ALK2-<b>LDN-213844</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00395%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-9%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00395" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679953a06cff3cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
